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1.  Periodontal diseases 
1.1.  Definition 
 Periodontal diseases are various periodontal tissue infections including gingivitis 
and periodontitis [1], [2]. These diseases are caused by bacterial biofilm residing on teeth 
adjacent to the gingiva, leading to an inflammation of the gums. While gingivitis is the 
milder form, which does not harm the underlying supporting structures of the teeth and is 
reversible, periodontitis results in the loss of connective tissues and bone support [1].   
 Although the global epidemiology study of periodontal diseases is limited by the 
lack of standardized design, the variation of disease definition and diagnosis method, it is 
known that periodontal diseases are highly prevalent worldwide. Gingivitis can affect 50 to 
90 % of the world population, depending on its definition [1]. Periodontitis is generally 
less prevalent but is a major cause of tooth loss in the world. In general, destructive 
periodontal disease is less common in young people than in adults. However, the incidence 
of loss of periodontal attachment and supporting bone increases in adolescents aged 12 to 
17 when compared to children aged 5 to 11. Some epidemiologic studies indicate that in 
the United States, the prevalence of severe attachment loss in children and young adults is 
approximately 0.2 % to 0.5 % [3]. According to the 2009 and 2010 report of the National 
Health and Nutrition Examination Survey (NHANES), the total prevalence of periodontitis 
in American adults aged of 30 years and older was 47.2 %. Among that, the prevalence of 
mild, moderate, and severe periodontitis was 8.7 %, 30.0 %, and 8.5 %, respectively. There 
is a clear and significant disparity of the age and gender among periodontal population. 
Indeed, total periodontitis ranged from 24.4 % in 30 to 34 year old adults to 70.1 % in 
adults aged of 65 years and older. At the same age, the occurrence of disease is 
significantly higher in males than in females [4]. Periodontitis is also more common in 
developing countries, where dental hygiene is less controlled and dental treatment is too 
expensive to be afforded [5]. 
Periodontal diseases were recognized and treated about 5000 years ago, following 
ancient Egyptian and Chinese documents. From the 10th century, many authors described 
their observations of these diseases. However, until the 19th century, there was still 
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insufficient knowledge about the etiology and pathogenesis of periodontal diseases [2]. 
Until now, the most acknowledged classification of periodontal diseases is the American 
Academy of Periodontology (AAP) classification. The 1999 AAP classification, 
summarized in table 1, is the most recognized and implemented in the world [2], [6], [7]. 
Table&1.!Abbreviated!version!of!the!1999!AAP!classification!of!periodontal!diseases.!
Adapted'from'[7].'(CAL'='Clinical'Attachment'Loss)'
I Gingival Diseases 
A. Dental plaque-induced gingival diseases  
B. Non-plaque-induced gingival lesions 
II Chronic Periodontitis 
(Slight: 1-2 mm CAL; moderate: 3-4 mm CAL; severe: > 5 mm CAL) 
A. Localized 
B. Generalized (> 30 % of sites are involved) 
III Aggressive Periodontitis 
(Slight: 1-2 mm CAL; moderate: 3-4 mm CAL; severe: > 5 mm CAL) 
A. Localized 
B. Generalized (> 30 % of sites are involved) 
IV Periodontitis as a Manifestation of Systemic Diseases  
A. Associated with hematological disorders 
B. Associated with genetic disorders 
C. Not otherwise specified 
V Necrotizing Periodontal Diseases 
A. Necrotizing ulcerative gingivitis 
B. Necrotizing ulcerative periodontitis 
VI Abscesses of the Periodontium  
A. Gingival abscess 
B. Periodontal abscess 
C. Pericoronal abscess 
VII Periodontitis Associated With Endodontic Lesions  
A. Combined periodontic-endodontic lesions 
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VIII Developmental or Acquired Deformities and Conditions 
A. A. Localized tooth-related factors that modify or predispose to plaque-
induced gingival diseases/periodontitis  
B. B. Mucogingival deformities and conditions around teeth  
C. C. Mucogingival deformities and conditions on edentulous ridges  
D. D. Occlusal trauma  
 
 The main cause of periodontal disease is the overgrowth of pathogenic bacteria 
disturbing the natural balance of host defense and commensal flora [8]. The oral cavity has 
a natural moist environment which provides good growth conditions for about 700 
bacterial species, including normal and pathogenic bacteria [8]–[11]. These organisms 
grow on tooth surfaces first as microcolonies, which then secrete a sticky extracellular 
polymeric substance helping the bacteria to attach to the surface and to each other [10]. 
These complex, co-dependent colonies are called biofilms – the intense polymicrobial 
structure with functional heterogeneity that diversify the microbial population [1], [10]. 
Gingivitis often advances by inadequate oral hygiene, causing the dental plaque, so called 
plaque-induced gingivitis. Others factors can contribute to the cause of this disease such as 
genetics, tobacco, alcohol intake, nutritional deficiencies, HIV infection, osteoporosis, 
diabetes, stress, impaired host response and certain medication [1], [12]. The early 
colonization of root surfaces is known by the coaggregation of gram positive aerobes and 
facultative anaerobes such as Streptococci and Actinomyces species into developing 
biofilm. If oral hygiene is not practiced regularly, dental plaque is developed into a mature 
state consisting of high proportion of anaerobic organisms. Among them, the predominant 
microorganisms are gram negatives such as Fusobacterium, Porphyromonas, Prevotella, 
Treponema and members of the phylum Synergistetes [11], [13].  
Untreated gingival lesions can progress to periodontitis, in which the plaque 
broadens and deepens below the gum, creating even better condition for bacteria colonies, 
especially gram negative and anaerobic bacteria [1], [14]. The transition from gingivitis to 
periodontitis depends not only on the presence and number of pathogenic bacteria, but 
also: (i) the degree of host susceptibility and (ii) the presence and number of protective 
bacteria. Indeed, the host defense mechanism is impaired by bacterial toxins and enzymes 
releasing from gram negative anaerobes such as: epitheliotoxins, endotoxins, leukotoxins, 
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collagenase, gellatinase, elastase, fibrinolysins and other proteolytic enzymes. On a 
susceptible host, these bacterial proteins irritate the gums, stimulate the inflammation 
response, leading to the destruction of the periodontium and alveolar bone [1], [2], [11]. 
By the time, the tight attachment of gingival tissues to the teeth is lost, causing the 
formation of periodontal pockets. The number of bacteria found in healthy shallow crevice 
is around 1 x 103 while in a periodontal pocket, this value increases to more than 105 times. 
As periodontitis progresses, these symptoms become more severe, resulting in occasional 
pain and discomfort, mastication and eventually tooth loss [1].  
Normal oral microbiota (always present at a level of 108 bacteria/mL of saliva) 
contains primarily gram positive aerobes and only several pathogenic species with low 
virulence. Pathogenic species associated with periodontitis consists primarily of gram 
negative anaerobes [10]. Each type of periodontitis presents a specific subgingival flora 
consisting of its own microorganisms. The change in bacterial combination with the 
occurrence of certain specific bacterial combinations in infected root canals may be a 
decisive factor in causation of symptoms.  
The first bacterial complex associated with periodontitis is called ‘orange complex’ 
and consists of the obligate anaerobe gram negative bacilli such as Prevotella intermedia 
and Fusobacterium nucleatum. The worse disease accompanies with ‘red complex’ 
microbiota including Porphyromonas gingivalis, Tannerella forsythia and Treponema 
denticola [1], [2], [10], [15], [16]. The facultative gram! negative Actinobacillus 
(Aggregatibacterium) actinomycetemcomitans is also commonly associated with this 
disease, especially in young adults [1], [2]. 
1.2.  Treatment 
The treatment of periodontal diseases aims to re-establish periodontal health by 
interrupting the disease progression, preventing its recurrence and preserving the teeth in a 
healthy state, comfort and function [1]. This objective can be achieved by various non-
surgical and surgical therapies, depending on the specific disease as well as its severity.  
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1.2.1.  Non-surgical treatment 
The first and essential therapy for the treatment of periodontal diseases consists of 
the plaque control, which is performed by personal oral hygiene care and professional 
treatment called scaling and root planing. Scaling is the careful cleaning of the dental root 
surface in both supra and sub-gingival position to remove plaque and calculus (tartar) from 
periodontal pockets. Consequently, root planing is carried out to smooth the tooth root to 
remove bacterial toxins, which adsorb on cemental surface and limit plaque recurrence. 
The scaling and root planing should be managed regularly to maintain the oral hygiene and 
re-stabilize the normal oral flora, which will stop the gingival inflammation. Otherwise, 
these techniques also help the periodontist to follow the progress of the disease as well as 
to predict possible recurrence of inflammation. Scaling and root planing are the first choice 
therapies for most clinicians and are broadly considered as the ‘gold standard’ of 
periodontitis treatment [10]. This non-surgical therapy can achieve good efficacy in initial 
periodontitis such as decreased tissue inflammation, improved clinical periodontal 
attachment [1]. However, in severe cases, this mechanical treatment alone is not enough to 
attain the desired clinical outcomes. For instance, re-colonization of pathogenic species 
associated with disease and the recurrence of periodontitis are quite common [10]. 
To reinforce the non-surgical treatment of periodontitis, antimicrobial therapy is 
often used as an adjunct to scaling and root planing [10]. Current protocols recommend 
that the first phase treatment of generalized aggressive periodontitis as well as chronic 
periodontitis should be aimed at reducing or eliminating the pathogenic microorganisms 
[17]. Systemic antibiotherapy has been applied for the treatment of severe periodontitis. 
However, this administration route faced some disadvantages because of their side effects 
including hypersensitivity, gastrointestinal intolerance. Moreover, the concentration of 
drug at the action site (periodontal tissue) is quite low and not sufficient for an effective 
antimicrobial treatment [18]. These limits would be improved by the local administration 
of antimicrobial agents. Placing into periodontal pocket a controlled delivery system 
containing active agent could significantly enhance the local concentration of drug. By 
controlling the release of drug, the undesired second effects can also be reduced [18]. 
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1.2.1.1.  Antimicrobial choice 
Generally, the choice of antimicrobial agents for the treatment of periodontitis is 
dependent on the bacterial etiology of the infection. Several antimicrobial agents have been 
tested for their efficacy against periodontitis. However, only a limited number of these 
substances have been used in the formulation of drug delivery systems for the treatment of 
periodontitis. These antimicrobial agents can be classified into 2 categories: antiseptic 
agents and antibiotic agents [18].  
Table&2a.!Antiseptic!agents!for!the!treatment!of!periodontal!diseases.!
Substance 
Mechanism of 
action 
Advantages Disadvantages 
Chlorhexidine Reduction in pellicle 
formation, alteration 
of bacterial adherence 
to teeth and bacterial 
cell wall. 
- Surface bacteriostatic 
action. 
- Improved wound healing. 
- Effective control of dental 
plaque. 
- Staining of teeth. 
- Taste disturbance. 
- Increase in calculus 
accumulation. 
- Limited effects to 
supra-gingival area. 
Sanguinarine Reduction of bacterial 
aggregation and 
attachment due to 
alteration of bacterial 
wall. 
- Plaque & gingivitis 
reduction in short time 
study. 
- Low antimicrobial 
activity (MIC against 
periodontal pathogens: 1 
to 32 µg/mL). 
- Low clinical efficacy 
in local controlled 
release system. 
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Table&2b.!Antibiotic!agents!for!the!treatment!of!periodontal!diseases.!
Substance Mechanism of action Advantages Disadvantages 
Tetracyclines 
(tetracycline, 
doxycycline, 
minocycline) 
Bacteriostatic action 
by interfering 
bacterial protein syn-
thesis & inhibiting 
tissue collagenase 
activity. 
- Broad spectrum of activity by inhibiting both gram negative and 
gram positive organisms. 
- Antiproteolytic properties due to inhibitory effect on oxygen radi-
cals, so prevent tissue destruction. 
- Tetracyclines, especially doxycycline, inhibit matrix metallopro-
teinases, helping to reduce tissue destruction & alveolar bone loss 
[10]. 
- Tetracycline exhibits high substantivity in periodontal environment. 
- Doxycycline & minocycline exhibit greater oral absorption, more 
prolonged half-lives & enhanced lipid solubility. 
- Most of subgingival microorganisms are susceptible to tetracycline 
at MIC ≤ 1 – 2 µg/mL. 
- Bacteria may develop resistance to anti-
biotic. 
- Some strains of Campylobacter & Veil-
lonella exhibited intrinsic tetracycline 
resistance (MIC ≥ 16 µg/mL). 
Metronidazole Inhibiting bacterial 
DNA synthesis. 
- Selective efficacy against obligate anaerobes. 
- Adjunctive metronidazole therapy was reported more effective in 
adults with deep pockets than with less advanced periodontitis. 
- Ineffective in vitro against Actinobacil-
lus actinomycetemcomitans. 
Clindamycin Bacteriostatic effect by 
inhibiting bacterial 
protein synthesis. 
- Broad-spectrum of activity against aerobic, anaerobic, and beta-
lactamase-producing pathogens [19]. 
- Limited number of study. 
- Reported recurrence of disease after both 
adjunctive systemic & local therapy. 
Ofloxacin Synthetic fluoroquino-
lone actives by inhibit-
ing bacterial cell divi-
sion [20]. 
- Activity against gram positive & anaerobic bacteria. 
- Marked antibacterial activity against periodontopathic bacteria in-
cluding Fusobacterium & Actinobacillus actinomycetemcomitans. 
- High chemical stability. 
- Increasing ofloxacin resistance in south-
east Asia. 
 
 INTRODUCTION 
!
! 9!
1.2.1.2.  Clinical studies on adjunctive antimicrobial therapy 
a. Antiseptics 
Many studies have focused on the clinical efficacy of antimicrobial treatment as an 
adjunctive therapy to scaling and root planing. Nevertheless, only modest results have been 
found till now. One systematically review of 7 clinical trials has analysed the efficacy of 
full-mouth treatment concepts for chronic periodontitis. Meta-analysis focused on full-
mouth scaling with or without the use of antiseptic chlorhexidine and quadrant scaling 
(control). The results showed that in adults with chronic periodontitis, only minor 
differences in treatment effects were observed between the treatment strategies [21]. In 
agreement with this, another meta-analysis concluded that the use of chlorhexidine and 
other antiseptics in full-mouth disinfection does not provide clinically relevant advantages 
over conventional staged debridement [22]. Full-mouth disinfection can never been 
achieved as a normal microbiota is always present at a high level. Moreover, chlorhexidine 
was found less effective than tetracycline and minocycline in probing depth reduction 
when used as local adjuncts to scaling and root planing in periodontal disease therapy [23]. 
In addition, antiseptics do not have the advantage of suppressing the host inflammatory 
response comparing to tetracyclines. Hence, antibiotics seem to be more potential in the 
research of adjunctive antimicrobial therapy [10].   
b. Antibiotics 
In the domain of antibiotics, there were numerous therapies of systemic antibiotics 
using alone or in combination with non-surgical or surgical periodontal treatment. Only a 
limited number of studies regarding the effect of antibiotic used alone have been 
published, for instance the 50-week term tetracycline therapy [24] or the metronidazole 
plus amoxicillin therapy [25]. Generally, systemic antibiotics should only be used as an 
adjunct to periodontal therapy, when patients do not respond to conventional mechanical 
therapy [26].  
• Metronidazole + amoxicillin 
One of the common adjunctive systemic antibiotic therapies, which interested 
clinical research, is metronidazole plus amoxicillin. Ribeiro et al. [27] evaluated the 
adjunctive clinical, microbiologic, and immunologic effects of the systemic administration 
of amoxicillin and metronidazole in the full-mouth ultrasonic debridement of patients (n = 
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25) with severe chronic periodontitis. For test groups, antibiotics were administered at the 
dose of 375 mg amoxicillin and 250 mg metronidazole, three times a day for 7 days. The 
outcome parameters were evaluated after 3 and 6 months of treatment. Significant clinical 
improvements were observed for both the test and control group. At 6 months post-
treatment, the test treatment resulted in significantly lower bleeding on probing (BOP) and 
an additional reduction (0.83 mm) in probing depth (PD) (p < 0.05). Moreover, percentage 
of sites with PD ≥ 5 mm exhibiting relative attachment level (RAL) gain ≥ 2 mm was 
higher (58.03 % in test patients versus 43.52 % in control patients) (p < 0.05). 
Nevertheless, no improvement in the microbiologic or immunologic outcomes was 
observed with the adjunctive use of systemic amoxicillin and metronidazole. With the 
same objective to figure out efficacy of amoxicillin/metronidazole therapy as an adjunct to 
full-mouth scaling in patients with chronic periodontitis, Cionca et al. [28] designed a 
study on 47 patients for 6 months, with the administration of 500 mg metronidazole and 
375 mg amoxicillin, three times a day for 7 days on the test group. Interestingly, positive 
clinical outcomes have been observed with significantly lower mean number of persisting 
pockets > 4 mm (0.4 ± 0.8 pockets in the test group versus 3.0 ± 4.3 pockets in the control 
group) and bleeding on probing that required further treatment (p = 0.005). Recently, a 
systemic review was accomplished aiming at testing the efficacy of systemic 
amoxicillin/metronidazole as an adjunctive therapy to full-mouth scaling and root planing 
(FMSRP) in the treatment of aggressive periodontitis. Meta-analysis results of six 
randomized clinical trials showed significant clinical attachment level gain and reduction 
in probing depth (p < 0.05) in favor of FMSRP + amoxicillin/metronidazole. These 
findings seem to support the efficacy and the clinical safety of FMSRP + 
amoxicillin/metronidazole [17]. In general, amoxicillin/metronidazole therapy in 
adjunction with FMSRP was proved to be efficient in the treatment of both aggressive and 
chronic periodontitis. However, considering the small number of included studies, future 
studies with larger sample size and standardized study designs are needed to confirm these 
results.  
• Tetracyclines 
Systemic tetracyclines may be indicated in periodontal infections due to their broad 
spectrum of activity and possible benefit of inhibiting matrix metalloproteinases (MMP). 
In particular, doxycycline and minocycline have great oral absorption and prolonged half-
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life. However, the low concentration of tetracyclines in gingival crevicular fluid after 
systemic use (from 0 to 8 µg/mL, 50 % of samples get less than 1 µg/mL) could be the 
reason for variable clinical response in practice [26]. Thus, the development of local 
tetracyclines therapy seems to be more appropriate in the research of periodontitis 
treatment.  
The use alone of a sustained-release, biodegradable gel containing 8.5 
% doxycycline was reported to be effective on chronic periodontitis (n = 45, divided into 2 
groups). Following this doxycycline administration, a significant decrease (p < 0.01) in 
total anaerobic counts in subgingival plaque was observed for 6 months after initiation of 
treatment. Regarding antibiotic susceptibility patterns associated with subgingival plaque 
and saliva, no change in the number of resistant bacteria or the acquisition of antibiotic 
resistance was observed [29]. When using in combination with full-mouth scaling and root 
planing, or full-mouth debridement, the local application of 8.5 % w/w doxycycline-loaded 
PLA/NMP (AtridoxTM) was effective in reducing clinical signs of chronic periodontitis (n 
= 105). After 3 month post-treatment, the proportion of pocket closure determined as 
probing pocket depth PPD < 4 mm was significantly increased (50 to 58 %); the clinical 
attachment level CAL gained from 0.5 to 0.8 mm and the proportion of sites showing a 
clinically significant CAL gain (> 2 mm) increased from 30 to 38 % compared to the 
baseline [30]. These results are quite reasonable regarding the pharmacokinetic profiles of 
local delivery of doxycycline gels in gingival crevicular fluid (GCF) and saliva given by 
the study of Kim et al. [31]. They measured local drug concentration after delivering Doxy 
(14 % doxycycline in PEG-PLGA copolymer gel) or AtridoxTM (8.5 % doxycycline in 
PLA/NMP polymer solution) in 10 patients with severe periodontitis. In GCF specimens, 
sites treated with AtridoxTM exhibited a faster decrease of mean doxycycline concentration 
(from 1085 to 274 µg/mL) than sites treated with Doxy (1388 to 804 µg/mL, measured at 2 
and 24 h after application, respectively). Both doxycycline gels demonstrated 
pharmacokinetics of controlled-release delivery systems, with doxycycline concentration 
in GCF after 12 days of 8 and 19 µg/mL for AtridoxTM and Doxy, respectively. In contrast, 
another recent study investigating the effect of topical doxycycline AtridoxTM as an adjunct 
to non-surgical periodontal treatment in chronic and aggressive periodontitis patients 
provided negative results. 10 chronic periodontitis patients and 8 aggressive periodontitis 
patients were divided into 4 groups treated by scaling and root planing with or without 
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doxycycline gel application. The results yielded at 1, 3 and 6 months post-treatment was 
found not statistically different between the test and control sites in probing depth, plaque 
scores and bleeding on probing values. Similarly, GCF MMP-8 levels presented no 
significant intergroup differences [32].  These contradictory results could be explained by 
the complexity of periodontitis with the variety of pathogen bacteria among which many 
are still unknown, and host modulation is not always a feasible issue.   
Among the tetracyclines, minocycline has the best absorption and tissue penetration 
[26]. This property provides advantages for local application in the treatment of 
periodontitis. Many studies on the efficacy of topical minocycline therapy have been 
carried out. Generally, local application of minocycline was reported inefficient when used 
as mono-therapy [33], but provided significant efficacy in combination with mechanical 
treatment. For instance, minocycline HCl 2 % ointment reported a significant reduction in 
microbial count and improvements in clinical parameters for the scaling with minocycline 
therapy versus scaling alone. With regard to the dose study, application of a 2 % ointment 
3 to 4 times every 2 weeks in combination with scaling and root planing was proved to 
provide significant improvement in microbiological and clinical parameters versus scaling 
and root planing for the treatment of adult periodontitis [34]. Another study evaluated the 
efficacy of 2 % minocycline gel as adjuncts to scaling and root planing in the treatment of 
persistent periodontal lesions. The clinical parameters were also found significantly 
improved in the test group (n = 21) over control group (n = 20), with mean probing depth 
reduction at 6 months was 1.10 mm versus 0.71 mm. Thus, the benefit of adjunctive local 
2 % minocycline gel was statistically significant [35]. In accordance with these previous 
studies, another research was performed on a total of 104 patients over 15-month period to 
investigate the role of subgingivally administered 2 % minocycline ointment following 
scaling and root planing. The administration of drug was done at baseline, week 2, and at 
month 1, 3, 6, 9, 12. Scaling and root planing was repeated at month 6 and 12. During the 
entire 15-month study period, positive results were collected in both microbiological and 
clinical issues. With regard to microbiological results, the number of 7 studied 
microorganisms reduced significantly in both treatment groups. Concerning clinical 
outcomes, significantly greater improvements were observed in sites treated with 
minocycline compared to the control sites. For instance, at the pockets with initial probing 
depth ≥ 5 mm: mean probing depth reduction was 1.9 mm in test sites versus 1.2 mm in 
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control sites; gain in attachment level was 0.9 mm versus 0.5 mm in the same order. 
Furthermore, none of the patients demonstrated hypersensitivity or any local site reactions, 
proving that minocycline ointment was well tolerated. This study confirmed the good 
efficacy of local adjunctive 2 % minocycline ointment as adjunct to scaling and root 
planing in chronic periodontitis over a long period of time [36]. Some other similar studies 
have been performed and also gained positive results [37]. Most recently, a study 
evaluating the efficacy of scaling and root planing with adjunctive local minocycline 
microspheres in the treatment of moderate to advance chronic periodontitis was performed. 
However, this combination therapy did not differ significantly from scaling and root 
planing alone in the reduction of probing depth and bleeding on probing [38]. In brief, the 
local administration of minocycline, especially the 2 % minocycline in gel formulation 
seems to be most promising when used as an adjunct to scaling and root planing in the 
treatment of chronic periodontitis.  
1.2.2.  Surgical treatment 
When non-surgical treatment failed to achieve periodontal health, surgery may be 
indicated to restore impaired periodontal anatomy by reducing periodontal pocket depth, 
gaining access for debridement of residual dental plaque and stimulating the regeneration 
of lost periodontal support [1]. Due to excessive gingival recession, tooth roots are 
exposed, facilitating further recession and bone loss. Gum graft surgery can be used to 
cover roots and compensate the lost gum tissue. A regenerative procedure is recommended 
to the patients with advance periodontitis whose bone and tissue supporting the teeth has 
been destroyed. Membranes, bone grafts or tissue-stimulating proteins can be used to 
encourage the regeneration on patients. The periodontal pocket reduction procedure is 
necessary for the patients who have too deep pockets to be cleaned by professional care. In 
this case, the bacteria accumulation inside periodontal pocket should be eliminated after 
folding back the gum tissue. Periodontal tissue is secured to be clean before placing back 
into place. Last but not least, dental implants and the replacement of defective prostheses 
are also important for periodontal therapy on patients who have lost a tooth or teeth [1].  
Briefly, the treatment therapies of periodontal diseases are various and can be 
tailored to individual patients depending on their etiology, severity and the associated 
systemic diseases. The success of the treatment depends much on oral home care, 
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continued efforts to control or remove risk factors, and regular maintenance or supportive 
follow-up therapy after active treatment. Adjunctive antibiotics re-treatment should be 
considered for patients with aggressive or refractory periodontitis, based on the present 
pathogenic microbial community and their sensitivity [1].  
2.  Local controlled delivery systems for the treatment of 
periodontitis 
In patients with periodontitis, the periodontal pockets can act as a natural reservoir 
filled with gingival crevicular fluid (GCF) for the administration of antimicrobial agents to 
periodontal tissues. GCF is characterized by a typical flow, giving a flushing action that 
leads to a rapid removing of substances from gingival sulcus. However, this effect can be 
compensated by the introduction of controlled release drug delivery into periodontal 
environment. Moreover, the isolation effect of GCF keeps the substance within pockets 
separated from saliva. These characteristics makes the periodontal pockets an ideal route 
for local antimicrobial therapy in periodontitis treatment [39], [40].   A broad variety of 
local delivery systems have been developed to maintain the concentration of antimicrobial 
agents in GCF higher than their minimum inhibitor concentration against bacteria. These 
numerous systems are diversified in materials (biodegradable or non-biodegradable 
polymers) as well as in device form (solid or semi-solid, adhesive or non-adhesive 
systems). The proposed formulations include fibers, films, brushite cements, wafers, strips, 
microspheres, microcapsules, microparticles and gels (Table 3).  
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Table&3.!Summary!of!some!investigated!local!controlled!delivery!systems!for!the!treatment!of!periodontitis.!
Drug delivery 
system 
Antimicrobial 
drug 
Drug 
load 
(w/w) 
Vehicle 
In vitro 
release at 
24 h 
Prolonged 
release  
duration 
Degrad-
ability of 
carrier 
Clinical study 
Refer-
ence 
Monolithic 
fibers 
Tetracycline HCl 25 % Ethylene vinyl acetate n.a. 9 d No Significant probing depth 
reduction (n = 26) 
[41] 
[42] Actisite® (Alza Corporation, Palo Alto, CA, USA)* 
Strip Doxycycline 30 % Polyethylmethacrylate > 50 % 4 d No No [43] 
Film 
Metronidazole 10 % PLA  
+ dichloromethane 
38 % 
(48 h)  
28 d Yes No [44] 
Tetracycline HCl 25 % PLGA (85:15) 
+ dichloromethane 
 
27 % 14 d Yes Decreasing bacterial count in 
intra-crevicular fluid & 
significant microbial 
inhibition for 2 weeks over 
placebo (n = 8)  
[45] 
Chlorhexidine 
diacetate 
20 %  Cross-linked protein 
(Bycoprotein + glycerol 
+ formaldehyde) 
40 % 4 d Yes No [46] 
Insert 
Chlorhexidine 
gluconate 
34 % 
(2.5 
mg) 
Hydrolyzed gelatin 
(cross-linked with 
glutaraldehyde) 
40 % 7 – 10 d Yes No additional antimicrobial 
advantage of Periochip to 
thorough SRP (n = 9) 
[47] 
[48] 
 
Periochip® (Dexcel Pharma, Northampton, UK)* 
Chlorhexidine 
gluconate 
n.a. Oxidized-dextrin-
grafted paper points  
30 % 28 d Yes No [49] 
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Drug delivery 
system 
Antimicrobial 
drug 
Drug 
load 
(w/w) 
Vehicle 
In vitro 
release at 
24 h 
Prolonged 
release  
duration 
Degrad-
ability of 
carrier 
Clinical study 
Refer-
ence 
Mucoadhesive 
gel 
Metronidazole 
 
5 % HEC + Carbopol 974P + 
polycarbophil 
n.a. n.a. No No [50] 
Tetracycline HCl 5 % HEC + PVP + 
polycarbophil 
n.a. n.a. No No [51] 
Lipid-like gel 
Metronidazole 
benzoate 
25 % Glycerilmono-oleate   
+ sesame oil 
n.a. n.a. No Significant improvement of 
clinical parameters (n = 27) 
[52] 
[42] 
Elyzol® (Dumex-Alpharma, Copenhagen, Denmark)* 
Gel 
 
Minocycline HCl 2 % HEC + aminoalkyl 
methacrylate copolymer  
+ triacetine + MgCl2  
+ glycerin 
n.a. n.a. No Significant probing depth 
reduction and clinical 
attachment gain 
(Dentomycin®) (n = 27) 
[18] 
[42] 
Dentomycin® (Blackwell -Supplies, Kent, UK)*  
Parocline® (Sunstar, Levallois-Perret, France)* 
Periocline® (Sunstar, Osaka, Japan)* 
In situ gel 
Meloxicam 3 % Pluronic 
 
n.a. n.a. No Significant improvement in 
chronic patients 
[53] 
Minocycline HCl 2 % n.a. 3 d (85 % 
drug 
released) 
In situ implants 
Doxycycline  
hyclate  
10 %  NMP (63.3 %)  
+ PLA (36.7 %) 
n.a. 7 d Yes Statistically superior to oral 
hygiene & control (n = 822) 
[54] 
 
Atridox® (TOLMAR Inc., Fort Colin, CO, USA)* 
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Drug delivery 
system 
Antimicrobial 
drug 
Drug 
load 
(w/w) 
Vehicle 
In vitro 
release at 
24 h 
Prolonged 
release  
duration 
Degrad-
ability of 
carrier 
Clinical study 
Refer-
ence 
Brushite  
cement 
Doxycycline  
hyclate 
n.a. Calcium phosphate 
biomaterials 
50 %  
(12 h) 
3.5 d No No [55] 
Wafers 
Silver nitrate 12 % PLGA (73 %) 
PEG (15 %) 
40 % 30 d in vitro,      
21 d in vivo 
Yes Significant reduction in 
anaerobic bacteria (n = 9) 
[56] 
Microspheres 
 
Minocycline HCl  
 
2 %  n.a. n.a. 14 d  Yes Reduced probing pocket 
depth compared to SRP in 
supportive periodontal 
therapy (n = 48) 
[33] 
Arestin® (OraPharma, Horsham, PA, USA)* 
 Doxycycline HCl 9 - 25 
% 
PLGA 50:50 + PCL 
+ dichloromethane 
45 - 60 % 7 - 11 d Yes Improved clinical outcomes 
(30 sites) 
[57] 
Microcapsules 
Minocycline 2, 5, or 
10 % 
Sodium alginate 
+ chitosan 
n.a. 7 d Yes Statistically significant 
suppression of pathogenic 
bacteria (n = 15) 
[58] 
Electrospun 
fibers 
Metronidazole 0.1 - 
40 % 
PLA (70:30) + acetone 15 - 40 % > 28 d Yes No [59] 
* Commercial name of the respective drug; n.a. = not available; PLA = poly(D,L-lactic acid);  PLGA  = poly(D,L-lactide-co-glycolide); HEC = 
hydroxyethylcellulose; PVP = polyvinylpyrrolidone; MgCl2 = magnesium chloride; NMP = N-methyl pyrrolidone; PEG = polyethylene glycol; PCL = poly(ε-
caprolactone); PLA (70:30) = poly(L-lactide-co-D/L-lactide) (70:30); SRP = scaling and root planing.
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Due to the etiology of periodontal diseases and the anatomy of periodontal pockets, 
the local drug delivery system designed for periodontitis treatment should satisfy some 
criteria as followed [60]: 
! It should be easy to place into the periodontal pocket and remain within the pocket 
during the whole treatment time to maintain the local drug concentration. The 
injectable delivery systems (gels, microparticles, microspheres) are convenient to be 
administered subgingivally. The bioadhesive systems are also preferable because of 
their potential adhesive force, which ensure good retention of the device after 
placement.  
! The locally applied system must deliver drug into the periodontal pocket at a sufficient 
level to suppress pathogenic bacteria and sustain the drug concentration to be 
clinically effective for a sufficient length of time. 
! To facilitate the interference of clinician and to improve the compliance of patients, 
the drug device should be biodegradable, so that it can erode after a certain period 
without any surgical procedure to remove device remnants.  
! The cost of device, the facility of production technique should also be considered as 
factors for drug research and development (R&D). 
The local controlled drug delivery systems for the treatment of periodontitis gain some 
advantages and also some potential disadvantages (Table 4) [18], [60]. 
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Table&4.!Principal!advantages!and!disadvantages!of!local!controlled!delivery!system!!for!the!treatment!of!periodontitis.!
Advantages Disadvantages 
Maintenance of drug concentration in its 
therapeutic range. 
Possible toxicity or lack of compatibility of 
material (solvent, polymer).  
Improved drug access to local site  
-> Improved clinical efficacy for a long 
duration of time. 
Mild discomfort caused by the presence of 
drug device within periodontal pocket. 
Improved pharmacokinetics  
-> Benefits to short half-lives drugs. 
Placement technique is needed to implant 
the device into target site. 
Lower total drug dosage  
-> Reduction or elimination of undesired 
side effects of drug. 
Expensive biodegradable polymer and high 
R&D cost leads to increase the price of 
some devices. 
Improved patient compliance.   
Smaller drug device with lower excipient 
quantity compared to systemic systems. 
 
 
Despite numerous studies aiming at designing and developing local drug delivery 
system for the treatment of periodontitis, only a small number of products have been 
marketed. The various pharmaceutical and practical demands as well as contradictory 
clinical results often reported for the same system challenged the R&D of these topical 
formulations. The first marketed subgingival system was Actisite®, which consists of fibers 
of ethylene vinyl acetate containing 25 % tetracycline HCl [41]. Although Actisite® 
prolonged the release of tetracycline for 9 days in vitro and showed good clinical efficacy 
[42], this system faced some difficulties in practice. These limits include the difficult and 
time-consuming placement technique for clinicians. In patients, main disadvantages were 
anesthesia needed for fiber placement, discomfort during treatment and significant adverse 
effects (gingival redness, tongue pigmentation). In addition, this system has to be securely 
fixed by cyanoacrylate adhesive due to the lack of bioadhesiveness [18]. The next 
marketed product was a lipid-like gel Elyzol® containing 25 % metronidazole, which can 
be placed easily into periodontal pocket by a provided syringe. Nevertheless, following 
various clinical studies, the efficacy of this gel used in combination with scaling and root 
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planing is controversial. This is possibly due to the poor retention of Elyzol® gel within 
periodontal pocket [18]. Similarly, the clinical efficacy of Periochip®, a biodegradable 
insert consisting of chlorhexidine gluconate in hydrolyzed gelatin was not confirmed. This 
biodegradable, adhesive insert can sustain drug release over 7 days. Although, following a 
systematic review enrolling 5 clinical studies, the microbiological and clinical results on 
Periochip® in conjunction with scaling and root planing therapy are limited and 
controversial [48]. Besides, the 2 % minocycline gel which has been commercialized under 
several trademarks: Dentomycin®, Periocline® and Parocline® seems to be good in clinical 
therapy. Adjunctive Dentomycin® was reported to provide significant probing depth 
reduction and clinical attachment gain [42] as well as more advantageous outcomes in 
bleeding on probing [18]. However, these gels still lack of biodegradability, leading to the 
need of removal of the empty device after treatment. A biodegradable injectable system 
that was broadly studied is Atridox®. This system consists of a biodegradable polymer 
PLA dissolved in a biocompatible solvent NMP with 10 % doxycycline hyclate drug 
loading. It is an in situ forming system due to its change from liquid to solid state after 
injection into periodontal pocket. This implant can sustain drug release over 7 days. In a 
very large clinical study (n = 822), Atridox® performed both clinical and statistical 
superiority for all parameters when compared to oral hygiene and the vehicle alone [54].  
Briefly, biodegradable in situ forming implant seems to be a very potential local 
drug delivery system for the adjunctive periodontal therapy. The liquid nature of drug 
device facilitates their placement by simple injection technique, which can reach the deep 
periodontal pockets. Subsequently, in situ formation occurs forming a hardened implant 
with a suitable form adapted to individual crevices. However, the retention of implant and 
drug release control are important issues to be solved in the research and development for 
such type of devices. 
!  
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3.  In situ forming implants 
In situ forming implants (ISFI) are parenteral liquid drug delivery formulations 
generating (semi) solid depot after injection via a syringe into the body [61], [62]. ISFI was 
first studied in the early 1980s with the goal of developing injectable antimicrobial 
formulations for local treatment of periodontal diseases by Southern Research Institute, 
then continued by ATRIX laboratories, USA [63]. Until now, ISFI are still attracting 
considerable attentions from researchers because of their advantageous over the other 
parenteral drug delivery devices such as liquids, liposomes, emulsions, microspheres, 
microparticles. The principal benefits from ISFI are relatively lower production cost and 
simple manufacturing procedure. Moreover, ISFI (semi) solid reservoir has higher local 
retention and stable drug distribution, thus provides better-controlled drug release [62]. 
Besides dental administration, ISFI has been investigated for applications in cancer 
treatment, ophthalmic delivery systems, tissue engineering, three-dimensional cell 
culturing or cell transplantation [64]–[66]. 
ISFI can be classified into 3 main groups, based on their mechanisms of implant 
formation (Figure 1). Among the various types of ISFI, the phase separation system by 
solvent exchange is very attractive because of its great commercial potential. 
Dunn et al. [67] invented the concept of ISFI based on polymer precipitation by 
solvent exchange in 1990. They dissolved a water-insoluble and biodegradable polymer 
poly(D,L-lactide) (PLA) or poly(D,L-lactide-co-glycolide) (PLGA) in a compatible water-
miscible organic solvent N-methyl pyrrolidone (NMP). Consequently, drug was 
incorporated into the polymer solution forming a solution or a suspension after mixing. 
After injection of the formulation into the body, the organic solvent diffuses into the 
surrounding tissues while aqueous body fluid diffuses into organic polymeric phase. This 
leads to phase separation and polymer precipitation, forming a depot at injection site. The 
active pharmaceutical ingredients (API) entrapped within the polymer matrix are released 
by diffusion through the water-pores and by erosion upon polymer degradation. So far, two 
polymer precipitation systems based on solvent exchange have been commercialized, 
namely Atridox® and Eligard®. Both of these products were approved by the American 
Food and Drug Administration (FDA) and were prepared using Atrigel® technology. 
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Atridox® is a controlled-release product used for the treatment of periodontitis, 
consisting of a two syringe mixing system. Syringe A contains 450 mg of 36.7 % PLA 
dissolved in 63.3 % NMP. Syringe B contains 50 mg of doxycycline hyclate, which is 
equivalent to 42.5 mg doxycycline. After mixing, the final product is a yellow viscous 
liquid containing 10 % of doxycycline hyclate, which is injected directly into the 
periodontal pocket. Upon contact with the gingival crevicular fluid, the liquid solution 
solidifies forming a depot allowing the controlled release of drug for a period of 7 days. 
Eligard® is subcutaneous injection system providing sustained release of leuprolide 
acetate (7.5, 22.5, 30 or 45 mg) over a long period of time (1 month, 3 months, 4 months or 
6 months, respectively), which is indicated for the treatment of advanced prostate cancer. 
These products also consist of 2 syringes: syringe A prefilled with PLGA dissolved in 
NMP; syringe B prefilled with leuprolide acetate powder. Prior to administration, two 
syringe parts are mixed in order to get a homogenous dispersion of drug. The controlled 
release of drug from Eligard® formulations is achieved by the variation of polymer type. 
In situ forming 
implants  Solubility change 
Cross-linked  
systems  
Solidifying     
organogels  
Photo-initiated 
Chemical  
Physical  
Phase separation 
systems  
pH  
Solvent exchange  
Temperature 
Type 
Trigger 
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Clinical studies proved the high efficacy of 1-month and 3-month Eligard® formulations in 
reducing mean testosterone levels below the medical castration level (50 ng/dL) over 6 
month treatment [68].    
3.1.  Compositions of in situ forming implants based on solvent exchange 
Since this thesis focus on the in situ forming implants based on solvent exchange, 
the abbreviation ISFI will be used to denote the phase separation systems by solvent 
exchange. The formulation of these ISFI systems generally consists of solvent, polymer 
and drug. 
3.1.1.  Solvent 
Relatively high amounts of solvent are used in ISFI to dissolve the polymer, 
forming a polymeric solution. As this carrier is then injected into the body and solvent 
diffuses into surrounding tissues, the employed solvent must meets some requirements. It 
must be non-toxic and biocompatible, hence it does not cause any severe tissue irritation or 
necrosis at injection site. Moreover, the solvent should be water miscible to diffuse quickly 
into the body fluid and allow water to diffuse into the polymeric solution, leading to 
polymer precipitation. Suitable solvents meeting those criteria includes N-methyl 
pyrrolidone, 2-pyrrolidone, acetone, dimethyl sulfoxide, methyl acetate, ethyl acetate, 
methyl ethyl ketone, ethanol, propylene glycol, dimethylformamide, tetrahydrofuran, 
caprolactam, decylmethylsulfoxide, oleic acid, and 1-dodecylazacycloheptan-2-one. The 
four first solvents are preferred due to their solvating ability and their compatibility [67]. 
N-methyl pyrrolidone (NMP) is the most frequently used organic solvent because 
of its solvating ability; allowing to dissolve a wide range of polymers. This solvent has 
good properties such as low volatility, low inflammability and relatively low toxicity. 
Following the European chemicals agency, NMP is classified as toxic for reproduction. 
3.1.2.  Polymer 
Biodegradable polymers which can be used in ISFI includes polylactides, 
polyglycolides, polycaprolactones, polyanhydrides, polyamides, polyurethanes, 
polyesteramides, polyorthoesters, polydioxanones, polyacetals, polyketals, polycarbonates, 
polyorthocarbonates, polyphosphazenes, polyhydroxybutyrates, polyhydroxyvalerates, 
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polyalkylene oxalates, polyalkylene succinates, poly (malic acid), poly (mino acid), 
polyvinylpyrrolidone, polyethylene glycol, polyhydroxycellulose, chitin, chitosan and 
copolymers, terpolymers, or blends of the materials mentioned above. Polymers with low 
degree of crystallinity and more hydrophobicity are preferable because of their high 
solubility in organic solvents. Examples of such polymers are polylactides, 
polycaprolactones, and poly(lactide-co-glycolide). They present more amorphous regions 
to enhance solubility [69]. These polymers are also widely studied because of their safety 
approved by FDA and long history of clinical use. 
Lactic acid (LA) and glycolic acid (GA) are organic acids found in the nature, 
which have the molecular structure as below: 
 
 
)*+,-%&/(!:0).&;)(#!/,#;&,;#.!01!)(&,$&!(&$*!(%*!-)2&0)$&!(&$*5!
'()*%+(#,-./#7<=90#
 
Lactic acid exists in two active forms: L(+)-lactic acid and D(-)-lactic acid. It was 
first isolated from milk in 1780, and polylactic acid (PLA) was reported since 1932, 
although its applications in medical research has attracted interest since 1960s [71]. 
Poly(L-lactide) (PLLA) is a crystalline polymer (37 % crystallinity) presenting good 
tensile strength compared to poly(D,L-lactide) (PDLLA), which is an amorphous polymer 
[72]. 
Glycolic acid can also be found in natural products such as sugar beets, unripe 
grapes, and wheat [70]. The polyglycolic acid (PGA) has been known since 1954 to be a 
potentially low cost fibre-forming polymer and was developed as the first synthetic 
Lactic acid (!-hydroxypropionic acid), CH3CH(OH)COOH!
Glycolic acid (!-hydroxyacetic acid), HOCH2COOH!
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absorbable suture in 1962 [73]. PGA is a highly crystalline polymer (45-55 %
crystallinity), hence exhibits a high tensile strength. Both PGA and PLA undergo 
hydrolytic degradation via the bulk erosion mechanism by the non-specific scission of the 
ester backbone. They break down into glycolic acid and lactic acid, which can be excreted 
in the urine or converted into water and carbon dioxide via the citric acid cycle [72].!*hese 
two monomers can be found in the human body under normal physiological conditions, as 
by-products of various metabolic pathways and can thus be considered as non-toxic. 
Poly(lactic-co-glycolic acid) PLGA is a copolymer of PLA and PGA. 
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The product range of PLGA is large, due to the copolymerization ability of both 
PLLA and PDLLA with various ratios of monomers. PLGA biodegrades in water by 
hydrolysis of its ester linkages. In controlled release drug delivery applications, the choice 
of a PLGA with suitable degradation kinetics is important to achieve desired release 
kinetics. PLA is more hydrophobic than PGA due to the presence of methyl group, 
therefore the lactide-rich PLGA copolymers are more hydrophobic, hence absorb less 
Polyglycolic acid (PGA)                                
Polylactic acid (PLA)!
Poly(lactic-co-glycolic acid) (PLGA)
!
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water and degrade more slowly. For instance, 50/50 poly(D,L-lactide-co-glycolide) 
degrades in 1-2 months, 75/25 in 4-5 months and 85/15 in 5-6 months.  These time frames 
also depend on the PLGA molecular weight, the shape and structure of polymer matrix 
[72], [74].  
Since 1970s, PGA, PLA and PLGA interested researchers as biodegradable 
materials in dental, orthopaedic and drug delivery application [73]. There were various 
studies investigating their biocompatibility and toxicity, especially for use as materials in 
wound suture and fixation device in orthopaedic fracture. Generally, the animals, human 
and in vitro tests proved that PGA and PLA provide satisfactory biocompatibility without 
significant toxicity neither inflammatory reaction [75]. In a cytological analysis, PGA has 
also been considered as immunologically inert implant material [76]. Approved by the 
FDA for the use in human, PLGA is considered as the best-defined biomaterial available 
for drug delivery with respect to design and performance so far [72]. 
3.1.3.  Drug 
The choice of active substance depends on ISFI application. For the treatment of 
periodontitis, chosen drugs are antiseptics or antibiotics with suitable antibacterial 
spectrum [18]. In prostate cancer treatment, the peptide agonist hormone receptor 
leuprolide acetate was chosen as active drug [64]. Besides, numerous ISFI devices has 
been studied using drug varying from small molecules such as diclofenac sodium [77], 
aspirin [78] to big molecule of proteins, namely bovine serum albumin [79], human growth 
hormone [80]. The properties of drug (molecular weight, solubility, affinity to the solvent) 
and its content in the formulation can affect the drug release profile of ISFI systems.  
3.2.  Mechanism of drug release from PLGA-based in situ forming 
implants 
Numerous studies have been performed to investigate the release mechanism of drug 
from PLGA-based drug delivery system, especially in films, microspheres, microparticles, 
preformed implants [81]. PLGA-based implants relying on in situ polymer precipitation by 
solvent exchange, however, have not yet been extensively studied. The main differences of 
ISFI are: (i) the shape of ISFI can only be defined after injection of polymeric solution; (ii) 
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during the transformation from liquid to solid state, a complex physico-chemical process 
takes place, affecting the depot structure and hence the following drug release profile. 
Therefore, the knowledge of these characteristics is essential to understand the drug release 
mechanism and develop controlled-release ISFI. 
3.2.1.  Release mechanism 
Drug release from PLGA-based ISFI results from a complex physico-chemical 
process occurring within PLGA matrix, from the injection of polymeric solution until the 
end of matrix degradation. These processes begin by the solvent exchange causing the 
polymer precipitation, subsequently leading to the formation of a solid depot. Within the 
PLGA matrix, the presence of water triggers the hydrolysis of PLGA, hence cuts the ester 
bonds and increases polymer chain mobility. The decrease in polymer molecular weight 
finally leads to the erosion of the polymeric matrix, which in turn might affect drug 
release. In brief, the underlying drug release mechanism can be resumed in two principal 
processes: diffusion and erosion. These mechanisms can occur concomitantly and are 
influenced by formulation parameters as well as the surrounding environment of the 
injection site. 
3.2.1.1.  Diffusion 
Diffusion has been described as one of the main release mechanism controlling 
drug release from PLGA-based drug delivery system. It is directly related to the porosity of 
the polymer matrix, and thus on the processes of pore formation [81]. In the case of ISFI, 
the solvent exchange occurring upon contact of the polymeric solution to the aqueous 
environment leads to a liquid-liquid phase separation. The polymer solution transforms to a 
mixture of gel phase located on the surface and solution phase downside, namely two-
phase, gelled structures. It was suggested that the initial drug release occurs mainly by 
diffusion through the interconnected polymer-lean phase that exists in gel region. Thus, 
fast gelling system has high burst release compared to low gelling system [82].  
The resulting solid depot consists of polymer matrix with a negligible or significant 
quantity of water-filled pores, depending on the type of solvent and polymer. The solvents 
with high affinity to water (NMP, DMSO) have been reported to create highly porous 
structure, in contrast to the dense sponge like morphology of systems based on low water 
 INTRODUCTION 
!
! 28!
miscible solvents (triacetin, ethyl benzoate) [83], [84]. The high density of water-filled 
pores provides multiple diffusion pathways to drug molecule, therefore improves the drug 
release rate. The biodegradable polymer, PLGA is hydrolyzed in the presence of water, 
resulting in shortened polymer chain length. As water uptake is faster than polymer 
degradation, PLGA generally undergoes bulk erosion. Erosion starts when the polymer 
degradation products can be dissolved in water and thus diffuses into the surrounding 
aqueous solution. Hydrolysis and erosion increase the pore size, hence accelerate the drug 
release. These effects are more pronounced on systems based on less hydrophobic PLGA 
(low molecular weight, low lactic:glycolic acid ratio and un-capped polymer end groups), 
which have greater water absorption, hydrolysis and erosion rate [81].  
The diffusion coefficient of drug from PLGA-based ISFI is dependent on the 
diffusion coefficient in the fluid filled the pores, the porosity and the tortuosity. 
Consequently, this parameter is not constant but time-dependent due to altered depot 
structure induced by polymer degradation [81]. 
3.2.1.2.  Erosion 
Erosion has been reported to start as the polymer molecular weight goes below a 
threshold of 15 kDa. This process can be considered as a rate-controlling release 
mechanism as well as a true-release mechanism. In the first case, erosion increases pore 
formation, and thus increases the rate of diffusion [81]. Besides, erosion can be considered 
as a true-release mechanism, inducing directly drug release in the mean time of polymer 
mass loss. In a study investigating the influence of the organic salt deoxycholate in the 
medium bath on the lysozyme release from PLGA/ethyl benzoate depot, Brodbeck et al. 
[83] have found a significant increase of protein release rate. Interestingly, the addition of 
this organic salt did not impact the bulk water absorption and the phase inversion dynamic 
of the system. Instead, the increased release rate was found as the result of increased 
PLGA erosion at the surface of the injected depot. The erosion is considered as a release 
mechanism in this case. 
Other mechanisms might be involved in the control of drug release from PLGA-
based drug delivery systems including diffusion through the polymer network and osmotic 
pumping, which are well described in the literature. In the case of PLGA-based in situ 
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implants, the absorption of water leads to pronounced polymer swelling. This phenomenon 
can compensate the osmotic pressure within systems. Therefore, diffusion through water-
filled pore is usually the dominant true release mechanism [81]. 
3.2.2.  Burst release and phase inversion dynamic 
Burst release can be defined as a high amount of drug released in the first hours up 
to 24 hours, which is often reported for PLGA-based ISFI. This phenomenon occurs due to 
the fact that solid depot formation can last from a few minutes to several hours. The rate of 
diffusion of the drug substance from the coagulating polymeric solution may be more rapid 
than the release rate from solid matrix. Consequently, a high leakage amount of API can be 
observed during implant formation, namely burst release [85]. The burst release is hence 
related to the liquid-liquid phase separation process, which is characterized by the phase 
inversion dynamic.   
Phase inversion dynamic is the dynamic of the interactions that takes place between 
the polymer solution and an aqueous (non-solvent) environment, causing the formation of 
polymer membrane at the interface. Accordingly, the solvent/non-solvent diffusion lowers 
the polymer solubility, thus leading the polymer solution to phase separate into a polymer-
rich matrix surrounding dispersed polymer-lean droplets. The arrangement of this two-
phase structure determines the separation characteristics, the device morphology and thus 
the drug release kinetics [82].  The phase inversion dynamic is influenced directly by the 
properties of organic solvent.  
There were a few studies investigating the role of organic solvent type on the phase 
inversion dynamic and drug release profile of a polymeric solution. It was concluded that 
the solutions based on strong, hydrophilic solvents that are miscible with water (NMP, 
DMSO…) generally cause a fast phase inversion. The solidification of these systems often 
takes place in the order of seconds to minutes, eventually forms a highly interconnected 
network with large finger pores, leading to a high burst release. In contrast, weaker 
solvents with lower water solubility (triacetin, ethyl benzoate…) leads to slower phase 
inversion resulting in a uniformly dense structure with few pores, and hence slower release 
rates, as illustrated in Figure 4 [84]. Brodbeck et al. [83] investigated the role of solvent 
type on the phase inversion, depot morphology and resulting release profile of lysozyme 
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from 50 wt. % PLGA-based polymeric solutions. The solvents used were NMP, triacetin 
and ethyl benzoate, which have solvent strengths reducing in the same order. The resulting 
data showed lower water diffusion and thus phase separation rate when decreasing the 
solvent/non-solvent affinity. For instance, water absorption of PLGA/NMP solution 
increased up to 20 % during the first day whereas it was almost zero in triacetin or ethyl 
benzoate solutions. Up to 14 days, significant differences could be clearly seen with water 
absorption reaching almost 80 %, 20 % and less than 10 % in NMP, triacetin and ethyl 
benzoate systems, respectively. This is in good agreement with the depots structure 
observed by scanning electron microscopy (SEM) (Figure 4). Indeed, NMP system showed 
a highly porous structure whereas pores were less visible in triacetin systems and even 
much less pronounced in ethyl benzoate systems. Interestingly, lysozyme release rate was 
much faster in NMP system (≈ 35 % drug release in 24 h) compared to the others (≈ 2 %). 
The subsequent release of triacetin system was faster than that of ethyl benzoate system 
due to the finite but higher water solubility of triacetin compared to ethyl benzoate (7 % 
versus 0.4 %, respectively).  
 
Figure&4.!SEM!images!and!scheme!of!matrix!structure!and!postulated!preferred!pathway!of!protein!release!for!NMP!(C),!triacetin!(D),!and!ethyl!benzoate!(E)!as!solvents.!In#schemes:#grey#regions#indicate#the#polymer=rich#phase,#bright#areas#
represent#water#filed#pores,#and#arrow#thickness#indicates#release#rates.##
Adapted#from#[86].#
Briefly, the phase inversion dynamic can be considered as an important 
characteristic of ISFI, which is essential for the gelation rate, depot morphology, and thus 
burst release as well as the overall drug release profile. Solvent type is important but is not 
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the only factor influencing the phase inversion dynamic of an in situ polymer precipitation 
system. 
3.3.  Impacts of various parameters on the drug release of PLGA-based 
in situ forming implants 
Many factors might influence drug release of PLGA-based ISFI, including the 
formulation parameters as well as the properties of the surrounding environment at the 
injection site.  
3.3.1.  Solvent 
As mentioned above, the organic solvent has a significant impact on the formation 
of the polymer matrix and subsequent drug release properties. Depending on the solvent 
strength (water miscibility) of solvent (Table 5), the resulted polymer matrix can be porous 
or almost dense without any pores. The solvents with high water miscibility (NMP, 
DMSO…) promote fast liquid-liquid phase separation and thus a porous structure, which 
can increase drug release. In contrast, the more uniform structure created by weaker 
solvents (triacetin, ethyl acetate, ethyl benzoate…) results in slower drug release [83], [87]. 
If all the solvents are miscible with water, the differences in drug release profiles of the 
systems depend on the polymer-solvent affinity. Comparing the 40 % PLA/NMP or DMSO 
systems, Kranz and Bodmeier [88] found that NMP has higher solvating power for PLA 
compared to DMSO. Therefore, the solution of PLA in NMP performed a slower polymer 
precipitation and subsequent less porous implant structure with slower drug release.  
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Table&5.!Aqueous!solubility!of!different!solvents!used!for!in#situ!forming!implants.!
Adapted#from#[86].!
Solvent Solubility in water (%) 
N-methyl pyrrolidone (NMP) Miscible 
Dimethylsulfoxide (DMSO) Miscible 
Polyethylene glycol (PEG) Miscible 
PEG-dimethylether (PEG-DME) Miscible 
Glycofurol Miscible 
Triacetin ≈ 7 
Triethyl citrate ≈ 5.7 
Ethyl benzoate ≈ 0.4 
Benzyl benzoate ≈ 0.15 
 
Besides, the polarity of solvent has also an impact on the drug release, due to its 
influence on polymer degradation. Slower degradation rate of PLGA has been observed in 
polar aprotic solvents (DMSO, NMP, triacetin) than in polar protic solvent (PEG 400, 2-
pyrrolidone, triethyl citrate). It was suggested that the polar protic solvents could donate 
hydrogen and possibly form hydrogen bonds with PLGA. Thus, the ester bonds of 
polymers can be exposed to residual water of solvent, and as a consequence enhance 
hydrolysis. In contrast, the ester bonds of the polymer might be shielded inside the 
polymer chains in the case of polar aprotic solvents, hence get less access to water [89]. 
This phenomenon has been confirmed in the study of Schoenhammer et al. [90], where 
they found block-copolymers during the degradation of PLGA in PEG 300. By capping the 
solvent with an alkyl-end group (PEG-dimethyl ether), the degradation rate of PLGA 
significantly reduced. Furthermore, the degradation of PLGA increased when increasing 
the water content of both protic and aprotic solvents [89]. Accordingly, the type of solvent 
and its water content should be taken into account for the design of PLGA-based ISFI, 
especially for the controlled-release devices over prolonged period of time. 
3.3.2.  Polymer 
The biodegradable polymer PLGA has been widely used in the formulation of in 
situ polymer precipitation systems. The biodegradation of PLGA provides great benefits to 
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the drug delivery system because of its capacity to modulate drug release profile. The 
effect of physico-chemical properties of PLGA on the resulting drug release kinetics has 
been extensively investigated in the literature. 
3.3.2.1.  Molecular weight 
The molecular weight (Mw) is a substantial property of PLGA, which is 
proportional to the polymer chain length and thus also proportional to its inherent 
viscosity. According to Ahmed et al. [91], low Mw PLGA results in a less hydrophobic 
polymer with increased rate of water absorption and matrix degradation, thus provide 
faster drug release rate compared to the higher Mw. The release profiles of the protein p55 
tumor necrosis factor receptor (sp55-R) from an injectable implant system significantly 
reduced when increasing PLGA 50:50 Mw (inherent viscosity η increased from 0.24 to 
0.38, 0.47 and 0.55 dL/g, respectively). This was explained by the fact that higher Mw 
polymers tend to solidify faster than low Mw polymers, leading to a smaller burst release 
and a higher amount of drug entrapped into polymer matrix. Regarding the degradation, it 
was found that low Mw polymer (η = 0.24 dL/g) degrades in a shorter time (5 days) to 
produce oligomers of 10 kDa compared to high Mw polymer (η = 0.59 dL/g) (over 40 
days). This trend is in agreement with slower release observed for high Mw polymer 
systems.  
In another study comparing the leuprolide acetate (LA) release profiles from 
PLGA/NMP systems, the PLGA RG 502 H led to a much lower initial release than RG 503 
H (18.8 vs. 48.1 %). Subsequently, a fast release phase was observed with RG 502 H, 
whereas a much slower release rate was observed with RG 503 H [92]. These trends were 
further evaluated and clarified later by Astaneh et al. [93]. It has been found that the 
morphology of PLGA-based solid depot correlated with the drug release profile. Among 3 
types of PLGA different in Mw, PLGA RG 502 H (Mw = 12 kDa) and PLGA RG 504 H 
(Mw = 48 kDa) presented thin skin and finger-like pore structure and thus similar shape of 
release profile. Due to the higher Mw, system based on RG 504 H released drug in a 
slower rate compared to RG 502 H. However, the PLGA RG 503 H (Mw = 34 kDa) depot 
exhibited a cellular-based surface with a sub-layer presenting a sponge-like structure. The 
cracking of cells containing dissolved LA leads to the highest content of initial drug 
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release compared to the others. After this burst, drug release from RG 503 H formulation 
was very slow because of the lack of diffusion path in such spongy structure.   
3.3.2.2.  Polymer concentration 
The effect of polymer concentration on the drug release kinetic from in situ 
polymer precipitation devices has widely been studied in the literature. Higher polymer 
concentration leads to increased viscosity and hydrophobicity of polymer solution 
compared to lower polymer concentration. Consequently, water influx rate, phase 
separation rate and diffusion of drug into release medium were limited, leading to slower 
release rates [82]. For instance, PLGA 50:50/glycofurol systems with increasing polymer 
concentration from 10 %, 15 % to 20 % reduced the bovine serum albumin (BSA) burst 
release. Similarly, the initial protein sp55-R release from 20 % PLGA matrix was smaller 
than from 10 % PLGA matrix. However, in both case, the long-term release kinetics after 
the burst were independent on the polymer concentration [91], [94].  
Moreover, it is suggested that higher polymer concentration conducts to a dense 
polymer matrix structure, hence increases the required time for degradation of the solid 
implant [95]. Graham et al. [82] reported the change in morphology of PLGA/NMP depots 
from finger to sponge transition when PLGA concentration increased from 40 % to 50 % 
and 60 %. As a result, the initial release was slowed down. In a recent study, it has been 
shown that in situ implant formulations with increasing PLGA concentration (20 %, 30 % 
and 40 %) sustained the release of haloperidol more effectively, regardless the type of 
solvent. For instance, in DMSO, the initial burst of drug was reduced (20 %, 17 % and 15 
% within the first 24 hours) and the release was extended over 24, 31 and 45 days, 
respectively [87].  
The degradation of PLGA matrix is known as a hydrolytic process resulting in the 
formation of carboxyl end groups which are able to catalyze the hydrolysis of other ester 
bond, namely autocatalysis [96]. Depending on matrix size, the diffusion pathways of 
degradation products are different; altering the neutralization of generated acids [97].  
Thus, the local degradation rate and subsequently the erosion characteristic of PLGA 
matrices are varied on system morphology. This dependence was pronounced in the case 
of PLGA-based films or PLGA-based microparticles, where degradation rate increased 
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with increasing device size [97], [98]. Similar effect can also be observed in the case of 
PLGA-based ISFI, hence altering the underlying drug release profiles. 
3.3.2.3.  Functional-end group 
The end group of polymer PLGA can be uncapped (carboxyl-end group) or capped 
with a hydrophobic ester group (ester-end group), leading to change in its chemical 
properties. Polymers with carboxyl-end group are more hydrophilic, thus increase the rate 
of water absorption and subsequent hydrolysis and erosion [81], [87]. Therefore, the 
functional-end group has a considerable impact on the drug release rate.  
In some prior studies, PLGA with carboxyl-end group has been reported to slow 
down the drug release rate compared to PLGA with ester-end group because of polymer-
protein interaction. For instance, the interaction of PLGA RG 503 H (carboxyl-end group) 
and the protein L-Asparaginase reduced the burst and subsequent release of drug compared 
to PLGA RG 503 (ester-end group) [99]. An ionic interaction between the terminal 
carboxylic end groups of PLGA and the basic amino acids of leuprolide acetate possibly 
occurred, thereby hindered drug diffusion [92]. 
3.3.2.4.  Ratio of lactic/glycolic acid (L:G) 
PLGA copolymers can be prepared in any ratio of lactic to glycolic acids. This 
proportion affects the polymer cristallinity and thus, the water uptake and degradation rate 
[91]. Due to the more hydrophilic property of PGA compared to PLA, low L:G ratio 
PLGA polymers are less hydrophobic than high L:G ratio. Consequently, they absorb more 
water and degrades more quickly [87], [95]. Since primary hydrolysis site of PLGA are the 
G-G or L-G linkages, the ester linkages of PLGA 50:50 are more accessible to water than 
those of the PLGA 75:25, causing faster degradation. Especially, the PLGA 50:50 
polymers are hydrolyzed and degrade much faster than those with higher proportion of 
either monomer. Consequently, both the burst release and the overall release rate can be 
reduced by increasing L:G ratio of PLGA. In practical results, Eliaz and Kost [91] have 
found that at high Mw, the PLGA 50:50 (η = 0.55 dL/g) leaded to higher protein release 
rate than PLGA 75:25 (η = 0.59 dL/g). Whereas at low Mw (η = 0.24 dL/g), the initial 
release reduced in increasing L:G ratio from 50:50 to 75:25. 
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3.3.3.  Drug 
3.3.3.1.  Drug properties 
In ISFI systems, drug can either be dissolved or dispersed into the polymeric 
solution, depending on its solubility in organic solvent. Since diffusion is considered as the 
main drug release mechanism, in which the drug must be dissolved in water before being 
release, the solubility of drug in the release medium is also an important parameter [81]. 
For example, risperidone and paliperidone present good solubility in NMP (69 mg/mL and 
40 mg/mL, respectively) but low solubility in DMSO (< 10 mg/mL) and poor solubility in 
phosphate buffer (< 0.2 mg/mL). These drugs were either dissolved in NMP or dispersed 
in DMSO (20 % drug loading). The resulting drug release kinetics were significantly 
different. Both ISFIs exhibited fast extraction of solvent in the surrounding aqueous 
medium. This led to a rapid release of the dissolved drugs from NMP-based ISFI but a 
sustained release in DMSO-based ISFI because most of the dispersed drug particles were 
encapsulated in the matrix after fast polymer precipitation [100]. On the other hand, the 
solubility of drug can alter the solvent exchange of the polymer solution, thus modify the 
drug release rate. Generally, hydrophilic drug leads to higher diffusion (swelling) rate and 
degradation rate than hydrophobic drug. It was assumed that the practical insoluble drug 
haloperidol could inhibit water diffusion into the matrix, thereby slowed down the erosion 
of implant and caused further decrease in drug release [87]. 
The release of drug from PLGA matrix is also dependent on the chemical property 
of drug. The basic drugs were found to create a strong ionic interaction with the polymer, 
keeping drugs dissolved in the matrix. This interaction shields the polymer terminal 
carboxyl groups, therefore declines the matrix erosion. Consequently, the drug diffusion 
through the matrix is restrained. In contrast, due to weak interaction with PLGA, the acidic 
and neutral drugs quickly precipitate out as crystals in the matrix during release time. 
Therefore, the solubility of these drugs in the hydrated matrix becomes the dominant 
parameter affecting drug diffusion [101], [102].  
On the other hand, drug can accelerate polymer degradation, thus leading to its 
faster release. The free acid N-acetyl cysteine encapsulated in PLGA 50:50 implant led to 
plasticization, increased catalytic degradation of polymer matrix, resulting in faster drug 
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release [103]. Another acidic drug, aspirin was found to facilitate the degradation of PLGA 
polymers and consequently faster release of drug from PLGA-based in situ gel system 
[78]. The plasticization effect was also observed in the case of ketoprofen, where hydrogen 
bonding of this drug and PLGA caused a lubricant effect on polymer chain and thus an 
accelerated drug release [104], [105]. 
3.3.3.2.  Drug concentration 
Drug loading can play a considerable role in modifying the release mechanism and 
resulting release rate of ISFI systems. Eliaz and Kost [91] investigated the impact of drug 
loading in injectable implant containing the protein sp55-R as an active agent and bovine 
serum albumin (BSA) acted as a carrier for sp55-R. They demonstrated that for both 
proteins, the release rate from the devices depended on the drug loading. At BSA loading 
of 3 % or lower, similar drug release profiles were observed, suggesting that the release 
mechanism was degradation dependent. At BSA loading of 10 % or higher, the drug 
release rate increased with increasing BSA content, indicating that both the diffusion and 
degradation affected the drug release. It was assumed that the high protein loading led to a 
more porous structure matrix, providing interconnected diffusion pathways, thus increasing 
matrix degradation and protein release. This correlates well with the in vivo results, in 
which more extended sp55-R serum concentration was measured in the case of 10 % BSA 
loading compared to 3 % (35 days vs. 20 days) [94]. 
For low Mw drug, the effect of drug loading was also found to be in agreement 
with these previous studies. When altering the fluorescein content of PLGA/NMP systems 
from 0.5 to 5 %, two different trends were observed. At low drug content (0.5 % or 1 %), 
there was no significant difference in drug release rate at 1 hour, 1 day and 1 week. 
However at higher drug content (2 % and 5 %), significantly higher release rates were 
observed [106]. Consequently, the increased drug loading did not only increase the initial 
drug release concentration but also the total release rate. 
3.3.4.  Additives 
The presence of a second polymer is often reported to modify drug release kinetics 
from in situ forming polymer matrices. It was suggested that the addition of a hydrophilic 
polymer into NMP-based depots could be a valuable tool to adjust their release properties. 
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For example polyvinylpyrrolidone (PVP) is known to influence the morphology of phase 
inversion membranes. Graham et al. [82] showed that the addition of only 3 wt. % PVP 
increased dramatically (8-fold) the liquid-liquid phase separation rate of PLGA/NMP 
solution. However, neither the water influx rate nor the overall depot morphology did 
change significantly. In contrast, the drug release rate, especially during the gel formation 
period (t < 1 day) was much higher for the solution containing PVP.  
The amphiphilic copolymer Pluronic also altered the release of lysozyme from 
PDLA/NMP solution but under different mechanisms. Pluronic triblock copolymers 
consist of blends of poly(ethylene oxide) (PEO)/poly(propylene oxide) (PPO)/poly-
(ethylene oxide) (PEO). In polymer blend systems, the hydrophobic PPO segments anchor 
in the polymer matrix, while the hydrophilic PEO segments extend into the surrounding 
aqueous phase. Due to the increased water uptake related to hydrophilic PEO blocks, the 
phase inversion rate of polymer solution increased. Nevertheless, the preferential 
segregation of Pluronic (PEO segments) into the hydrophilic polymer-lean phase primarily 
affected the release characteristic of the system. Increasing the Pluronic concentration 
(from 3.6 to 7.2 %) resulted in a decrease in the initial release rates as well as a change in 
the overall release profile. On the other hand, at the same Pluronic concentration (5.4 %), 
increasing PEO block length led to a reduced burst release but did not affected the drug 
release rate [84], [107]. Patel et al. [106] however found that Pluronic only reduced the 
burst release of fluorescein form PLGA/NMP system at 2.5 %. No significant difference in 
release profiles was reported when using Pluronic at lower neither higher concentration. 
Another way in which the drug release can be influenced by the change of phase 
inversion rate is by adding a co-solvent. Co-solvents with low water miscibility were 
reported to restrain the phase inversion process, leading to less porous structure and 
subsequently slower burst release. Such investigated co-solvents were glycerol, ethyl 
heptanoate [108] or triacetin [82], [109]. 
Some other authors have investigated the effect of plasticizer additive on the 
release profile of the semi-cristalline polymer PLLA matrix. As expected, the high Tg of 
polymer PLLA reduced from 67.3 oC to 59.4 oC after adding 5 wt. % PEG 4000 into the 
matrix, thus accelerated the polymer degradation onset. Consequently, the burst release of 
heparin from plasticized matrix was suppressed, followed by a faster drug release 
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compared to the matrix without plasticizer. This could be explained by the increased 
hydrophilicity of PEG-plasticized PLLA that improved the solubility of heparin in the 
matrix [110]. Similarly, the addition of PEG 400 into the PLGA/NMP solution led to the 
suppression of the initial release of aspirin. However, the subsequent release of aspirin did 
not change significantly [78]. 
Finally, the addition of an excipient that can interact with the drug is also an 
effective way to modify drug release profile from PLGA system. For instance, the cationic 
chitosan can interact with negatively charged drugs to hinder drug diffusion out of the 
matrix. It has been found that the re-encapsulation of thymosin alpha 1 in chitosan before 
charging into PLGA/NMP ISFI systems effectively slowed down drug release. Not only a 
much lower initial release was reported but the overall continuous release period was also 
prolonged [109]. 
3.3.5.  Injection site 
In vitro – in vivo correlation is an important issue for any drug delivery systems, 
due to the fact that in vitro conditions cannot always imitate the real in vivo condition. 
Especially for ISFI systems, there is no standardized in vitro release method so far, the in 
vitro release set-ups are very different and can lead to significant variations in the obtained 
results. To understand this correlation, there were some studies investigating the influence 
of injection site on ISFI drug release kinetics, including the impact of composition of body 
fluid in vitro as well as the real release profiles in vivo. 
3.3.5.1.  Bath composition 
It is known that there are many potential reactions between the injectable drug 
solution and the surrounding aqueous solution at injection site. For example, acids and 
bases can have pronounced effects on PLGA degradation, subsequently influencing the 
drug release rate. In vitro condition normally employs the phosphate-buffered saline (PBS) 
pH 7.4 as the physiological solution for testing. However, there are other compositions 
existing in the body fluid (enzyme, ester lipid, organic salts…), among that, triglyceride 
and organic salts are found in subcutaneous space.  
The impacts of triglyceride (triacetin) and deoxycholate (an organic bile salt) on the 
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phase inversion and drug release dynamics of lysozyme on PLGA/solvent systems were 
investigated by Brodbeck et al. [83]. It was found that the addition of 6 % triacetin in PBS 
solution resulted in a decrease in the burst release of PLGA/NMP, but still presented as a 
rapid phase inversion, high burst system. Nevertheless, in the PLGA/ethyl benzoate 
system, a much higher initial release and significant elevation in overall protein release 
rate was reported. This could be explained by the fact that the strong, hydrophilic solvent 
NMP-based system was insensitive to the weak, less hydrophilic solvent triacetin 
presented in the bath. Thus, the phase inversion and drug release dynamic of NMP systems 
was not significantly influenced. In contrast, for the hydrophobic solvent ethyl benzoate, 
triacetin could diffuse from the aqueous solution and therefore increased the hydrophilicity 
of the polymer solution. Consequently, overall depot viscosity decreased and water uptake 
increased, leading to faster phase inversion dynamic and faster drug release. Regarding the 
impact of deoxycholate on the PLGA/ethyl benzoate system, a steep increase of protein 
release was reported after addition of this organic salt from 0.5 to 3 wt. %. Whereas no 
change in phase inversion dynamic and water absorption was observed, this alteration was 
supposed to be the result of PLGA erosion at the surface of the injected depot. 
3.3.5.2.  In vitro – in vivo correlation 
To understand the correlation between in vitro and in vivo behavior of PLGA-based 
ISFI, Patel et al. [111] conducted a study, in which implant formation and drug release 
were measured in both conditions. The administration of ISFI in vivo was varied from 
subcutaneous injection to necrotic, non-necrotic and ablated tumor (in rat). The obtained 
results showed that the burst release from ISFI in vivo was significantly greater than in 
vitro for all formulations. Varying in vivo environment led to variations in drug release 
with fastest release in ablated tumor followed by implants in non-necrotic tumor, in 
subcutaneous tissue and finally in necrotic tumor. In addition, ultrasound implant imaging 
method revealed that in vivo ISFI solidified much quicker than what has previously been 
shown in vitro. Thus, the rate of implant formation correlated with the rate of implant drug 
release.  
However, these results are discordant with a previous study, in which little 
difference between solvent exchange and implant precipitation in vitro and in vivo 
(subcutaneous in rat) was found by electron paramagnetic resonance (EPR) method [112]. 
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Regarding the release kinetics, some previous studies reported good agreement between in 
vitro and in vivo release. Liu et al. [109] found that the release of thymosin alpha1 from 
PLGA/NMP/triacetin in vitro was slightly slower than in vivo (subcutaneous in rat). 
Nevertheless, both in vitro and in vivo release followed Higuchi kinetics and the linear 
correlation coefficient between them was 0.9, showing a good correlation. In a precedent 
study, the sustained release of human growth hormone in vivo by injection into 
subcutaneous tissue of rat was obtained from PLGA/ethyl benzoate solution, as in the case 
of in vitro experimentation [80].  
Since there existed controversial results on the correlation between in vitro – in 
vivo release of ISFI, it is so still challenging to conclude about the difference in the 
behavior of ISFI systems in these two environments. Besides the effect of different 
composition of release medium in vitro and in vivo, its amount is also a factor altering 
implant formation and subsequent drug release. Generally, the amount of body fluid in vivo 
is low, thus the depot structure can be varied. The shape of hardened depot is also not 
similar in vivo to in vitro, possibly leading to different degradation rates of PLGA matrix. 
Eliaz et al. [94] showed that increased injection speed of polymer solution into 
subcutaneous tissue can result in the formation of a more compacted structure of implant, 
thus burst release can be reduced in vivo. Therefore, artificial effects should also be taking 
into consideration when comparing the results from in vitro and in vivo tests. 
4.  Research objectives 
The present study aimed to develop new in situ forming implants (ISFI) for the 
treatment of periodontitis with improved adhesive properties. These systems were prepared 
from the biodegradable polymer, polylactic acid (PLA) or poly(lactic-co-glycolic acid) 
(PLGA) dissolved in the biocompatible solvent N-methyl pyrrolidone (NMP). With the 
addition of bioadhesive agents and plasticizers, the developed ISFI would have 
bioadhesiveness and convenient mechanical properties to avoid the risk of premature 
expulsion from periodontal pocket. The release of antibiotic from depot system would be 
controlled for a prolonged period of at least 7 days, simultaneously with the degradation of 
PLGA matrix. However, the underlying drug release profile would be modified due to the 
presence of these additives. Therefore, their effects on the drug release kinetics were 
investigated to compromise both mentioned requirements. 
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The main objectives of this research includes: 
(i) Preparation and characterization of the mechanical properties of ISFI. 
(ii) Investigation of the effects of formulation parameters (the type and content of 
PLGA polymer, bioadhesive agent, plasticizer) on resulting drug release kinetics. 
(iii) Elucidation of underlying drug release mechanisms based on the physico-chemical 
techniques such as: optical microscopy, gel permeation chromatography (GPC), 
electron paramagnetic resonance (EPR), proton nuclear magnetic resonance (1H 
NMR). 
(iv) Evaluation of antimicrobial activity of developed ISFI by microbiological tests on 
the complex periodontal samples and on isolated bacteria from gingival crevicular 
fluid of periodontitis patients.  
!  
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Abstract 
Novel in situ forming implants are presented showing a promising potential to overcome 
one of the major practical hurdles associated with local periodontitis treatment: limited 
adhesion to the surrounding tissue, resulting in accidental expulsion of at least parts of the 
implants from the patients’ pockets. This leads to high uncertainties in the systems’ 
residence times at the site of action and in the resulting drug exposure. In the present study, 
the addition of different types and amounts of plasticizers (acetyltributyl citrate and dibutyl 
sebacate) as well as of adhesive polymers (e.g., cellulose derivatives such as 
hydroxypropyl methylcellulose) is shown to allow for a significant increase in the 
stickiness of poly(lactic-co-glycolic acid)-based implants. The systems are formed in situ 
from N-methyl pyrrolidone-based liquid formulations. Importantly, at the same time, good 
plastic deformability of the implants can be provided and desired drug release patterns can 
be fine-tuned using several formulation tools. The antimicrobial activity of this new type 
of in situ forming implants, loaded with doxycycline hyclate, was demonstrated using the 
agar well diffusion method and multiple Streptococcus strains isolated from the oral 
microflora of patients suffering from periodontitis. 
Keywords: in situ forming implant; periodontitis; local drug delivery; PLGA; doxycycline 
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1. Introduction 
“Periodontitis” can be defined as “a disease that affects the periodontal structures 
and, as a result of interactions between periodontopathogens and the host immune 
response, leads to the destruction of the tooth supporting tissues, periodontal ligament and 
alveolar bone” [1–3]. Briefly, microorganisms colonizing the patients’ periodontal pockets 
are considered as a major factor, causing inflammation and tissue destruction [4]. It seems 
that the microflora in the disease state is different from that in healthy subjects. For 
example, the number of gram negative anaerobic bacteria is likely to be increased and 
certain clinical forms of periodontitis might be associated with specific microbiota [5]. 
Recently, Silva-Boghossian et al. [1] reported that Streptococcus species (such as 
Streptococcus sanguinis) are also associated with suppuration in periodontitis subjects. Up 
to date, the exact mechanisms underlying this disease are not yet fully understood. It is 
hypothesized that: (i) suspected periodontal pathogens produce biologically active 
molecules, which directly attack the host tissue, and/or that (ii) the immune response of the 
host to these pathogens results in the tissue destruction. The consequence of the tissue loss 
is the deepening of the periodontal pockets, and -once the mechanical anchorage of the 
tooth becomes insufficient -the latter is lost. Periodontitis is indeed the main cause for 
tooth loss in adults [6]. 
At present, the standard treatment method of periodontitis is the mechanical 
removal of the bacteria (especially of the bacterial biofilms): a procedure, which is also 
called “root planing”. However, the geometry of the patients’ pockets can be very 
disadvantageous, hindering complete bacterial removal and in various cases the pathogens 
re-colonize the cavities after the treatments. To minimize the risk of this re-appearance of 
the pathogenic microorganisms, the use of different antimicrobial drugs has been proposed 
[4,7,8], in combination with root planing. This includes antibiotics (e.g., tetracycline 
[9,10], doxycycline [11–14], minocycline [15–17], and metronidazole [18,19]) as well as 
antiseptic agents (e.g., chlorhexidine) [20–22]. A major challenge for this type of drug 
treatment is the appropriate administration: (i) Systemic administration leads to the 
exposure of the entire organism to the respective drugs, resulting in potentially severe side 
effects and development of bacterial resistances. (ii) Mouth rinsing does not allow 
achieving sufficient drug concentrations in the periodontal pockets. (iii) Local drug 
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delivery systems, releasing the active agent in a time-controlled manner over a pre-
determined period of time directly at the site of action, are currently considered as the most 
promising approach. 
A variety of local controlled drug delivery systems for periodontitis treatment have 
been proposed, including fibers [23,24], films and strips [25–28], inserts and wafers [29–
32], microparticles [32–34], gels and other semi-solid formulations [35–41], and 
biodegradable in situ forming implants [42]. The latter type of systems provides important 
advantages, namely: (i) Relatively easy administration using standard syringes. 
(ii) Efficient spreading within the periodontal pockets. Consequently, the geometry and 
size of the resulting implants is adapted to each individual cavity (“personalized”). 
(iii) The resulting drug release rate can be time-controlled. (iv) There is no need to remove 
empty remnants. (v) Biocompatible excipients can be used. 
Atridox® is such an in situ forming implant formulation, which is commercially 
available. It consists of the biodegradable and biocompatible matrix former poly(D,L-lactic 
acid) (PLA, 36.7 %), the organic solvent N-methyl pyrrolidone (NMP, 63.3 %), and is 
loaded with 10 % doxycycline hyclate. The PLA is dissolved in the NMP. Upon injection 
into the periodontal pocket, the NMP diffuses into the surrounding environment and water 
penetrates into the formulation. Consequently, the solubility of the PLA decreases and the 
polymer precipitates, entrapping the drug [43–46]. The latter is released at the site of 
action through the degrading polyester matrix during about 1 week. A multicenter clinical 
trial has shown the superior efficacy of Atridox® compared to oral hygiene in patients with 
chronic adult periodontitis [47]. However, a major practical disadvantage of this type of 
systems is the limited adhesion of the in situ formed implants to the environmental tissue. 
Consequently, parts of the devices, or the entire implants can accidentally be expulsed 
from the periodontal pockets. This is in part caused by the non-negligible flow of gingival 
crevicular fluid in these cavities: a few to dozens of microliters per hour have been 
reported in the literature, depending on the severity of disease [48]. Thus, there is a 
considerable uncertainty how much drug really reaches its target site. To reduce this 
uncertainty, the administration of Atridox® is recommended to be accompanied with the 
placement of a periodontal dressing or cyanoacrylate dental adhesive. But this additional 
procedure complicates the administration of the system (increasing the costs and 
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prolonging the time of the intervention), and the efficacy of such “in-place holders” is not 
guaranteed. 
The major aim of the present study is to help overcoming this crucial practical 
hurdle of limited bioadhesion of the in situ formed implants. The idea is to add different 
types of compounds, namely plasticizers and bioadhesive polymers, to the liquid 
formulations in order to improve the adherence of the devices to the surrounding tissue, 
resulting in prolonged and more reliable residence times in the periodontal pockets. In 
addition, the impact of these additives on other key properties of the systems was to be 
investigated, namely their plasticity/elasticity and drug release kinetics. For reasons of 
comparison, the commercially available drug product Parocline® was studied [a “dental 
gel” consisting of hydroxyethylcellulose, magnesium chloride, Eudragit® RS, triacetin, 
glycerol and minocycline (2 %)]. 
2. Materials and methods 
2.1. Materials 
Poly(D,L-lactic-co-glycolic acid) (PLGA, Resomer® RG 502 H; Evonik, 
Darmstadt, Germany); acetyltributyl citrate (ATBC) and dibutyl citrate (DBS) (Morflex, 
Greensboro, NC, USA); hydroxypropyl methylcellulose (HPMC, Methocel® E5, E50; 
Colorcon, Dartford, UK); poloxamer (Lutrol® micro 68, 127) and polyvinylpyrrolidone 
(PVP; Kollidon® 25) (BASF, Ludwigshafen, Germany); hydroxypropyl cellulose (HPC; 
Klucel® LF Pharm) and hydroxyethyl cellulose (HEC; Natrosol® 250 G Pharm) (Hercules, 
Wilmington, DE, USA); N-methyl pyrrolidone (NMP, 99 %), glucose and cysteine 
hydrochloride (Acros organics, Geel, Belgium); doxycycline hyclate (Fagron, Colombes, 
France); sodium metabisulfite (Merck, Darmstadt, Germany); agarose (GenAgarose® LE; 
Genaxxon BioScience, Ulm, Germany); Columbia agar base and agar (Oxoid, 
Basingstoke, UK); defibrinated horse blood (E&O Laboratories, Burnhouse, UK); 
Parocline® (2 % minocycline; Sunstar France, Levallois-Perret, France). 
2.2. Preparation of the liquid formulations 
PLGA (28 %, 32 % or 37 % w/w, based on the total liquid formulation without 
drug) was dissolved in NMP at 25 °C for 30 min under stirring in a glass vial. Optionally, a 
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plasticizer (ATBC or DBS) and a second polymer (10 % or 20 % w/w, based on the PLGA 
mass) was/were added and the mixture vortexed for 3 min, followed by standing for 3 h at 
25 °C. Subsequently, doxycycline hyclate (2 %, 5 % or 10 % w/w, based on the total liquid 
formulation without drug) was added, and the mixture vortexed for 3 min, followed 
standing for 3 h at 25 °C. To eliminate air bubbles, the formulations were ultrasonicated for 
10 min. The formulations were stored at -20 °C and protected from light to avoid drug 
degradation. 
2.3. In situ implant formation and drug release measurements 
One hundred microliters of the respective formulation was injected at the bottom of 
an Eppendorf vial using a standard syringe. One and a half milliliters preheated (37 °C) 
phosphate buffer pH 7.4 (USP 35) was carefully added using a pipette, initiating solvent 
exchange and implant formation. The vials were horizontally shaken at 37 °C at 80 rpm 
(GFL 3033; Gesellschaft fuer Labortechnik, Burgwedel, Germany). At pre-determined 
time points, the bulk fluid was completely withdrawn and replaced with fresh phosphate 
buffer pH 7.4. The drug content in the samples was determined UV-spectrophotometrically 
(λ = 325 nm; UV-1650PC, Shimadzu, Champs-sur-Marne, France). For reasons of 
comparison, the commercially available formulation Parocline® was also studied (note that 
this product contains a different drug: minocycline). In this case, the 100 µL of formulation 
was injected using the supplied syringe and 0.01 % sodium metabisulfite was added to the 
release medium to improve the drug’s stability. The drug content was determined UV-
spectrophotometrically at λ = 324 nm (UV-1650PC). Each experiment was conducted in 
triplicate, and the results are presented as mean values ± standard deviation. 
2.4. Monitoring of dynamic changes in the implants’ mass 
Implants were prepared and treated as described in Section 2.3. In situ implant 
formation and drug release measurements. At pre-determined time points, implants were 
weighed (after removal of excess water by careful blotting with precision wipes) [mass 
(t)]. The mass change in percent was calculated as follows: 
mass change (%) = 100 * [mass (t) – mass (t=0)] / mass (t=0)  (1) 
where mass (t=0) is the initial weight of the formulation used for implant preparation.  
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2.5. Mechanical and adhesive properties 
The mechanical and adhesive properties of the investigated in situ forming implants 
were determined with a texture analyzer (TA.XT.Plus; Stable Micro Systems, Surrey, UK) 
using the experimental set-up schematically illustrated in Figure 1.  
 
Figure'1.! Schematic!presentation!of! the!experimental! set2up!used! to!determine! the!mechanical!and!adhesive!properties!of!the!investigated!in#situ!forming!implants.!
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Agarose was dissolved in boiling water (0.6 % w/v), and the solutions were cast 
into Petri dishes (diameter = 9 cm). Upon cooling to room temperature, gels formed. At the 
center of the gels, cylindrical holes (diameter = 6 mm) were made and filled with 100 "L 
liquid formulation using a standard syringe and a drop of distilled water. Upon solvent 
exchange, the implants formed. At pre-determined time points, a spherical probe (diameter 
= 5 mm) was driven downwards (at a speed of 0.5 mm/s). Once in contact with the 
implant, the applied force and displacement of the probe were recorded as a function of 
time. When the penetration depth was 1.5 mm, this position was held for 60 s. Then, the 
probe was driven upwards at a speed of 10 mm/s.  
 
!"#$%&'*)!89*)#'1!:/.+#%2()&%;!4)'6+'&!.<(')-%4!=)($!($%!'**1)%4!%0*%+)&%-('1!,%(23*!
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Figure 2 shows a typical force-time diagram obtained with this type of 
measurements. Here, the maximum deformation force (Fmax deformation) is the force measured 
at maximum probe penetration into the implant. The force measured after the 60 s holding 
time is called “remaining force” (Fremaining). In this study, the “adhesion force” is defined as 
the maximum force measured with this set-up during the upward movement of the probe, 
accounting for the negative sign/direction of the force (Fadhesion). The ratio “Fremaining/Fmax 
deformation” is used as a measure for the elasticity/plasticity of the implant. High values 
indicate high elasticity, low values indicate high plasticity. Each experiment was 
conducted in triplicate, and the results are presented as mean values ± standard deviation. 
!
Fmax deformation 
Fremaining 
Fadhesion 
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2.6. Antibacterial activity 
The in vitro efficacy of the investigated implants against bacteria associated with 
periodontitis was assessed using the agar well diffusion method. Columbia agar was 
prepared from Columbia base, glucose, cysteine hydrochloride, and agar. The systems 
were sterilized in an autoclave (121 oC for 15 min). Prior to plating, Columbia agar was 
enriched with defibrinated horse blood (5 % v/v) and cast into Petri dishes. After cooling 
to room temperature, 0.1 mL of the following bacterial suspensions were inoculated onto 
the agar surface: Streptococcus sp. (1) (D36A12), Streptococcus sp. (2) (D20B9), 
Streptococcus salivarius (D28A9), Streptococcus sanguinis (D28A11), and Streptococcus 
cristatus (D18A2) (which were isolated from samples from periodontal pockets from 
patients suffering from periodontitis). A cylindrical hole (diameter = 6 mm) was 
subsequently made at the center of the agar, and filled with 30 µL of liquid formulation 
using a standard syringe. Upon solvent exchange, the implants formed in situ. The Petri 
dishes were incubated for 4 d under optimum culture conditions (35 °C, anaerobic 
atmosphere) (Whitley A85 workstation, Don Whitley Scientific, West Yorkshire, UK). 
The diameter of the observed bacteria growth inhibition zones around the center of the 
Petri dishes was measured using a ruler. Each experiment was conducted in triplicate, and 
the results are presented as mean values ± standard deviation. 
3. Results and discussion 
3.1. Effects of the addition of plasticizers 
Figure 3a shows the impact of adding 10 % or 20 % ATBC or DBS on the adhesion 
forces of in situ forming implants, based on PLGA RG 502 H (37 % w/w) and loaded with 
10 % doxycycline hyclate. The adhesion force was measured as a function of the exposure 
time to phosphate buffer pH 7.4. For reasons of comparison, also plasticizer-free implants 
(dotted curve) as well as the commercially available product Parocline® were studied. Very 
clearly, the addition of the plasticizers significantly increased the adhesion forces of the 
systems (probably due to the increased mobility of the macromolecules, allowing for 
facilitated interaction with the environment). This can be expected to be a great benefit in 
practice, since accidental expulsion of the implants (or parts thereof) from the periodontal 
pockets of the patient is a major source of uncertainty for all currently available 
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formulations. This can at least partially be attributed to the non-negligible flow of gingival 
crevicular fluid [48]. Consequently, it is uncertain how much drug is delivered for which 
period of time at the site of action. The plasticizer-containing systems show a promising 
potential to overcome this crucial practical hurdle: As it can be seen in Figure 3a, all 
ATBC/DBS containing implants showed much higher adhesive forces than the 
commercially available product Parocline® during the entire observation period. The 
observed time-dependent changes can at least partially be explained by the dynamic 
changes in the systems’ composition (e.g., decreasing NMP content, increasing water 
content), which are particularly pronounced at early time points. Furthermore, it can be 
seen in Figure 3a that increasing the plasticizer level generally leads to increased adhesion 
forces, irrespective of the type of plasticizer. 
In addition to the adhesion/stickiness of the in situ formed implants, also their 
elasticity/plasticity can be expected to play a major role for their residence times in the 
patients’ periodontal pockets: If the system is difficult to deform plastically, the implant is 
unlikely to be able to adapt its geometry to dynamic changes in the periodontal pocket’ 
size and shape with time. A fully elastic implant would force the periodontal pocket to 
keep its geometry and dimensions, which is not desirable. As a measure for the “plasticity” 
of the investigated in situ forming implants, the ratio of the “force remaining at the end of 
the 60 s holding time” (Fremaining) to the “maximum deformation force” (Fmax deformation) was 
used in this study (Figures 1 and 2). A value of “1” indicates that the system is ideally 
elastic (does not change its inner structure during the holding time in a permanent manner 
and fully recovers, once the pressure is released), whereas a low value indicates that the 
implant structure at least partially changes in a permanent manner during the holding time. 
As it can be seen in Figure 3b, all the investigated in situ forming implants exhibit much 
lower Fremaining/Fmax deformation ratios than Parocline®, indicating that they are much more 
easy to deform in a permanent manner and can more likely adapt to changes in the 
patients’ pockets’ geometry. 
                       
 
 
 CHAPTER I 
!
! 62!
a) 
 
b) 
 
Figure'3.!Effects!of!the!addition!of!different!types!and!amounts!of!plasticizers!on!the:!a)!adhesion!force,!and!b)!mechanical!properties!of!in#situ!forming!implants,!based!on!PLGA!RG!502!H!(37!%!w/w)!and!loaded!with!10!%!doxycycline!hyclate.!For!reasons!of!comparison,!also!Parocline®!was!studied.!
Based on these results, it can be expected that adding ATBC or DBS to PLGA 
based in situ forming implants is likely to allow for a substantial increase in the residence 
time in the periodontal pockets of the patients (due to increased adhesion), while the 
systems provide good deformability. This can be expected to help overcoming a crucial 
current hurdle for efficient local periodontitis treatment. However, the addition of the 
plasticizers might also affect the resulting antimicrobial activity of the implants. For this 
reason, the capability of the different systems to inhibit the growth of bacterial strains 
isolated from periodontal pockets has been studied.   
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3.2. Antimicrobial activity 
Figure 4a shows the inhibition zones observed with in situ forming implants based 
on PLGA RG 502 H (37 % w/w), loaded with 10 % doxycycline hyclate and containing 10 
% or 20 % ATBC or DBS (as indicated). For reasons of comparison, also “plasticizer-free” 
and “plasticizer-free and drug-free” systems have been studied. The investigated bacteria 
(isolated from periodontal pockets from patients suffering from periodontitis) were 5 
Streptococcus strains, two strains could not be identified to the species level, the others 
were Streptococcus salivarius, Streptococcus sanguinis and Streptococcus cristatus. Very 
clearly, all drug-loaded implants were effectively limiting the growth of all these bacteria. 
The measured inhibition zone diameter varied from 2.4 to 3.5 cm, depending on the 
specific bacterial strain. Importantly, the addition of 10 % or 20 % ATBC or DBS did not 
alter the antimicrobial activity of the systems. As an example, Figure 4b shows a picture of 
a Petri dish incubated with Streptococcus sanguinis for 4 d. The white circle in the middle 
shows an in situ formed implant based on PLGA RG 502 H (37 % w/w), loaded with 10 % 
doxycycline hyclate and containing 10 % ATBC. Figure 4c is a zoom on the center of this 
Petri dish, highlighting the inhibition zone and the implant. The negative controls 
(implants free of drug) did not show any inhibition of the proliferation of the bacteria 
(Figure 4a). 
Based on these results, 10 % ATBC was selected for further experiments, showing 
a substantial increase in the adhesive force, while providing good deformability as well as 
a clear antimicrobial activity, and requiring only the addition of a limited amount of 
substance. To further improve the implants’ properties (especially, adhesion to the 
periodontal pocket and plasticity), a second type of polymer was added to the systems. 
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3.3. Effects of the addition of a second type of polymer 
Figure 5a shows the adhesive forces (and dynamic changes thereof with time) of 
doxycycline hyclate-loaded (10 %) in situ forming implants based on PLGA RG 502 H 
(37 %), ATBC (10 %) and 10 % hydroxypropyl methylcellulose (Methocel® E5 or E50), 
hydroxypropyl cellulose (Klucel® LF), hydroxyethyl cellulose (Natrosol® 250 G), 
polyvinylpyrrolidone (Kollidon® 25), or poloxamer (Lutrol® micro 68, 127). These 
polymers have been reported to show a promising potential for bioadhesion, since they can 
be expected to be able to attract water from the gingival crevicular fluid, hydrate and 
facilitate adhesive interactions [49-54]. For reasons of comparison, also implants free of 
these polymers as well as the commercially available product Parocline® were studied. As 
it can be seen, all implants showed much higher adhesive forces than Parocline®. 
Interestingly, some of the 2nd polymers further improved the systems’ adhesion during the 
observation period, namely Methocel® E5 and E50, whereas others decreased the implants’ 
stickiness, namely Lutrol® micro 68 and 127. This might at least partially be attributable to 
differences in the interactions between these compounds with PLGA, ATBC, NMP and 
water. The observed time-dependent changes in the adhesive forces of the systems can at 
least partially be attributed to the time-dependent changes of the implants’ composition: 
NMP leaches out into the surrounding environment and water penetrates into the systems. 
Figure 5b shows the Fremaining/Fmax deformation ratios of the respective in situ forming implants 
as well as time-dependent changes thereof. Again, the two Lutrol® types had a negative 
effect on the systems’ properties with respect to expected prolonged residence times in the 
patients’ periodontal pockets, whereas an increase in plasticity was observed at later time 
points with Natrosol® 250G and Kollidon® 25. The mechanical properties of Methocel®-
free and Methocel®-containing implants were rather similar. In all cases, the plastic 
deformability was significantly superior to that of the commercial reference product 
Parocline®. Since the most promising adhesion results were obtained with the two 
hydroxypropyl methylcellulose types (differing in their molecular weight), while not 
affecting the plasticity of the implants, Methocel® E5 or E50 were selected for all further 
studies. 
                 
 
 
 CHAPTER I 
!
! 66!
a)            
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Figure' 5.! Impact! of! the! addition! of! a! second! type! of! polymer! (indicated! in! the!diagrams,! 10!%!w/w)! on! the:! a)!adhesion! force,! and! b)!mechanical! properties! of! in#
situ!forming!implants!based!on!PLGA!RG!502!H!(37!%),!ATBC!(10!%),!and!loaded!with!10!%!doxycycline!hyclate.!For!reasons!of!comparison,!also!Parocline®!was!studied.!
Figure 6a illustrates the impact of the addition of different amounts (10 % and 
20 %) of Methocel® E5 and E50 on the adhesive forces of in situ forming implants based 
on PLGA RG 502 H, ATBC (10 %), loaded with 10 % doxycycline hyclate, but containing 
only 32 % PLGA in the liquid formulation. The change in PLGA concentration from 37 to 
32 % was required to allow for the incorporation of higher amounts of HPMC, otherwise 
the liquid formulations became too viscous for injection. Note that this difference in PLGA 
concentration can be expected to impact the resulting solvent exchange kinetics (NMP 
leaching into the aqueous phase and water penetration into the implants). Thus, some 
caution should be paid when comparing these results (Figure 6) with those shown in 
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Figure 5. Importantly, the implants’ stickiness could be further increased when increasing 
the HPMC content (Figure 6a): Adhesion forces as high as 0.4 N were measured with 20 % 
of the higher molecular weight Methocel®. This might be explained as follows: The longer 
the polymer chains, the easier they can create highly entangled networks. Furthermore, the 
higher the HPMC content, the denser and stronger are the resulting macromolecular 
networks. Again, the dynamic changes in the implants’ stickiness at early time points can 
probably be explained by the dynamic changes in the systems’ composition, due to solvent 
exchange. Note that the presence of the hydrophilic HPMC can be expected to impact the 
rate at which water enters the system and to impact the rate at which NMP leaches into the 
bulk fluid. Importantly, the adhesion forces of the implants remained high during the entire 
observation period.  
However, the presence of significant amounts of a hydrophilic polymer might also 
significantly affect the plasticity/elasticity of the respective in situ formed implants, e.g. 
via altered solvent exchange kinetics (which might affect polymer precipitation and, thus, 
the inner implants’ structure) as well as via the presence of an additional polymeric 
network. This is why also the mechanical properties of the implants (and potential dynamic 
changes thereof with time) were measured. As it can be seen in Figure 6b, the plasticity of 
the systems decreased, especially in the case of Methocel® E50 (the Fremaining/Fmax deformation 
ratio increased). This is in contrast to Figure 5b, showing systems prepared with a higher 
PLGA concentration (37 % versus 32 %). Thus, the difference can probably be explained 
by altered polymer precipitation kinetics, resulting in altered inner implant structures. In 
any case, the Fremaining/Fmax deformation values remained well below the reference values 
observed for the commercially available drug product Parocline®. Again, the observed 
time-dependent changes are likely to be attributable to time-dependent changes in the 
implants’ composition, following solvent exchange. 
In practice, a compromise should be made, taking into account the adhesiveness of 
the system as well as its deformability to optimize the resulting residence times in the 
patients’ periodontal pockets. Of course, in addition to these key properties, also the drug 
release kinetics of the in situ formed implants is of major importance for the systems’ 
performance. This is why the impact of the addition of different amounts and types of 
HPMC on doxycycline release was studied.!
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a) 
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Figure'6.!Effects!of!the!addition!of!different!types!and!amounts!of!HPMC!(Methocel®!E5! and! E50)! on! the:! a)!adhesion! force,! b)!mechanical! properties! of! in# situ! forming!implants,! based! on! PLGA! RG! 502! H! (32!%),! ATBC! (10!%),! and! loaded! with! 10!%!doxycycline!hyclate.!For!reasons!of!comparison,!also!Parocline®!was!studied.!
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3.4. Drug release kinetics 
Figure 7 shows the drug release kinetics from in situ forming implants based on 
PLGA RG 502 H (32 %), ATBC (10 %) and 10 or 20 % Methocel® E5 or E50 (as 
indicated). The initial drug loading was varied from: a) 10 %, b) 5 %, to c) 2 % 
doxycycline hyclate. For reasons of comparison, also doxycycline release from HPMC-
free systems is indicated (dotted curves). Furthermore, drug release from the commercially 
available product Parocline® is illustrated. However, some care should be taken when 
comparing the results with this commercially available product, since the drug is different: 
minocycline hydrochloride (in Parocline®) versus doxycycline hyclate (in the investigated 
PLGA implants). Very clearly, drug release is sustained during several days from all 
systems. Importantly, the novel in situ forming implants show significantly slower drug 
release than the commercially available product at all drug loadings (Parocline® contains 
2 % drug). Furthermore, it can be seen that the addition of HPMC generally decreases the 
resulting drug release rate, irrespective of its molecular weight and the initial drug loading. 
Interestingly, the addition of shorter chain Methocel® E5 seems to retard drug release more 
effectively than the addition of longer chain Methocel® E50, and there is no clear tendency 
concerning the effect of the amount of added HPMC: 0 % versus 10 % versus 20 %. The 
addition of 10 % HPMC generally results in the slowest drug release patterns, irrespective 
of the Methocel® type and initial drug loading. 
To better understand the observed effects of the addition of HPMC to the in situ 
forming implants on the resulting drug release kinetics, the dynamic changes in the 
systems’ mass were monitored gravimetrically. These changes reflect the solvent exchange 
kinetics: NMP leaching into the bulk fluid and water penetration into the implants. 
Figure 8 shows the experimentally measured changes in the mass of the implants, drug 
release of which is illustrated in Figure 7 (being based on 32 % PLGA RG 502 H, 10 % 
ATBC, 10 % or 20 % Methocel® E5 or E50, and loaded with 2 to 10 % doxycycline 
hyclate). 
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b) 
 
    c) 
 
Figure'7.!Impact!of!the!addition!of!different!types!and!amounts!of!HPMC!(Methocel®!E5!and!E50)!on!drug!release!from!in#situ!forming!implants!based!on!PLGA!RG!502!H!(32!%)! and! ATBC! (10!%),! loaded!with:! a)!10!%,! b)!5!%,! c)!2!%! doxycycline! hyclate.!For! reasons!of! comparison,! also!minocycline! release! from!Parocline®! is! shown,! but!note!that!this!is!a!different!drug.!
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Figure'8.!Impact!of!the!addition!of!different!types!and!amounts!of!HPMC!(Methocel®!E5!and!E50)!on!the!dynamic!changes!in!the!mass!of!in#situ!forming!implants!based!on!PLGA! RG! 502! H! (32!%)! and! ATBC! (10!%),! loaded! with:! a)!10!%,! b)!5!%,! c)!2!%!doxycycline!hyclate.!
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As it can be seen, in all cases the implant mass increases with time during the 
observation period, which can be attributed to a more important water penetration into the 
devices than NMP leaching out of the systems. Interestingly, the addition of the 
hydrophilic compound HPMC generally decreases the rate and extent of this increase in 
mass, irrespective of the Methocel® type and initial drug loading. This might eventually be 
attributable to altered polymer precipitation kinetics: The presence of hydrophilic HPMC 
can be expected to facilitate water penetration into the system, leading to accelerated 
polymer precipitation and, hence, altered inner implant structures. Furthermore, it can be 
seen that longer chain Methocel® E50 generally more effectively hinders the mass increase 
at all initial drug loadings than shorter chain Methocel® E5. This correlates with generally 
faster drug release from these systems (Figure 7). Furthermore, there is a rough ranking 
order with respect to the effect of the amount of added HPMC on the rate and extent in 
mass increase of the implants: 0 % > 10 % > 20 %. This is in contrast to the observed drug 
release kinetics, where 10 % Methocel® resulted in the slowest release rates (Figure 7). 
These findings clearly point out: (i) that the underlying mass transport phenomena are not 
straightforward, and (ii) that the addition of different amounts and types of HPMC can be 
effectively used to fine-tune desired drug release kinetics (in addition to improving the 
implants’ stickiness, while providing good deformability). 
As a potential further tool to adjust desired drug release kinetics from the 
investigated in situ forming implants, the impact of varying the concentration of the PLGA 
in the liquid formulation was studied: Figure 9a shows the release of doxycycline from 
implants based on only 28 % (instead of 32 % as in Figure 7) PLGA RG 502 H, 10 % 
ATBC, and loaded with 5 % doxycycline hyclate. Comparing Figure 9a with Figure 7b 
(showing the same type of system, but with a higher PLGA concentration in the liquid 
formulation), it can be seen that the PLGA concentration indeed plays a crucial role for 
drug release. At 28 % PLGA content, the addition of HPMC seems to have only a very 
minor effect, even up to 30 % Methocel® E50 (Figure 9a). This is in contrast to the 
implants prepared with 32 % PLGA, for which HPMC addition impacted drug release 
(Figure 7b). Figure 9b shows the significant impact of adding 20 %, 25 % or 30 % 
Methocel® E50 to implants prepared with 28 % PLGA on their dynamic changes in mass. 
Interestingly, the addition of all three HPMC levels similarly strongly hindered the 
increase in implant mass (compared to HPMC-free systems, dotted curve). This confirms 
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the complex interplay between the two types of polymers (PLGA and HPMC), the 
plasticizer (ATBC), the drug (doxycycline hyclate) and the two solvents (NMP and water). 
Future studies using advanced characterization methods (such as EPR and NMR 
measurements) will aim at a better understanding of the involved mass transport processes. 
a) 
 
b) 
 
Figure'9.!Effects!of!the!addition!of!different!types!and!amounts!of!HPMC!(Methocel®!E5!and!E50)!on!the:!a)!drug!release!kinetics,!b)!dynamic!changes!in!the!mass!from/of!
in#situ! forming! implants!based!on!PLGA!RG!502!H!(28!%)!and!ATBC!(10!%),! loaded!with!5!%!doxycycline!hyclate.!!
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4. Conclusion 
The newly presented in situ forming implants show an interesting potential for the 
local treatment of periodontitis, since they are much more adhesive than prior art systems, 
while providing appropriate plasticity, the ability to control drug release during several 
days and show antimicrobial activity against relevant Streptococcus strains. In future 
studies the underlying mass transport mechanisms will be further elucidated and different 
types of drug incorporated. 
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Abstract 
In situ forming implant formulations based on poly(lactic-co-glycolic acid) 
(PLGA), acetyltributyl citrate (ATBC), minocycline HCl, N-methyl pyrrolidone (NMP) 
and optionally hydroxypropyl methylcellulose (HPMC) were prepared and thoroughly 
characterized in vitro. This includes electron paramagnetic resonance (EPR), nuclear 
magnetic resonance (1H NMR), mass change and drug release measurements under 
different conditions, optical microscopy, size exclusion chromatography (SEC) as well as 
antibacterial activity tests using gingival crevicular fluid samples from periodontal pockets 
of periodontitis patients. Based on these results, deeper insight into the physico-chemical 
phenomena involved in implant formation and the control of drug release could be gained. 
For instance, the effects of adding HPMC to the formulations, resulting in improved 
implant adherence and reduced swelling, could be explained. Importantly, the in situ 
formed implants effectively hindered the growth of bacteria present in the patients’ 
periodontal pockets. Interestingly, the systems were more effectively hindering the growth 
of pathogenic bacterial strains (e.g., Fusobacterium nucleatum) than of physiological 
strains (e.g., Streptococcus). In vivo, such a preferential action against the pathogenic 
bacteria can be expected to give a chance to the healthy flora to re-colonize the periodontal 
pockets. 
Keywords: In situ forming implant; periodontitis; PLGA; antibacterial activity; 
EPR; NMR. 
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1. Introduction 
Periodontitis is a highly prevalent, chronic inflammatory disease of the periodontium 
[1–3]. It may be defined as “a disease that affects the periodontal structures and, as a result of 
interactions between periodontopathogens and the host immune response, leads to the 
destruction of the tooth supporting tissues, periodontal ligament and alveolar bone” [1]. 
Briefly, microorganisms colonizing the patients’ periodontal pockets are considered as a major 
factor, causing inflammation and tissue destruction [4]. It seems that the bacterial flora in the 
disease state is different from that in healthy subjects. For example, the number of gram 
negative anaerobic bacteria is likely to be increased, and certain clinical forms of periodontitis 
might be related to specific microbiota [5]. For instance, Silva-Boghossian et al. [1] reported 
that Streptococcus strains (such as Streptococcus sanguinis) are associated with suppuration in 
periodontitis subjects. However, up to date, the exact mechanisms underlying this disease are 
not yet fully understood. It is hypothesized that: (i) suspected periodontal pathogens produce 
biologically active molecules, which directly attack the host tissue, and/or that (ii) the immune 
response of the host organism (human body) to these pathogens results in the tissue 
destruction. The consequence of the tissue loss is the deepening of the periodontal pockets, and 
-once the mechanical anchorage of the tooth becomes insufficient -the latter is lost. 
Periodontitis is in fact the main cause for tooth loss in adults [6]. A recent survey estimates that 
47 % of the US adults have mild, moderate or severe periodontitis [7]. The prevalence rate 
even increases to 64 % for adults, which are older than 65 years. 
At present, the standard treatment method of periodontitis is the mechanical removal of 
the bacteria (in particular of bacterial biofilms). This is a procedure also called “root planing”. 
But the geometry of the patients’ pockets can be very challenging for this type of treatment: 
Parts of the pockets might be very difficult to access with the dentist’s instruments. Thus, the 
removal of the bacteria might be incomplete. In theses cases, the remaining pathogenic 
microorganisms have a chance to re-colonize the periodontal pockets soon after the treatment. 
In order to reduce the risk of such pathogen re-appearance, it has been suggested to combine 
mechanical root planing with drug treatments [4,8,9]. However, appropriate delivery of drugs 
to the site of action is difficult, since many compounds do not easily partition into the 
periodontal pockets. In addition, the gingival crevicular fluid (GCF) flow generally rapidly 
eliminates the drug from its site of action [10]. For instance, it has been estimated that the 
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contents in a 5 mm periodontal pocket is renewed 40 times per hour [11]. Thus, using 
conventional administration routes, often high systemic drug levels are required, while the 
drug concentrations at the target site remain low. This leads to potentially severe side effects 
combined with limited or insufficient therapeutic efficacy, despite the availability of highly 
potent drugs, able to act against the pathogenic flora and inflammation. Controlled local drug 
delivery systems offer the possibility to overcome these crucial hurdles of limited drug 
accessibility to the site of action and rapid elimination, releasing the drug in a controlled 
manner directly in the periodontal pockets during prolonged periods of time [4,12–14]. In situ 
forming implants are particularly promising for this purpose, since these are liquid 
formulations, which upon injection into the periodontal pockets form customized solid 
implants: The fluids readily spread within the cavities, assuring that the entire pockets are filled 
with formulation and that the shape and geometry of the resulting implants are fully adapted to 
the characteristics of every single patient and each single pocket. 
In this study, poly(lactic-co-glycolic acid) (PLGA) has been chosen as a matrix former 
for such in situ forming implants for periodontitis treatment, due to its biocompatibility and 
biodegradability. Together with the drug (here minocycline HCl) the polymer is dissolved in 
N-methyl pyrrolidone (NMP). Once injected, the organic solvent diffuses into the surrounding 
environment and aqueous biological fluids from the periodontal pocket penetrate into the 
liquid formulations. Since PLGA is not soluble in water, it subsequently precipitates and 
entraps the drug. This type of advanced local drug delivery systems for periodontitis treatment 
offers various important advantages, including: (1) A relatively easy administration (injection 
of a liquid, compared for instance with the placement of a pre-formed implant). (2) There is no 
need to remove empty remnants upon drug exhaust, due to complete biodegradability of the 
system. (3) The geometry and size of the resulting implants are adapted to the patient’s dental 
pockets (personalized medicine). (4) The incorporated drug is locally released in a time-
controlled manner through the slowly degrading polymeric system. 
However, up to date major challenges remain to be addressed, namely the fact that: 
(i) The adherence of such in situ formed implants to human tissue is yet poor, resulting in pre-
mature and uncontrolled expulsion of at least parts of the implants from the dental pockets due 
to the non-negligible flow of gingival crevicular fluid [15]. This leads to a considerable 
uncertainty with respect to the amount of drug, which really reaches the target site and with 
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respect to the time periods during which therapeutic drug levels are provided. (ii) The 
elasticity/plasticity of the formed implants is generally not adapted to this type of local 
administration: Systems, which are difficult to deform plastically are not able to adapt their 
geometry to dynamic changes in the periodontal pocket’ size and shape with time. Also, fully 
elastic implants force the periodontal pockets to keep their geometry and dimensions, which is 
not desirable. It has recently been proposed to add plasticizers, such as acetyltributyl citrate 
(ATBC) as well as a second type of polymer, such as hydroxypropyl methylcellulose (HPMC) 
to the liquid formulations in order to improve the adhesive and mechanical properties of the 
resulting implants [16]. However, yet it is unclear how these additives affect the underlying 
physico-chemical phenomena involved in implant formation and the control of drug release, 
and whether the antibacterial activity of the implants is altered. 
It is well documented that the physical and chemical processes in the formation of 
implants based on such solvent induced phase separation are complex and that the impact of 
the composition of the systems on drug release is not straightforward [17–22]. For example, 
McHugh and co-workers reported that the addition of polyvinylpyrrolidone (PVP) accelerates 
the phase separation and increases the release rate of lysozyme at early time points, but does 
not significantly affect the water influx rate and implant morphology [23]. Increasing the 
polymer concentration in the formulation led to a decrease in the phase separation rate, a 
decreased water uptake rate and significant changes in the implants’ porosity. The addition of 
triacetine also slowed down the phase separation rate and altered the implants’ morphology, 
resulting in decreased drug release rates. Interestingly, the type of release medium (water 
versus phosphate buffer versus horse serum) did not affect the phase separation and water 
uptake rates as well as the implants’ morphology to a noteworthy extent. In a later study, they 
also showed that the addition of Pluronic® led to faster phase separation and increased water 
uptake, but decreased lysozyme release rates [24]. Importantly, advanced physico-chemical 
characterization techniques, such as electron paramagnetic resonance (EPR) and nuclear 
magnetic resonance (1H NMR) measurements can be expected to be able to provide highly 
valuable new insight into the underlying mass transport phenomena [25,26].  
The aim of this study was to better understand the physico-chemical processes 
involved in the formation of PLGA-based implants and the control of drug release. EPR, 1H 
NMR, mass change and drug release measurements under different conditions, optical 
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microscopy and size exclusion chromatography (SEC) were applied. Particular attention was 
paid to: (i) the impact of adding HPMC to the formulation, which improves the adhesive forces 
and mechanical properties of the implants, as well as (ii) the antibacterial activity of the 
systems, using gingival crevicular fluid samples, obtained from periodontal pockets of 
periodontitis patients.  
2. Materials and methods 
2.1. Materials 
  Poly(D,L-lactic-co-glycolic acid) (PLGA, Resomer® RG 504 H; Evonik, 
Darmstadt, Germany); acetyltributyl citrate (ATBC; Morflex, Greensboro, NC, USA); 
hydroxypropyl methylcellulose (HPMC, Methocel® E50; Colorcon, Dartford, UK); N-
methyl pyrrolidone (NMP, 99 %), glucose and cysteine hydrochloride (Acros organics, 
Geel, Belgium); minocycline hydrochloride dihydrate (minocycline HCl; Fagron, 
Colombes, France); ascorbic acid (Cooper, Melun, France); sodium metabisulfite (Merck, 
Darmstadt, Germany); dimethyl sulfoxide (DMSO, 99.5 %; Gruessing, Filsum, Germany); 
tetrahydrofuran (THF, 99.99 %, analytical reagent grade, stabilized with 0.025 % 
butylhydroxytoluene), acetonitrile (HPLC grade) (Fisher Scientific, Loughborough, UK); 
oxalic acid (Sigma-Aldrich, Saint-Quentin Fallavier, France); ethylenediamine tetraacetic 
acid (EDTA; VWR, Haasrode, Belgium); 4-hydroxy-tempo benzoate (TB; Sigma-Aldrich, 
Seelze, Germany); agarose (GenAgarose® LE; Genaxxon BioScience, Ulm, Germany); 
Columbia agar base and agar (Oxoid, Basingstoke, UK); defibrinated horse blood (E&O 
Laboratories, Burnhouse, UK); Parocline® (2 % minocycline; Sunstar France, Levallois-
Perret, France). 
2.2. Preparation of the liquid formulations 
PLGA (25 % w/w, based on the total liquid formulation without drug) was 
dissolved in NMP at 25 °C in a glass vial (30 min stirring). Optionally, the plasticizer 
ATBC (10 % w/w, based on the PLGA mass) and/or HPMC (10, 15, 20, 25 or 30 % w/w, 
based on the PLGA mass) was/were added and the mixture was vortexed for 3 min, 
followed by standing for 3 h at 25 °C. Subsequently, minocycline HCl (2 % w/w, based on 
the total liquid formulation) and ascorbic acid (0.01 % w/w, based on the total liquid 
formulation; minimizing drug oxidation) were added, and the mixture was vortexed for 
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3 min, followed by standing for 3 h at 25 °C. To eliminate air bubbles, the liquids were 
ultrasonicated for 10 min. The formulations were stored at -20 °C and protected from light 
to avoid drug degradation. 
2.3. In situ implant formation and drug release measurements 
Agitated vials: One hundred microliters of the respective formulation was injected 
at the bottom of an Eppendorf vial using a standard syringe. One and a half milliliters 
preheated (37 °C), degassed phosphate buffered saline pH 7.4 (Ph. Eur. 7) containing 0.01 
% sodium metabisulfite (to minimize drug oxidation) was carefully added using a pipette, 
initiating solvent exchange and implant formation. The vials were horizontally shaken at 
37 °C at 80 rpm (GFL 3033; Gesellschaft fuer Labortechnik, Burgwedel, Germany). At 
pre-determined time points, the bulk fluid was completely withdrawn and replaced with 
fresh medium. The drug content in the samples was determined UV-
spectrophotometrically (λ = 324 nm; UV-1650PC, Shimadzu, Champs-sur-Marne, France) 
(degraded and non-degraded drug) and by HPLC (non-degraded drug). The HPLC system 
was equipped with a ProStar 210 pump, a ProStar 410 auto-sampler, a ProStar 335 
Photodiode Array Detector (Varian, Agilent Technologies, Les Ulis, France). A Kinetex 
column C8 (2.6 µm, 100 x 4.6 mm; Phenomenex, Le Pecq, France) was used for the 
separation. The mobile phase consisted of 22 % acetonitrile and 78 % of an aqueous 
solution (deionized water) of oxalic acid (0.02 M) and EDTA (0.0005 M), which was 
adjusted to pH 2.8 with aqueous sodium hydroxide solution (2 M). The operating mode 
was isocratic, the flow rate 1.0 mL/min, the injection volume 20 µL and the drug was 
detected by UV-Vis spectrophotometry at 351 nm. For reasons of comparison, also the 
commercially available formulation Parocline® was studied. In this case, the 100 µL of the 
formulation was injected using the supplied syringe. 
Flow-through cells: A continuous flow-through system, as described in detail by 
Aubert-Pouessel et al. [27], was used. Briefly, 100 µL of the respective formulation was 
filled into an empty Omega column (4.6 x 50 mm; Upchurch Scientific, Oak Harbor, WA, 
USA) using a standard syringe. Degassed phosphate buffered saline pH 7.4 (Ph. Eur. 7) 
containing 0.01 % sodium metabisulfite was pumped through the column at 44 µL/h (PHD 
2000 syringe pump; Harvard Apparatus, Holliston, MA, USA), simulating the continuous 
gingival fluid flow in patients’ periodontal pockets [15]. The column was maintained at 
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37 °C with a water bath. The eluent was cooled to 4 °C to minimize minocycline 
degradation and analyzed by UV and HPLC as described above. 
All tests were performed in triplicate and the results were shown as mean values ± 
standard deviation. 
2.4. Monitoring of dynamic changes in the implants’ mass 
Implants were prepared and treated as described in Section 2.3. Agitated vials. At 
pre-determined time points, implants were weighed [mass (t)]. The mass change in percent 
was calculated as follows: 
mass change (%) (t) = 100 * [mass (t) – mass (t=0)] / mass (t=0)  (1) 
where mass (t=0) is the initial weight of the formulation used for implant preparation.  
2.5. Electron paramagnetic resonance (EPR) measurements 
In situ forming liquid implant formulations were prepared as described in section 
2.2. The spin probe 4-hydroxy-tempo benzoate (TB) was dissolved in these liquids 
(1 mM). Two hundred µL of the formulations were placed into cylindrical holders, which 
were immerged into 3 mL phosphate buffered saline pH 7.4 (Ph. Eur. 7). As illustrated in 
Figure 1a, only the top circular surface of the cylindrical holder was open, the other 
surfaces were impermeable. The system was kept constant at 37 °C and horizontally 
shaken at 30 rpm (GFL 1083; Gesellschaft fuer Labortechnik, Burgwedel, Germany). At 
pre-determined time points, samples (implants with holders) were withdrawn and analysed 
using an EPR L-band spectrometer (MagnetTech, Berlin, Germany), operating at a low 
microwave frequency (1 GHz). To create EPR images, twenty-five scans were 
accumulated using the following parameters: field centre = 48.9 mT; scan range = 8 mT; 
scan time = 40 s. For the measurement of EPR spectra, a scan range of 10 mT and scan 
time of 100 s were applied. The typical EPR parameters were calculated from the recorded 
EPR spectra or spectral cut of EPR images (Figures 1b and 1c). 
 CHAPTER II 
!
! 87 
 
!"#$%&' ()! "#!$%&'(")*%! *++,-).")*/0! /1! "0! *(2+"0)! 3*)&! &/+4'.! ,-'4! 1/.! 567!
('"-,.'('0)-8!90+:! )&'! %*.%,+".! )/2! -,.1"%'! /1! )&'! %:+*04.*%"+! &/+4'.!3"-! /2'0;! "++!
/)&'.!-,.1"%'-!3'.'!*(2'.('"<+'8!<# 567!-2'%).,(!/1!=>!4*--/+?'4!*0!@A6 B!"# $%&'()"
(*+)%,-./;!(0"#"12+/34%'/"$+)%,,%'&"56'$,(',78!%#!567!*("C'!"04!%'0)."+!-2'%)."+!%,)!/1!
"0!*(2+"0)!BDE!F!6GHI;!JK!F!I=>L;!DK!F!M6AL;!J!(A!=>#!.'%/.4'4!"1)'.!K;!J!"04!
N!&!'O2/-,.'!)/!2&/-2&")'!<,11'.8!!
2.6. 1H NMR measurements 
One hundred "L of the respective formulation was injected at the bottom of an 
Eppendorf vial filled with 1.5 mL phosphate buffered saline pH 7.4 (Ph. Eur. 7), using a 
standard syringe. The vials were kept constant at 37 °C and horizontally shaken at 30 rpm
(GFL 1083). At predetermined time points, implants were withdrawn, carefully dried with 
a tissue paper and subsequently dissolved in DMSO (1:10 w/v). NMR spectra were 
recorded with a 400 MHz 1H NMR spectrometer (Varian Gemini 2000; Varian, Agilent 
Technologies, Waldbronn, Germany). 
2.7. Optical microscopy 
Implants were prepared as described in Section 2.3. At predetermined time points, 
implants were withdrawn and freeze-dried (Epsilon 2-4 LSC; Christ, Osterode, Germany). 
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The process consisted of 3 phases: (i) freezing at -45 °C for 2 h; (ii) primary drying at 
0.014 mbar and -9 °C shelf temperature for 10 h; (iii) secondary drying at 0.0014 mbar and 
20 °C shelf temperature for 10 h. Cross-sections were obtained with a knife and analysed 
with a SMZ-U zoom 1:10 microscope (Nikon, Tokyo, Japan), equipped with a TV lens C-
0.45x (Nikon) and a digital camera AxioCam ICc1 (Carl Zeiss, Oberkochen, Germany). 
2.8. PLGA degradation 
The weight average molecular weight (Mw) of PLGA was determined by size 
exclusion chromatography (SEC) using a Varian Prostar HPLC System (Varian, Agilent 
Technologies, Les Ulis, France) consisting of a Galaxie system controller, a ProStar 410 
autosampler, a Prostar 230 pump and a Varian 356-LC RI detector. Freeze-dried implants 
were dissolved in tetrahydrofuran (0.3 % w/v) prior to the measurements. Fifty µL samples 
were injected into a PLGel pre-column (5 µm, 50 x 7.5 mm), which was followed by a 
PLGel High performance GPC column (5 µm, MIXED-D, 300 x 7.5 mm) (Polymer 
laboratories, Varian). The mobile phase was tetrahydrofuran, the flow rate 1.0 mL/min, the 
column temperature 35 °C. Polystyrene narrow molecular weight standards (Polystyrene 
calibration kit S-M2-10, 580 – 271,800 Da; Agilent Technologies) were used for 
calibration. The Mw was calculated using the Cirrus GPC software (Agilent 
Technologies). 
2.9. Microbiological tests 
Samples from periodontal pockets of periodontitis patients: Thirteen patients (4 
women, 9 men; from 35 to 69 years old) were enrolled in this study (14 periodontal 
pockets were sampled). They were admitted at the clinical site of the Faculty of Dental 
Surgery, University of Lille, France. Participants did not receive any hygienic treatment at 
the teeth with periodontitis prior to sampling. Sterile paper points (Roeko, Coltene, 
Germany) were carefully inserted into each periodontal pocket (1 paper point per pocket) 
and left for 10 s to allow for absorption of gingival crevicular fluid (GCF). Each paper 
point was placed into an Eppendorf vial, filled with 1.5 mL of Ringer Cysteine. 
Independently, 10 paper points were weighed before and after sampling to estimate the 
mean amount of GCF absorbed (5.7 ± 0.6 mg) to allow for the quantification of bacteria. 
Further tenfold dilutions (-2 to -7) of these GCF solutions (-1) were obtained for 
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microbiological testing. 
Susceptibility of periodontal bacteria to minocycline: Columbia agar was prepared 
from Columbia agar base, glucose, cysteine hydrochloride, and agar. The systems were 
sterilized in an autoclave (121 °C for 15 min). Prior to plating, Columbia agar was 
enriched with defibrinated horse blood (5 % v/v), without or with minocycline (32 mg/L) 
and cast into Petri dishes. After cooling to room temperature, 0.1 mL of diluted GCF 
solutions (from -1 to -7) was inoculated onto the agar surface (35 °C, anaerobic 
atmosphere; Whitley A85 workstation, Don Whitley Scientific, West Yorkshire, UK). 
After 5 d of incubation, the number of bacterial colonies was counted for each Petri dish, 
the predominant colonies were subcultured and identified to enlarge the strain collection, 
and the mean log CFU/g was calculated. 
Antibacterial activity of the in situ forming implants: The in vitro efficacy of the 
investigated implants was assessed by their antibacterial activity against the whole 
periodontitis samples and against isolated bacterial strains, using the agar well diffusion 
method. Columbia agar was enriched with horse blood (5 % v/v) and cast into Petri dishes. 
After cooling to room temperature, 0.1 mL of diluted GCF (dilution -2 and -3) or isolated 
bacterial suspension was inoculated onto the agar surface. A cylindrical hole (diameter = 
6 mm) was subsequently made at the center of the agar, and filled with 30 µL of liquid 
formulation using a standard syringe. Upon solvent exchange, the implants formed in situ. 
The Petri dishes were incubated for 4 d (isolated bacterial strains) or 5 d (diluted entire 
GCF samples) under optimum culture conditions (35 °C, anaerobic atmosphere; Whitley 
A85 workstation). The diameter of the observed bacteria growth inhibition zones around 
the center of the Petri dishes was measured using a ruler. Each experiment was conducted 
in triplicate, the results are presented as mean values ± standard deviation. 
Minimal inhibitory concentration (MIC) of minocycline on selected strains: The 
MIC of minocycline was determined using the broth dilution method [28]. One hundred 
µL of Wilkins-West broth were pipetted into each well of a 96-well plate, except for the 
first column. A minocycline stock solution (64 mg/L) was prepared in the same broth, 
200 µL of which were introduced into the first column of microplate wells. After thorough 
mixing, 100 µL of the first well was added to the second well and so on. Finally, 100 µL of 
bacterial suspension in Ringer Cysteine solution was introduced into each well, leading to 
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2-fold dilution of the drug concentration (1-fold dilution in the first well). At the end, each 
well row contained a dilution series of the drug from the left to the right, with 
progressively lower concentrations (decreasing from 32 to 0.016 mg/L). After incubation 
at 35 °C under anaerobic conditions (Whitley A85 workstation), the lowest concentration 
of drug that prevented visible growth of bacteria was determined as the MIC. According to 
the 2013 guideline of the Société Française de Microbiologie (SFM), a microorganism is 
called “susceptible” to minocycline if MIC ≤ 4 mg/L and “resistant” to minocycline if MIC 
> 8 mg/L [29]. For these tests, the bacterial strains were provided from the collection of the 
Laboratory of Bacteriology of the College of Pharmacy, University of Lille, France (also 
obtained from patients suffering from periodontitis). 
3. Results and discussion 
3.1. Impact of HPMC addition on the implants’ key properties 
Significant implant swelling with time can lead to accidental and premature 
expulsion of at least parts of the formulations from the patients’ periodontal pockets. 
Hence, ideally, system swelling should remain limited with time. Figure 2 shows the 
experimentally measured changes in the mass of implants prepared with formulations 
containing 25 % PLGA, 10 % ATBC and optionally up to 30 % HPMC, upon exposure to 
phosphate buffer. For reasons of comparison also the behavior of the commercially 
available drug product Parocline® is illustrated. Very clearly, Parocline® exhibits a 
substantial increase in system mass with time, indicating very important water uptake. This 
is consistent with the visually observed significant swelling of the gel and can at least 
partially explain the reported premature expulsion of parts of this formulation from the 
patients’ pockets. Very importantly, the addition of increasing amounts of HPMC to the 
investigated PLGA-based implants substantially decreased the increase in system mass 
(Figure 2), which is highly promising with respect to the in vivo performance of these 
devices. 
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Figure' 2.! Effects! of! the! addition! of! different! amounts! of! HPMC! (indicated! in! the!figure)!on!the!dynamic!changes!in!the!mass!of!in"situ!forming!implants!prepared!with!formulations! containing! 25!%! PLGA! and! 10!%! ATBC,! upon! exposure! to! phosphate!buffer!(agitated!vial!setPup).!
Furthermore, it has been reported that the addition of HPMC to PLGA implants 
increases the latter’s stickiness [16]. However, the presence of this hydrophilic polymer 
can also be expected to impact other implant characteristics, its drug release kinetics. The 
effects of adding different amounts of HPMC to liquid formulations based on PLGA 
(25 %) and ATBC (10 %) on the resulting minocycline release kinetics from the in situ 
formed implants are shown in Figure 3 (2 % initial drug loading). In Figure 3a, the total 
amount of drug release is illustrated, in Figure 3b the percentages of degraded drug in the 
withdrawn samples. Importantly, minocycline is not stable in aqueous solution. This is not 
a concern in vivo, since the living body eliminates the drug anyway, once it is released. 
The decisive question is whether the observed in vitro drug degradation occurs within the 
implants, or only once the drug is released into the bulk fluid. As it can be seen in 
Figure 3b, the percentage of degraded drug in the withdrawn samples strongly depended 
on the sampling frequency: When the sampling interval was short, the percentage of 
degraded drug was much lower compared to large sampling intervals. This is a good 
indication for the fact that a major part of minocycline degradation occurred outside of the 
implants. Within the implants, the acidic microenvironment induced by PLGA degradation 
may be responsible for a part of drug degradation. However, this limit can be minimized in 
practice considering the tinier volume of periodontal pockets (up to 1.5 µL [15]) than in 
vitro set-up (100 µL). Interestingly, the addition of HPMC to the implants led to increasing 
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release rates. This is in contrast to previously observed moderate to pronounced decreasing 
release rates when adding HPMC to PLGA-based in situ forming implants containing the 
drug doxycycline [16]. For reasons of comparison, also minocycline release from the 
commercial product Parocline® was measured (filled circles in Figure 3a). As it can be 
seen, drug release from all the investigated PLGA-HPMC implants was slower than from 
the commercial product. This can be expected to be advantageous in practice, combined 
with the improved adhesion and reduced system swelling described above. To better 
understand the underlying mass transport mechanisms, also EPR and NMR spectroscopy 
were applied to characterize the systems and dynamic changes thereof during drug release. 
!
 
Figure' 3.! Drug! release! from! in" situ! forming! implants! prepared! from! liquid!formulations! based! on! PLGA! (25!%),! ATBC! (10!%)! and! 2!%! minocycline! HCl:!a)!cumulative! total! drug! release,! b)!percentage! of! degraded! drug! within! the!withdrawn!samples!(agitated!vial!setPup).  
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3.2. Monitoring of the in situ implant formation by EPR and 1H NMR 
It is well known that the spectral splitting of nitroxyl radicals is sensitive to both, 
the molecular motion (microviscosity of the surrounding) and the polarity of their direct 
environment [30]. In this study, the spin probe 4-hydroxy-tempo benzoate (TB) was 
initially dissolved in the different liquid formulations, which formed implants in situ. Upon 
contact with phosphate buffer, solvent exchange led to substantial changes in the 
environment of this probe. To monitor these changes, the dependence of the hyperfine 
splitting (2aN) on the composition of a “NMP:phosphate buffer” mixture was studied. As it 
can be seen in Figure 4a, the 2aN values increased linearly (R2 = 0.9886) with increasing 
buffer content (polarity). Based on this dependence, 2aN values measured in in situ forming 
implants can be used as indicators for the solvent exchange process. 
      
 
Figure' 4.! a)!Polarity! dependence! of! the! hyperfine! splitting! of! TBPloaded!“NMP:phosphate!buffer”!mixtures.!b)!Spatially! resolved!profiles!of!TBPloaded! in" situ!forming!implants.!!
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Figure 4b shows the experimentally determined hyperfine splitting of TB in in situ 
forming implants prepared with formulations based on PLGA (25 %), ATBC (10 %) and 
optionally HPMC (20 %). The set-up schematically illustrated in Figure 1a was used, the 
spatial position is plotted on the x-axis: 3.1 mm corresponds to the interface “formulation – 
release medium”, 0 mm corresponds to the bottom of the cylindrical holder. The 
measurements were made before exposure to the phosphate buffer (t = 0), as well as after 
1, 4 and 8 h exposure. As it can be seen, the 2aN values were about position-independent 
and very similar at t = 0 for HPMC-free and HPMC-containing systems: around 32.3 G. 
This is consistent with the results shown in Figure 4a, indicating 0 % phosphate buffer for 
this 2aN value. Importantly, after 1 h, clear spatial hyperfine splitting gradients were visible 
in both types of formulations: The 2aN values decreased from about 33.3 to 32.7 G from 
the interface “formulation – release medium” to the bottom of the cylindrical holder. This 
indicates that water started to penetrate into the formulations and that surface near regions 
were much more hydrated than regions far from the surface at this time point. 
Interestingly, there was still no major difference between HPMC-containing and HPMC-
free systems. At 4 h exposure time, much higher water contents were observed than after 
1 h, and there were still spatial gradients visible between the surface and the bottom of the 
system, although less steep. Importantly, HPMC-containing implants showed higher water 
contents than HPMC-free implants at this time point (filled versus open triangles), 
indicating that the presence of HPMC facilitates the penetration of water into the devices. 
At 8 h, the water content in HPMC-containing implants is about homogeneous throughout 
the device (filled diamonds) and, again, higher than the water content in HPMC-free 
implants. The latter still exhibited a spatial concentration gradient (open diamonds). This 
further confirms that the presence of the hydrophilic polymer HPMC facilitates the 
penetration of water into the in situ forming implants, especially after a couple of hours, 
when the systems become more and more hydrophobic due to PLGA precipitation. 
Figure 5a shows the 1H NMR spectra of a liquid in situ forming implant 
formulation containing PLGA (25 %), ATBC (10 %), NMP, minocycline HCl (2 %), 
ascorbic acid (0.01 %), and HPMC (20 %) before exposure to the release medium (t = 0). 
Figure 5b shows the same system, but after 3 d exposure to phosphate buffer pH 7.4. Table 
1 lists the peak assignments for these spectra (obtained with reference spectra of the 
different pure compounds). Clearly, upon exposure to the phosphate buffer, the peak 
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intensity of NMP decreased, whereas the peak intensity of water increased (Figure 5b 
versus 5a). 
!
!
Figure' 5.! 1H! NMR! spectrum! of:! a)!a! liquid! in" situ! forming! implant! formulation!containing! PLGA! (25!%),! ATBC! (10!%),! NMP,! minocycline! HCl! (2!%),! ascorbic! acid!(0.01!%),! and!HPMC! (20!%);! (b)!the! system! shown! in! a),! but! after! 3!d! exposure! to!phosphate!buffered!saline!pH!7.4!(agitated!vial!setPup).!
Table'1.!Assignments!of!the!peaks!observed!in!the!1H!NMR!spectra!of!the!in"situ!forming!implant!formulations!shown!in!Figure!5!(the!implants!were!dissolved!in!DMSO!to!obtain!the!NMR!!!!!!!!!!!!!spectra).!
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Figure 6 shows the dynamic changes in these peak intensities for HPMC-free and 
HPMC-containing systems as a function of the exposure time to the release medium. 
Clearly, the peak intensity of NMP (and, thus, the amount of NMP remaining within the in 
situ forming implant) decreases much more rapidly in HPMC-containing devices 
compared to HPMC-free formulations (black versus white bars in Figure 6a). At the same 
time, the water penetration rate into the system is initially increased in the presence of 
HPMC, as it can be seen in Figure 6b at 1 d. This is consistent with the above described 
EPR measurements (e.g., Figure 4) and confirms that the presence of this hydrophilic 
polymer facilitates water uptake into the formulation. However, at much later time points 
(e.g., 3 d), the water content of HPMC-containing devices is lower than the water content 
of HPMC-free systems (Figure 6b). This might be explained by the fact that HPMC is well 
known to be able to form hydrogels, which can limit mass transport [31] and is in good 
agreement with the observed dynamic changes in implants’ mass (Figure 2). 
 
Figure'6.!Dynamic!changes!in!the!peak!intensity!of:!a)!NMP!and!b)!water!observed!by!1H!NMR!spectroscopy!in!in"situ!forming!implant!formulations!based!on!PLGA!(25!%),!ATBC!(10!%),!NMP!and!optional!HPMC!(20!%)!upon!exposure!to!phosphate!buffer.!
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Thus, the EPR and 1H NMR measurements clearly showed that the addition of 
HPMC significantly affected the solvent exchange kinetics in in situ forming implants: The 
leaching of NMP out of the formulations is facilitated, whereas the penetration of water 
into the devices is accelerated at early time points (leading to faster polymer precipitation), 
but slowed down at late time points. Furthermore, the building up and disappearance of 
water concentration gradients within the systems could be evidenced. 
3.3. Optical microscopy 
Figure 7 shows optical microscopy pictures of cross-sections of in situ formed 
implants after different exposure times to the release medium (as indicated). The systems 
were based on PLGA, ATBC, minocycline HCl and optionally contained HPMC. Note that 
the structures on the left hand side collapsed during sample preparation. Since the implants 
were prepared using the agitated vial set-up, they all have a cone-like shape (the geometry 
of the bottom of an Eppendorf vial). Clearly, the presence of HPMC within the formulation 
led to a rapid PLGA precipitation throughout the system: an about homogeneous, highly 
porous inner implant structure is visible on the right hand side of Figure 7. In contrast, 
highly heterogeneous inner structures were visible in HPMC-free implants (Figure 7, left 
hand side): A more dense outer shell can be distinguished from a highly porous, not even 
yet completely solidified inner core at early time points. These very marked differences in 
the implants’ morphology are in good agreement with the above discussed water 
penetration kinetics into the systems (e.g., Figure 4b) as well as NMP diffusion kinetics out 
of the systems (e.g., Figure 6a), and can (at least partially) explain the observed drug 
release kinetics (Figure 3): In the presence of the hydrophilic polymer HPMC, water 
penetration into and NMP transport out of the formulation is facilitated, leading to rapid 
PLGA precipitation throughout the device and a highly porous system structure, resulting 
in high drug mobility within the implant and, thus, increased release rates. In contrast, in 
the absence of HPMC, the system is less hydrophilic, water penetration into the 
formulation and NMP transport out of the system is slowed down, leading to the formation 
of a denser outer system shell and a more slowly solidifying inner core. Drug transport 
through the denser outer PLGA shell is effectively hindered, leading to reduced drug 
release rates.  
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However, care should be taken when drawing conclusions from in vitro 
experiments, especially in the case of PLGA-based systems and in situ forming devices, 
since the surrounding environment might potentially significantly affect the polymer 
precipitation kinetics and the overall mass transport processes [32–34]. For these reasons, 
the same liquid formulations were also used to prepare in situ forming implants in a flow-
          0 % HPMC 20 % HPMC  
1 d 
5 d 
7 d 
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through cell set-up [27]. Briefly, the liquids were filled into empty HPLC columns, 
through which the release medium was pumped at 44 µL/h. The idea was to better simulate 
the continuous gingival fluid flow in patients’ periodontal pockets. As it can be seen in 
Figure 8a, the type of release set-up tremendously affected the resulting drug release 
kinetics: (1) In HPMC-free systems, drug release was much faster in flow-through cells 
than in agitated vials, whereas (2) in HPMC-containing systems drug release was very 
similar for both types of release set-ups. (3) The addition of HPMC significantly 
accelerated drug release in agitated vials and had only a moderate effect in flow-through 
cells. To better understand these phenomena, also the PLGA degradation kinetics in these 
systems as well as the latter’s morphology were monitored (Figures 8b and 9). 
As it can be seen in Figure 8b, PLGA degradation was much faster when using the 
agitated vial set-up compared to the flow-through cell set-up. Also, the addition of HPMC 
led to a slight slowing down of polymer degradation, irrespective of the experimental 
conditions. Comparing Figures 9 and 7, it becomes visible that the shape of the implants 
was very much dependent on the experimental set-up: the implants were “cone”-shaped in 
the case of agitated vials (please note the collapse in HPMC-free systems during sample 
preparation), and more “film”-like in the case of flow-through cells. This difference is due 
to the difference in the surrounding geometry during implant formation (cone-shaped 
bottom of an Eppendorf vial versus inner cylinder of an HPLC column, through which the 
release medium flows). Obviously, this difference in device geometry fundamentally 
affects the resulting polymer precipitation kinetics, PLGA degradation kinetics and drug 
release rates. In the case of flow-through cells, the film-like geometry leads to a high 
surface area in contact with the release medium and rapid polymer precipitation through 
the implants in all cases (HPMC-free and HPMC-containing systems), because the 
distances to be overcome by the water and NMP are short. This leads to a relatively 
similar, highly porous inner implant structure, irrespective of the presence of HPMC. The 
short pathways to be overcome and high system porosity lead to high and similar drug 
release rates (Figure 8a, top curves). These observations are also in good agreement with 
the relatively slow PLGA degradation rates observed in flow-through cells (Figure 8b), 
since the creation of acidic microclimates within the implants is unlikely. In contrast, in the 
case of agitated vials, the diffusion pathways to be overcome by acids generated upon 
PLGA degradation are much longer within cone-shaped implants. This renders the creation 
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of acidic microclimates much more likely, resulting in more pronounced autocatalytic 
effects [35–39] and, thus, accelerated polymer degradation, as it can be seen in Figure 8b. 
The longer diffusion pathways and the formation of the above discussed denser outer 
implant shells in the case of HPMC-free formulations are responsible for the observed 
slow release from these systems in agitated vials (Figure 8a). 
 
 
Figure' 8.! Impact! of! the! experimental! setPup! on:! a)!drug! release,! and! b)!PLGA!degradation! from/of! in" situ! forming! implants! (25!%! PLGA,! 10!%! ATBC,! 2! %!minocycline!HCl),!optionally!containing!20!%!HPMC.!
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3.4. Antimicrobial activity  
First, the susceptibility of the bacteria present in the periodontal pockets of patients 
suffering from periodontitis against minocycline was studied. For this purpose, gingival 
crevicular fluid (GCF) samples were incubated in the presence or absence of minocycline 
on Columbia agar enriched with defibrinated horse blood in Petri dishes. After 5 d, the 
number of bacterial colonies was counted. Table 2 shows the mean log CFU (Colony 
Forming Units) per gram GCF, observed with 14 samples from deep periodontal pockets 
of 13 patients. As it can be seen, there was no obvious relation between the pockets’ depth 
and the CFU/g value, indicating the diversity of the bacterial levels in the different 
subjects. No colonies formed upon incubation of GCF samples on minocycline-loaded agar 
in 12 samples. Two samples showed growth of 1 colony, identified as Candida pelliculosa 
and Candida albicans, which are fungi. Thus, the calculated mean log CFU/g values for 
bacteria were ≤ 3.42 (our detection level) for all samples. On minocycline-free agar, much 
higher log CFU/g values were found, ranging from 5.37 to 10.07. The differences of mean 
log CFU/g found between the two types of agar varied from 1.94 to 6.64. It is assumed that 
there was less than 1 bacterium over 100 to 10,000,000 that may be resistant to 
minocycline. These results indicate that minocycline is suitable for the antibiotherapy of 
periodontitis. 
In addition to these studies on bacterial cocktails, also the Minimum Inhibitory 
Concentration (MIC) of minocycline against ten isolated bacterial strains from periodontal 
pockets of patients suffering from periodontitis was determined. As shown in Table 3, 8 of 
the investigated 10 strains were susceptible to minocycline according to the Société 
Française de Microbiologie (SFM) requirements; and all strains were susceptible at the 
minocycline concentration used in the in situ forming implant formulations (2 %). 
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Table'2.!Susceptibility!of!periodontal!pathogenic!bacteria!to!minocycline!(n.m.!=!not!measured).!
Sample 
Pocket depth 
(mm) 
Mean log CFU/g of GCF 
on non selective agar 
Mean log CFU/g of GCF  
on minocycline agar 
D86 n.m. 6.88 <3.42 
D87 n.m. 8.08 <3.42 
D88 7 7.10 <3.42 
D89 9 8.21 <3.42 
D90 9 6.63 <3.42 
D91 6 5.37 <3.42 
D92 9 7.70 <3.42 
D93 6 7.84 <3.42 
D94 7 8.04 3.42 
D95 7 8.68 <3.42 
D96 6 8.15 <3.42 
D97 8 7.72 <3.42 
D98 5 10.07 <3.42 
D99 6 7.97 3.42 
 
Table' 3.! Minimum! Inhibitory! Concentration! (MIC)! of! minocycline! against! specific!periodontal!strains.!
Bacterial strain Reference MIC (mg/L) 
Streptococcus vestibularis D28A1 0.1 
Veillonella sp. D18B13 0.1 
Fusobacterium nucleatum  JD7 0.1 
Veillonella sp. D36A19 0.2 
Streptococcus mitis D29A5 32 
Streptococcus sanguinis D28A11 0.2 
Streptococcus australis D37A12 0.1 
Streptococcus salivarius D28A9 0.1 
Streptococcus cristatus D18A2 0.1 
Streptococcus sanguis D30A3 16 
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Furthermore, the activity of the in situ forming implants against the bacteria cocktails 
present in the patients’ periodontal pockets were studied. Figure 10 shows the inhibition zone 
diameters observed upon incubation of GCF samples in Columbia agar enriched with horse 
blood in Petri dishes. Cylindrical holes were made at the center of the agar and filled with 30 
µL of liquid formulation. Upon solvent exchange, the implants formed in situ, and the Petri 
dishes were incubated for 5 d under anaerobic conditions. The biological samples were diluted 
either 100 times, or 1000 times, as indicated. Drug-free formulations served as negative 
controls. For reasons of comparison, also the activity of the commercial product Parocline® 
was studied with certain GCF samples. Clearly, all drug-loaded in situ forming implants could 
effectively inhibit the growth of the various bacteria present in the patients’ pockets (the 
inhibition zone diameter varied from 1.7 to 5.3 cm). The negative controls showed negligible 
or only very minor growth inhibition, with 1 exception – the “D91” sample. In this case, the 
D91-2 and D91-3 Petri dishes recorded inhibition zone diameters of 1 and 2.9 cm, 
respectively. This can probably be attributed to the exceptionally low CFU concentrations 
present in these specific cases (9 and 88 CFU/g, respectively), leading to non-representative 
bacterial amounts in 0.1 mL inoculated solution. Otherwise, the bacterial loads were much 
higher. For instance, 1 mL of 1000 times diluted “D90” sample contained about 16,000 CFU 
and 1 mL of 100 times diluted “D90” sample about 160,000 CFU. As expected, the inhibition 
zone diameters were generally higher in the case of the 1000 fold dilutions compared to the 
100 fold dilutions (since the bacterial load was 10-fold smaller). Importantly, the antibacterial 
efficacy of the investigated formulations forming implants in situ was comparable to the 
activity of the commercial product Parocline®. 
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Figure'10.!Antimicrobial!activity!of!in"situ!forming!implants!(25!%!PLGA,!10!%!ATBC,!20!%! HPMC,! 2!%!minocycline! HCl)! against! bacterial! cocktails! present! in! the! periodontal!pockets!of!periodontitis!patients:! Inhibition!zone!diameters!measured!upon! incubation!of!GCF!samples!in!agar!(“#”!indicates!n!=!2!instead!of!3;!“*”!indicates!that!no!inhibition!zone! was! detected;! “100! x”! indicates! a! sample! dilution! by! a! factor! of! 100;! “1000! x”!indicates!a!sample!dilution!by!a!factor!of!1000).!For!reasons!of!comparison,!Parocline®!was!also!tested!with!certain!samples.!
The observed variation in the inhibition zone diameters can at least partially be 
attributed to the variability of the composition of the bacterial cocktails present in different 
GCF samples (with respect to quality and quantity). Indeed, the microflora of periodontal 
pockets is known to be diversified, depending for instance on the severity of the disease and 
on the individual subject. To get a better understanding of which specific bacterial strains 
might be of importance, the dominant colonies of all samples after incubation were isolated 
and identified. The antibacterial efficacy of the new in situ forming implants was also tested 
against these isolated bacteria strains. Out of the total 23 isolated microorganisms, there were 
21 anaerobes comprising 3 gram positive, 6 gram negative obligate anaerobes and 12 gram 
positive facultative anaerobes. Only 2 aerobes were found, including 1 gram negative 
bacterium and 1 fungus. These results are in good agreement with reports in the literature, 
indicating a dominance of anaerobic bacteria in periodontal pockets [8,40–42]. These 
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microorganisms included both, “initial colonizers” (Streptococcus spp., Actinomyces spp., 
Veillonella spp.) as well as strains frequently found in more mature biofilms (Fusobacterium 
spp., Prevotella spp.) [42]. The microbial “orange complex” associated with periodontitis was 
also found, including black-pigmented Prevotella sp. and Fusobacterium nucleatum [8]. This 
is a good indication for the fact that the bacteria isolated in this study are likely to be 
representative for the microorganisms, which can be found in the periodontal pockets of 
patients suffering from periodontitis. As it can be seen in Figure 11, the investigated in situ 
forming implants were effectively inhibiting the growth of the various isolated bacteria strains, 
whereas the negative controls (formulations free of drug) showed no, or only very minor 
inhibitory effects, with 1 exception: Candida pelliculosa, a fungus that can be found in the 
mouth. But this microorganism is not specifically associated with periodontitis and is not 
susceptible to minocycline. Importantly, the antimicrobial efficacy of the in situ forming 
implants was comparable to that of the commercial product Parocline® with the investigated 
strains. 
In addition, it has to be pointed out that the inhibition zone diameters observed with the 
commensal oral bacteria were generally smaller than those observed with pathogenic bacteria: 
The average inhibition zone diameters obtained with 7 Streptococcus species (commensal 
flora) was 2.0 cm, while those obtained with Prevotella sp. and Fusobacterium nucleatum 
(pathogenic strains) were 4.8 cm and 5.2 cm, respectively. This is a very interesting 
difference, since it indicates that minocycline is likely to rapidly destroy pathogenic bacteria, 
but not as quickly inhibit commensals. The commensal flora will, thus, have a chance to 
continue colonization and subsequently re-establish the natural microbiological balance, as in 
healthy subjects.  
Furthermore, the impact of the amount of added HPMC on the antibacterial activity of 
the in situ forming implants was studied, using 4 selected periodontal strains. Parocline® as 
well as drug-free and HPMC-free systems were tested for reasons of comparison. As it can be 
seen in Figure 12, all drug-containing systems effectively inhibited the growth of all 4 
bacterial strains, irrespective of their HPMC content. This is of importance, since HPMC 
addition can significantly improve key features of the implants, such as their adhesion forces, 
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but does not impact their antimicrobial activity to a significant extent. Also, the activity of the 
in situ forming implants was similar to the antibacterial activity of Parocline®. 
 
Figure'11.!Antimicrobial!activity!of!in"situ!forming!implants!(25!%!PLGA,!10!%!ATBC,!20!%! HPMC,! 2! %! minocycline! HCl)! against! isolated" bacteria! strains! obtained! from! GCF!samples! from! periodontitis! patients:! Inhibition! zone! diameters! measured! upon!incubation!in!agar!(“#”!indicates!n!=!2!instead!of!3;!“!”!indicates!n!=!1!instead!of!3;!“*”!indicates! that!no! inhibition!zone!was!detected).!For!reasons!of!comparison,!Parocline®!was!also!tested!with!certain!bacteria!strains.!
                                                                                                 
Figure' 12.! Effects! of! the! addition! of!different! amounts! of! HPMC! to! the! in" situ!forming! implant! formulations! on! the!antimicrobial! activity! of! the! systems!(25!%!PLGA,!10!%!ATBC,!2!%!minocycline!HCl).! For! reasons! of! comparison,! also!Parocline®! and! drugPfree! and! HPMCPfree!systems! were! studied! (“*”! indicates! that!no!inhibition!zone!was!detected).!
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4. Conclusion 
The proposed in situ forming implant formulations exhibit a promising potential for 
improved periodontitis treatment. The addition of HPMC increases the systems’ adhesive 
forces and limits system swelling, while the antibacterial activity remains about unaltered. The 
novel insight obtained by EPR and NMR measurements allows for a better understanding of 
the underlying mass transport mechanisms in these rather complex systems and, thus, 
facilitated device optimization in the future, including other applications (e.g. for different 
drugs or drug combinations). Interestingly, the implants more strongly inhibited the growth of 
pathogenic bacterial strains isolated from the periodontal pockets of patients suffering from 
periodontitis compared to bacteria encountered in healthy subjects. In vivo, such a preferential 
action against the pathogenic strains can be expected to give a chance to the healthy flora to 
re-colonize the periodontal pockets. 
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Abstract 
Periodontitis is the primary cause of tooth loss in adults and a very widespread 
disease: 47 % of the US adults have mild, moderate or severe periodontitis, and 64 % of 
the population older than 65 years is affected. The treatment of periodontitis is highly 
challenging, because drug partitioning into the periodontal pockets is not very pronounced 
and gingival crevicular fluid flow rapidly eliminates drugs from their site of action. Thus, 
using conventional administration routes high systemic drug levels are required, while the 
drug concentration at the target site remains low, resulting in potentially severe side effects 
and low or negligible treatment efficacy. Biodegradable in situ forming implants offer an 
interesting potential to overcome these hurdles: These are liquid formulations, which upon 
injection into the periodontal pockets form solid implants. The latter subsequently controls 
drug release at the site of action during pre-programmed periods of time. However, 
currently available systems suffer from poor adherence to the human tissue, resulting in 
pre-mature and uncontrolled expulsion of implant fragments from the periodontal pockets 
during the treatment period. This leads to unreliable drug exposure to the patient. 
Composite implants based on a drug release rate controlling polymer and an adhesive 
polymer can overcome this limitation. However, the processes involved in implant 
formation and the control of drug release are complex and the relationships between the 
systems’ composition and the implants’ performance are yet unclear. This study applies 
advanced characterization techniques, such as EPR analysis, to better understand in situ 
forming implants based on two different types of poly(lactic-co-glycolic acid) (PLGA), 
hydroxypropyl methylcellulose (HPMC) and doxycycline or metronidazole. Interestingly, 
HPMC addition to shorter chain PLGA slightly decreased drug release, whereas in the case 
of longer chain PLGA the release rate substantially increased. These tendencies could be 
explained based on the mass transport kinetics during implant formation and the systems’ 
inner structures. Furthermore, the implants’ antimicrobial activity against microorganisms 
present in the periodontal pockets of patients suffering from periodontitis is evaluated. 
Interestingly, the systems more effectively hinder the growth of pathogenic bacteria than of 
physiological microorganisms. Thus, a re-colonization of the patients’ pockets with 
healthy flora can be expected to be favored in vivo. 
Keywords: in situ forming implant; periodontitis; PLGA; EPR; doxycycline!
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1. Introduction 
Periodontitis is a highly prevalent, chronic inflammatory disease of the 
periodontium. A recent survey estimates that 47 % of the US adults have mild, moderate or 
severe periodontitis [1]. Prevalence rates increase to 64 % for adults older than 65 years. 
Periodontitis is characterized by a progressive loss of the alveolar bone and periodontal 
ligament, leading to the formation of periodontal pockets [2–4]. If untreated, periodontitis 
can lead to the loosening and subsequent loss of the teeth. It is indeed the primary cause of 
tooth loss in adults [5]. The initiating factors of periodontitis are likely to be pathogenic 
bacteria and bacterial products, which form a biofilm covering the teeth’ surface in the 
subgingival area. It seems that the microflora in the disease state is different from that in 
healthy subjects. For example, the number of gram negative anaerobic bacteria is likely to 
be increased and certain clinical forms of periodontitis might be associated with specific 
microbiota [6]. Recently, Silva-Boghossian et al. [2] reported that Streptococcus strains 
(such as Streptococcus sanguinis) are also associated with suppuration in periodontitis 
subjects. However, up to date, the exact mechanisms underlying this disease are not yet 
fully understood. It is hypothesized that: (i) the suspected periodontal pathogens produce 
biologically active molecules, which directly attack the host tissue, and/or that (ii) the 
immune response of the host organism (human body) to these pathogens results in the 
tissue destruction. The consequence of the tissue loss is the deepening of the periodontal 
pockets, and -once the mechanical anchorage of the tooth becomes insufficient -the latter is 
lost. 
The treatment of periodontitis is highly challenging, since drug partitioning into the 
periodontal pockets is generally not very pronounced and gingival crevicular fluid flow 
rapidly eliminates drugs from the site of action [7]. For example, it has been estimated that 
the contents in a 5 mm periodontal pocket is renewed 40 times per hour [8]. Thus, using 
conventional administration routes (such as oral, intravenous, intramuscular, subcutaneous 
etc.) often high systemic drug levels are required, while the drug concentration at the target 
site remains low. This leads to potentially severe side effects and limited or insufficient 
therapeutic efficacy, despite the availability of highly potent drugs able to act against the 
pathogenic flora and inflammation. Importantly, the crucial hurdles of limited accessibility 
of the site of action and rapid elimination can be overcome using advanced local drug 
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delivery systems, releasing the drug in a time-controlled manner in the periodontal pockets 
during prolonged periods of time [9–16]. Biodegradable in situ forming implants are 
particularly promising for this purpose [17]. These are liquid formulations, which upon 
injection into the periodontal pockets form solid implants. The implant formation can be 
induced by different mechanisms [12,18–21], for example solvent exchange: Briefly, the 
basic idea is to dissolve the drug and a biocompatible and biodegradable matrix former 
[e.g., poly(lactic-co-glycolic acid), PLGA] in an appropriate organic solvent [e.g., N-
methyl pyrrolidone, NMP] [22–26]. This liquid phase can easily be injected into the 
periodontal cavities. Once injected, the NMP diffuses into the surrounding environment 
and water from the periodontal pocket penetrates into the liquid formulations. Since PLGA 
is not soluble in water, it subsequently precipitates and entraps the drug. Major advantages 
of this type of biodegradable, in situ forming implants include the fact that: (i) The 
injection of a liquid formulation is relatively easy (compared to the implantation of “pre-
formed” implants). (ii) There is no need to remove empty remnants upon drug exhaust, due 
to complete biodegradability of the system. (iii) The geometry and size of the implants are 
adapted to the patient’s periodontal pockets (customized systems, personalized medicine). 
(iv) The incorporated drug is locally released in a time-controlled manner through the 
slowly degrading polymer network. 
However, up to date major challenges remain to be addressed, namely the fact that: 
(i) The adherence of in situ formed implants to human tissue is yet poor, resulting in pre-
mature and uncontrolled expulsion of implant fragments from the periodontal pockets due 
to the non-negligible flow of gingival crevicular fluid [8,27]. This leads to a considerable 
uncertainty with respect to the amount of drug reaching the target site and the time periods 
during which therapeutic drug levels are provided. (ii) The elasticity/plasticity of the 
formed implants is generally not adapted to this type of local administration: Systems, 
which are difficult to deform plastically are not able to adapt their geometry to dynamic 
changes in the periodontal pocket’ size and shape with time. In contrast, fully elastic 
implants force the periodontal pockets to keep their geometry and dimensions, which is 
also not desirable. Recently, the addition of plasticizers, such as acetyltributyl citrate and 
dibutyl sebacate, as well as a second type of polymer, such as hydroxypropyl 
methylcellulose, has been proposed to increase the adhesiveness of the implants [28,29]. 
However, yet it is unclear how the systems’ composition affects the key properties of the 
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in situ formed implants. The aim of this study was to better understand the physico-
chemical phenomena involved in implant formation and the control of drug release as well 
as to evaluate the antimicrobial activity of doxycycline-loaded formulations. 
2. Materials and methods 
2.1. Materials 
Poly(D,L-lactic-co-glycolic acid) (PLGA, Resomer® RG 502 H and 504 H; Evonik, 
Darmstadt, Germany); acetyltributyl citrate (ATBC; Morflex, Greensboro, NC, USA); 
hydroxypropyl methylcellulose (HPMC, Methocel® E5 and E50; Colorcon, Dartford, UK); 
N-methyl pyrrolidone (NMP, 99 %), glucose and cysteine hydrochloride (Acros organics, 
Geel, Belgium); doxycycline hyclate and metronidazole (Fagron, Colombes, France); 4-
hydroxy-tempo benzoate (TB; Sigma-Aldrich, Seelze, Germany); agarose (GenAgarose® 
LE; Genaxxon BioScience, Ulm, Germany); Columbia agar base and agar (Oxoid, 
Basingstoke, UK); defibrinated horse blood (E&O Laboratories, Burnhouse, UK); 
Parocline® (2 % minocycline; Sunstar France, Levallois-Perret, France). 
2.2. Preparation of the liquid formulations 
PLGA (28 or 32 % w/w, based on the total liquid formulation without drug) was 
dissolved in NMP at 25 °C in a glass vial (30 min stirring). Optionally, the plasticizer 
ATBC (10 % w/w, based on the PLGA mass) and/or HPMC (10, 20, 25 or 30 % w/w, 
based on the PLGA mass) was/were added and the mixture was vortexed for 3 min, 
followed by standing for 3 h at 25 °C. Subsequently, 5 or 10 % doxycycline hyclate or 1 or 
10 % metronidazole (w/w, based on the total liquid formulation without drug) was added, 
and the mixture was vortexed for 3 min, followed by standing for 3 h at 25 °C. To 
eliminate air bubbles, the liquids were ultrasonicated for 10 min. The formulations were 
stored at -20 °C and protected from light to avoid drug degradation. 
2.3. In situ implant formation and drug release measurements 
One hundred microliters of the respective formulation was injected at the bottom of 
an Eppendorf vial using a standard syringe. One and a half milliliters preheated (37 °C), 
degassed phosphate buffer pH 7.4 (USP 35) was carefully added using a pipette, initiating 
solvent exchange and implant formation. The vials were horizontally shaken at 37 °C at 
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80 rpm (GFL 3033; Gesellschaft fuer Labortechnik, Burgwedel, Germany). At pre-
determined time points, the bulk fluid was completely withdrawn and replaced with fresh 
medium. The drug content in the samples was determined UV-spectrophotometrically (λ = 
325 nm for doxycycline and λ = 351 nm for metronidazole; UV-1650PC, Shimadzu, 
Champs-sur-Marne, France). All tests were performed in triplicate and the results were 
shown as mean values ± standard deviation. 
2.4. Monitoring of dynamic changes in the implants’ mass 
Implants were prepared and treated as described in Section 2.3. In situ implant 
formation and drug release measurements. At pre-determined time points, implants were 
weighed [mass (t)]. The mass change in percent was calculated as follows: 
mass change (%) (t) = 100 * [mass (t) – mass (t=0)] / mass (t=0) 
where mass (t=0) is the initial weight of the formulation used for implant preparation.  
2.5. Electron paramagnetic resonance (EPR) measurements 
In situ forming liquid implant formulations were prepared as described in section 
2.2. Preparation of the liquid formulations. The spin probe 4-hydroxy-tempo benzoate 
(TB) was dissolved in these liquids (1 mM). Two hundred µL of the formulations were 
placed into cylindrical holders, which were immerged into 3 mL phosphate buffer pH 7.4 
(USP 35). As illustrated in Figure 1a, only the top circular surface of the cylindrical holder 
was open, the other surfaces were impermeable. The system was kept constant at 37 °C 
and horizontally shaken at 30 rpm (GFL 1083; Gesellschaft fuer Labortechnik, Burgwedel, 
Germany). At pre-determined time points, samples (implants with holders) were 
withdrawn and analysed using an EPR L-band spectrometer (MagnetTech, Berlin, 
Germany), operating at a low microwave frequency (1 GHz). To create EPR images, 
twenty-five scans were accumulated using the following parameters: field centre = 48.9 
mT; scan range = 8 mT; scan time = 40 s. For the measurement of EPR spectra, a scan 
range of 10 mT and scan time of 100 s were applied. The typical EPR parameters were 
calculated from the recorded EPR spectra (first derivative) or integrated first derivative 
(absorption). Figures 1b shows an EPR spectrum of TB dissolved in NMP and Figure 1c 
shows examples for data recorded with an implant prepared from a liquid formulation 
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containing 32 % PLGA RG 502 H, 10 % ATBC, 20 % HPMC and 1 mM TB before and 
after exposure to phosphate buffer pH 7.4.  
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2.6. Mechanical and adhesive properties 
The mechanical and adhesive properties of the investigated in situ forming implants 
were determined with a texture analyzer (TA.XT.Plus; Stable Micro Systems, Surrey, UK) 
using the experimental set-up, which has previously been described in detail [28]. Briefly, 
agarose was dissolved in boiling water (0.6 % w/v), and the solutions were cast into Petri 
dishes (diameter = 9 cm). Upon cooling to room temperature, gels formed. At the center of 
the gels, cylindrical holes (diameter = 6 mm) were made and filled with 100 µL liquid 
formulation using a standard syringe and a drop of distilled water. Upon solvent exchange, 
the implants formed. At pre-determined time points, a spherical probe (diameter = 5 mm) 
was driven downwards (at a speed of 0.5 mm/s). Once in contact with the implant, the 
applied force and displacement of the probe were recorded as a function of time. When the 
penetration depth was 1.5 mm, this position was held for 60 s. Then, the probe was driven 
upwards at a speed of 10 mm/s. The maximum deformation force (Fmax deformation) is the 
force measured once the probe reaches the maximum penetration depth into the implant. 
The force measured after the 60 s holding time is called “remaining force” (Fremaining). In 
this study, the ratio “Fremaining/Fmax deformation” is used as a measure for the 
elasticity/plasticity of the implant. High values indicate high elasticity, low values indicate 
high plasticity. The “adhesion force” is defined as the maximum force measured with this 
set-up during the upward movement of the probe, accounting for the negative 
sign/direction of the force (Fadhesion). Each experiment was conducted in triplicate, the 
results are presented as mean values ± standard deviation. 
2.7. Optical microscopy 
Implants were prepared as described in Section 2.3. In situ implant formation and 
drug release measurements. At predetermined time points, implants were withdrawn and 
freeze-dried (Epsilon 2-4 LSC; Christ, Osterode, Germany). The process comprised 3 
phases: (i) freezing at -45 °C for 2 h; (ii) primary drying at 0.014 mbar and -9 °C shelf 
temperature for 10 h; (iii) secondary drying at 0.0014 mbar and 20 °C shelf temperature for 
10 h. Cross-sections were obtained with a knife and analysed with a SMZ-U zoom 1:10 
microscope (Nikon, Tokyo, Japan), equipped with a TV lens C-0.45x (Nikon) and a digital 
camera AxioCam ICc1 (Carl Zeiss, Oberkochen, Germany). 
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2.8. Microbiological tests 
Samples from periodontal pockets of periodontitis patients: Thirteen patients (4 
women, 9 men; from 35 to 69 years old) were enrolled in this study (14 periodontal 
pockets were sampled). They were admitted at the clinical site of the Faculty of Dental 
Surgery, University of Lille, France. Participants did not receive any hygienic treatment at 
the teeth with periodontitis prior to sampling. Sterile paper points (Roeko, Coltene, 
Germany) were carefully inserted into each periodontal pocket (1 paper point per pocket) 
and left for 10 s to allow for absorption of gingival crevicular fluid (GCF). Each paper 
point was placed into an Eppendorf vial, filled with 1.5 mL of Ringer Cysteine. 
Independently, 10 paper points were weighed before and after sampling to estimate the 
mean amount of GCF absorbed (5.7 ± 0.6 mg) to allow for the quantification of bacteria. 
Further tenfold dilutions (-2 to -7) of these GCF solutions (-1) were obtained for 
microbiological testing. 
Susceptibility of periodontal bacteria to doxycycline: Columbia agar was prepared 
from Columbia agar base, glucose, cysteine hydrochloride, and agar. The systems were 
sterilized in an autoclave (121 °C for 15 min). Prior to plating, Columbia agar was 
enriched with defibrinated horse blood (5 % v/v), without or with doxycycline hyclate 
(32 mg/L) and cast into Petri dishes. After cooling to room temperature, 0.1 mL of diluted 
GCF solutions (from -1 to -7) was inoculated onto the agar surface (35 °C, anaerobic 
atmosphere; Whitley A85 workstation, Don Whitley Scientific, West Yorkshire, UK). 
After 5 d of incubation, the number of bacterial colonies was counted for each Petri dish, 
the predominant colonies were subcultured and identified. 
Antibacterial activity of the in situ forming implants: The in vitro efficacy of the 
investigated implants was assessed by their antibacterial activity against entire 
periodontitis samples from patients’ periodontal pockets and against isolated bacterial 
strains, using the agar well diffusion method. Columbia agar was enriched with horse 
blood (5 % v/v) and cast into Petri dishes. After cooling to room temperature, 0.1 mL of 
diluted GCF (dilution -2 and -3) or isolated bacterial strains was inoculated onto the agar 
surface. A cylindrical hole (diameter = 6 mm) was subsequently made at the center of the 
agar, and filled with 30 µL of liquid formulation using a standard syringe. Upon solvent 
exchange, the implants formed in situ. The Petri dishes were incubated for 4 d (isolated 
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bacterial strains) or 5 d (diluted entire GCF samples) under optimum culture conditions 
(35 °C, anaerobic atmosphere; Whitley A85 workstation). The diameter of the observed 
bacteria growth inhibition zones around the center of the Petri dishes was measured using a 
ruler. Each experiment was conducted in triplicate, the results are presented as mean values 
± standard deviation. 
Minimal inhibitory concentration (MIC) of doxycycline on selected strains: The 
MIC of doxycycline was determined using the broth dilution method [30]. One hundred µL 
of Wilkins-West broth were pipetted into each well of a 96-well plate, except for the first 
column. A doxycycline stock solution (64 mg/L) was prepared in the same broth, 200 µL 
of which were introduced into the first column of microplate wells. After thorough mixing, 
100 µL of the first well was added to the second well and so on. Finally, 100 µL of 
bacterial suspension in Ringer Cysteine solution was introduced into each well, leading to 
2-fold dilution of the drug concentration (1-fold dilution in the first well). At the end, each 
well row contained a dilution series of the drug from the left to the right, with 
progressively lower concentrations (decreasing from 32 to 0.016 mg/L). After incubation 
at 35 °C under anaerobic conditions (Whitley A85 workstation), the lowest concentration 
of drug that prevented visible growth of bacteria was determined as the MIC. According to 
the 2013 guideline of the Société Française de Microbiologie (SFM), a microorganism is 
called “susceptible” to doxycycline if MIC ≤ 4 mg/L and “resistant” to doxycycline if MIC 
> 8 mg/L [31]. For these tests, the bacterial strains were provided from the collection of the 
Laboratory of Bacteriology of the College of Pharmacy, University of Lille, France (also 
obtained from patients suffering from periodontitis). 
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3. Results and discussion 
3.1. Key properties of the implants: Adhesiveness, plasticity and drug 
release 
The therapeutic efficacy and safety of in situ forming implants used for 
periodontitis treatment strongly depends on the systems’: (i) ability to remain within the 
periodontal pockets during the treatment period (and, thus, on their adhesiveness to the 
surrounding tissue), (ii) mechanical properties, in particular their capacity to adapt their 
size and shape to dynamic changes in the pockets’ geometry, and (iii) drug release kinetics. 
These factors are fundamental to assure reliable drug delivery to the site of action at a pre-
programmed rate during a pre-defined period of time. 
Figure 2a shows the adhesion forces of composite implants formed in situ, 
measured with a texture analyzer and a spherical probe, as described in detail in the 
Materials and Methods section. Briefly, liquids containing the matrix former PLGA, the 
drug, a plasticizer and optionally a second polymer dissolved/dispersed in an organic, 
water-miscible solvent were injected into cylindrical holes at the center of agar gels in 
Petri dishes. The formulations contained PLGA RG 504 H (25 % w/w, referred to the total 
liquid), ATBC (10 % w/w, referred to the PLGA), NMP (solvent), metronidazole (1 % 
w/w, referred to the total liquid), and optionally up to 30 % HPMC (Methocel® E50; w/w, 
referred to the PLGA). Upon injection the solvent diffuses into the surrounding agarose gel 
and water from this gel penetrates into the liquid formulations, resulting in PLGA 
precipitation and drug entrapment. At different time points, a spherical probe moves 
downwards, penetrates into the formulation up to 1.5 mm depth, is held for 60 s and moves 
again upwards, while recording the forces and displacements. The maximum measured 
force during the upward movement of the probe is defined as the adhesion force in this 
study. For reasons of comparison, also the adhesiveness of the commercially available 
drug product Parocline® was measured (filled circles in Figure 2a). Clearly, the stickiness 
of the implants significantly increased with increasing HPMC contents. Importantly, the 
proposed new systems exhibit much higher adhesive forces than the commercial reference 
product. Thus, they show a very promising potential to overcome one of the fundamental 
bottlenecks of the current state of the art: The uncontrolled expulsion of at least parts of the 
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implants during the treatment period, resulting in unreliable drug exposure to the target 
site. 
a) 
 
b) 
 
Figure'2.! Importance!of! the!composition!of! the! liquid!formulations!on!the!resulting!implants’:! a)!adhesion! force,! b)!mechanical! properties.! The! formulations! contained!25!%! PLGA! RG! 504! H,! 10!%! ATBC,! NMP,! 1!%!metronidazole,! and! optionally! up! to!30!%!HPMC!(here!Methocel®!E50).!For!reasons!of!comparison,!also! the!commercial!product!Parocline®!was!studied.!
Furthermore, the impact of the formulations’ composition on the 
plasticity/elasticity of the in situ forming implants was quantified: The ratio of the force 
measured after the 60 s holding time to the maximum deformation force (“Fremaining/Fmax 
deformation“) was used for this purpose. A value of 1 indicates ideally elastic behavior, values 
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well below 1 indicate high plasticity. Again, the commercial product Parocline® was 
studied for reasons of comparison. As it can be seen in Figure 2b, the proposed new 
composite implants all exhibit substantially higher plasticity than the commercially 
available reference formulation. Thus, these composite implants can much easier adapt 
their size and shape to dynamic changes in the geometry of the periodontal pockets of the 
patients suffering from periodontitis. This key property will further contribute to a more 
reliable maintenance of the systems at their target site and, hence, improve the therapeutic 
efficacy of the treatment and the patients’ safety. Interestingly, the addition of up to 30 % 
HPMC did not substantially affect the “Fremaining/Fmax deformation“ ratio. 
The effects of adding up to 30 % HPMC to liquid formulations forming implants in 
situ on the resulting drug release kinetics are illustrated in Figure 3. To simulate the limited 
volumes of liquid the formulations are exposed to in the periodontal pockets, the 
experiments were conducted in Eppendorf vials. Briefly, 100 µL of a formulation was 
injected at the bottom of a vial, and 1.5 mL phosphate buffer pH 7.4 was added, followed 
by horizontal shaking at 37 °C. At pre-determined time points, the bulk fluid was 
completely exchanged with fresh medium. Two types of PLGA were investigated: PLGA 
502 H and PLGA 504 H, differing in the average polymer molecular weight (Mw ≈ 12 and 
50 kDa, respectively). Also two types of drugs were studied: metronidazole and 
doxycycline. The drug loadings were 1 and 5 %, respectively. Interestingly, the addition of 
HPMC substantially increased the resulting drug release rate in the case of longer chain 
PLGA 504 H, whereas it slightly decreased the release rate in the case of shorter chain 
PLGA 502 H. This was true for both types of drugs. This opposite impact on drug release 
was rather surprising, since the only difference in the formulations was the polymer 
molecular weight. All other compounds were identical as well as the relative amounts of 
all ingredients. The slight decrease in drug release upon addition of up to 30 % HPMC in 
the case of PLGA 502 H-based implants was further confirmed with systems containing 
10 % (instead of 1 %) metronidazole, prepared with more concentrated PLGA solutions 
(32 instead of 28 %) and containing two types of HPMC: Methocel® E5 and E50 (differing 
in the average polymer molecular weight) (Figure 4a). Thus, the phenomenon was also 
independent of the initial drug loading, the polymer content of the formulation and the 
polymeric chain length of the HPMC (at least within the investigated ranges). From a 
practical point of view, it is very important to precisely control the resulting drug release 
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rate at the site of action: Too high drug concentrations lead to potentially serious side 
effects, whereas drug concentrations below the minimal effective concentration lead to 
treatment failure. To better understand why the addition of HPMC (improving the 
implants’ adhesiveness and plasticity, as shown above) substantially increased the release 
rate in the case of PLGA 504 H, but decreased the release rate in the case of PLGA 502 H, 
the respective systems were thoroughly characterized physico-chemically during implant 
formation and drug release. 
!
  
Figure'3.! Impact!of! the!addition!of!different!amounts!of!HPMC!(Methocel®!E50)!on!drug! release! from! in# situ! forming! implants! based! on! PLGA!RG! 502!H! (top! row)! or!PLGA!RG!504!H! (bottom!row)! (28!%,! referred! to! the! total! liquid)! and!ATBC! (10!%,!referred! to! the!PLGA).!On! the! left!hand! side! systems!containing!1!%!metronidazole!are!shown,!on!the!right!hand!side!formulations!initially!loaded!with!5!%!doxycycline!hyclate.!
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a)   b) 
!  
Figure'4.'Effects!of!adding!different!types!and!amounts!of!HPMC!(Methocel®!E5!and!E50)!on:!a)!drug!release,!b)!dynamic!changes!in!the!mass!of!in#situ!forming!implants!based! on! PLGA! RG! 502! H! (32!%,! referred! to! the! total! liquid)! and! ATBC! (10!%,!referred!to!the!PLGA),!loaded!with!10!%!metronidazole.!!
3.2. Underlying mass transport mechanisms 
Figures 4b and 5 show the dynamic changes in the systems’ mass upon exposure to 
the release medium. The observed mass change is essentially a consequence of the NMP 
diffusion into the phosphate buffer and water penetration into the formulations. As it can 
be seen, in all cases the mass generally increased during the observation period. This 
indicates that the mass gain due to water penetration is more important than the mass loss 
due to NMP diffusion. In practice, it is important that the mass gain is not too pronounced. 
Otherwise, the implants will increase too much in volume in the periodontal pockets, 
increasing the risk of accidental device expulsion. Importantly, the addition of HPMC led 
to less pronounced water uptake in all cases, further confirming the very positive impact of 
this compound on the maintenance of the systems within the patients’ pockets. However, 
there is no straightforward relationship between the changes in the systems’ mass and the 
observed release rates (Figures 3-5): HPMC addition led to faster drug release in the case 
of PLGA 504 H and slower drug release in the case of PLGA 502 H, whereas the increase 
in implant mass was reduced, irrespective of the type of PLGA. This was true for both 
types of drug, all investigated initial drug loadings, PLGA concentrations and HPMC 
polymer molecular weights. 
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Figure'5.! Impact!of! the!addition!of!different!amounts!of!HPMC!(Methocel®!E50)!on!the!dynamic!changes!in!the!mass!of!in#situ!forming!implants!based!on!PLGA!RG!502!H!(top! row)!or!PLGA!RG!504!H! (bottom!row)! (28!%,! referred! to! the! total! liquid)! and!ATBC! (10!%,! referred! to! the! PLGA).! On! the! left! hand! side! systems! containing! 1!%!metronidazole! are! shown,! on! the! right! hand! side! formulations! initially! loaded!with!5!%!doxycycline!hyclate.!
To gain deeper insight into the rather complex phenomena involved in the in situ 
formation of the investigated implants and the control of drug release from the systems, 
Electron paramagnetic resonance (EPR) was applied. Briefly, an EPR spin-probe [in this 
study,! 4-hydroxy-tempo benzoate (TB), 1 mM] was incorporated into the liquid 
formulations. TB is a nitroxyl radical, the spectral splitting of which is sensitive to both: 
the molecular motion (microviscosity of the surrounding) as well as the polarity of its 
environment [32]. Once the liquid formulation comes into contact with the release 
medium, the solvent NMP diffuses out and water penetrates into the system. This leads to 
PLGA precipitation and significant changes in the spin probe’s environment, which can be 
monitored by EPR analysis. To be able to estimate the water contents of the systems at a 
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specific position and time point, a quantitative relationship between the measured 
hyperfine splitting (2aN) and the phosphate buffer content in the spin probe’s environment 
(here, NMP:phosphate buffer mixtures) was established. Figure 6a shows that a linear 
relationship was obtained in this case (R2 = 0.9886). Thus, experimentally measured 2aN 
values can be used as indicators for the changes in the systems’ composition. 
a) b) 
!  
Figure' 6.! a)! Polarity! dependence! of! the! hyperfine! splitting! of! TB[loaded!“NMP:phosphate! buffer”! mixtures.! b)!Spatially! resolved! profiles! of! TB[loaded!implants!based!on!PLGA!RG!502!H!(32!%),!ATBC!(10!%)!and!optionally!20!%!HPMC.!
Figure 6b shows the hyperfine splitting values measured at different time points in 
implants forming in situ upon exposure of NMP solutions of PLGA 502 H (32 %), ATBC 
(10 %) and optionally 20 % HPMC (Methocel® E50) to phosphate buffer. The spatial 
position is plotted on the x-axis and corresponds to the experimental set-up shown in 
Figure 1a: “0 mm” indicates the bottom of the holder and “3.1 mm” the interface “liquid 
formulation/implant – release medium”. Before exposure to the release medium, the 2aN 
values were about 32.3 G and constant within the liquid, irrespective of the presence or 
absence of HPMC in the formulation (open and filled circles). According to Figure 6a, 
32.3 G corresponds to about 0 % phosphate buffer. This is sound, since the formulations 
were not yet exposed to the release medium. Importantly, the EPR measurements allowed 
visualizing clear water concentration gradients built up within the formulations after 1 h 
exposure time to the phosphate buffer (squares in Figure 6b). This indicates that surface 
near regions of the implants are water-rich compared to regions close to the bottom of the 
holder. Interestingly, the water concentration gradients in these PLGA 502 H-based 
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systems were very similar, irrespective of the presence or absence of 20 % HPMC (filled 
versus open symbols in Figure 6b). This is in contrast to previous findings with PLGA 
504 H-based formulations, which showed accelerated water penetration into the systems in 
the presence of HPMC [29]. The difference might be explained by the different relative 
hydrophilicity of the two PLGA types: Both, PLGA 502 H and PLGA 504H exhibit more 
hydrophilic end groups at their chains (-COOH groups) and more lipophilic polymer 
backbones. Since the average polymer molecular weight is smaller for PLGA 502 H than 
for PLGA 504 H (about 12 versus 50 kDa), PLGA 502 H is more hydrophilic than 
PLGA 504H. This is consistent with the more pronounced water uptake of PLGA 502 H-
based implants compared to PLGA 504 H-based implants shown in Figure 5 (top versus 
bottom row). Thus, adding hydrophilic HPMC to more hydrophobic PLGA 504 H has a 
more pronounced impact than when adding it to less hydrophobic PLGA 502 H. In the 
case of the more hydrophobic PLGA 504 H, the presence of HPMC very much facilitates 
water penetration into the system, whereas this effect is less pronounced in the case of the 
less hydrophobic PLGA 502 H. This tendency is confirmed also at later time points, 
namely 4 and 8 h (triangles and diamonds in Figure 6b): The water concentration profiles 
in PLGA 502 H-based implants are very similar in HPMC-containing and HPMC-free 
systems. Note that at these late time points in HPMC-containing systems, the 2aN values 
close to the interface “implant – release medium” decrease (in contrast to HPMC-free 
devices). This is probably due to the fact that the formation of a HPMC gel alters the 
microviscosity of the environment of the spin probe and, thus, biases the measurements. In 
fact, increasing the viscosity of the probe’s environment has been reported to decrease the 
molecular tumbling rate of the nitroxyl radical [32]. 
Interestingly, the fact that the addition of HPMC has a major impact on the water 
penetration kinetics in the case of PLGA 504 H-based implant formulations (as reported in 
[29]) corresponds well to the major impact of HPMC addition on the resulting drug release 
kinetics from these systems (Figure 3). And the absence of such a major effect of HPMC 
addition on the water penetration kinetics in the case of PLGA 502 H-based formulations 
(Figure 6b) corresponds well with the absence of a major effect on the resulting drug 
release kinetics from these systems (Figures 3 and 4a). This clearly demonstrates that the 
water penetration kinetics into the in situ forming implants is decisive for the systems’ key 
properties. But yet it is unclear why accelerated water penetration into the formulations 
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leads to accelerated drug release. To better understand these phenomena, the morphology 
of the implants was studied using optical microscopy. Figures 7 and 8 show pictures of 
cross-sections of in situ formed implants based on PLGA 502 H and PLGA 504 H, 
respectively. The systems were exposed to phosphate buffer pH 7.4 for different time 
periods, as indicated (treated as for the drug release studies). The left columns show 
implants free of HPMC, the right columns systems containing 20 % HPMC (Methocel® 
E50). Very clearly, the implants solidified more rapidly in the presence of HPMC, 
irrespective of the PLGA type. This can probably at least partially be attributed to a faster 
NMP diffusion rate out of the systems, as reported in the literature [29]. Interestingly, 
longer chain PLGA 504 H led to a more porous inner implant structure compared to PLGA 
502 H (right columns in Figures 8 versus 7) in HPMC-containing devices. This might at 
least partially be explained by the higher hydrophobicity of PLGA 504 H compared to 
502 H, resulting in more rapid polymer precipitation upon water penetration into the 
systems and NMP diffusion out of the formulations. Importantly, the resulting high 
implant porosity can explain the significant increase in the drug release rate upon HPMC 
addition to these systems (Figure 3). In contrast, the much lower porosity observed in the 
case of PLGA 502 H corresponds very well to the substantially different effect of HPMC 
addition on drug release from these systems (Figures 3 and 4a). In all cases, the absence of 
HPMC led to slower implant solidification (Figures 7 and 8). 
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The EPR measurements could also be used to quantify the release of the spin probe 
TB: The “normalized AUC” calculated from the EPR spectra can be used as a measure for 
the amount of TB still remaining within the system. Figure 9 illustrates how these values 
decreased with time upon exposure of formulations based on PLGA 502 H to the release 
medium. Open symbols correspond to HPMC-free formulations, closed symbols to 
HPMC-containing formulations. The triangles, squares and circles correspond to three 
different samples. As it can be seen, the “normalized AUC” values decreased more rapidly 
in HPMC-free systems than in HPMC-containing devices. This indicates faster TB release 
from HPMC-free implants and is consistent with the generally faster drug release observed 
with HPMC-free formulations based on PLGA 502 H compared to HPMC-containing 
systems (Figures 3 and 4). Eventually, the presence of HPMC leads to gel formation in the 
tiny implant pores and, thus, increased resistance for drug and spin probe diffusion [33]. 
 
Figure' 9.! Release! of! the! EPR! spin! probe! TB! (expressed! as! the! decrease! in! the!normalized!AUC)!from!implants!based!on!PLGA!RG!502!H!(32!%),!ATBC!(10!%),!being!free! of! Methocel®! E50! (open! symbols)! or! containing! 20!%!Methocel®! E50! (closed!symbols)! upon! exposure! to! phosphate! buffer! pH!7.4,! determined! via! double!integration! of! EPR! spectra.! The! triangles,! squares! and! circles! correspond! to! three!different!samples.!
3.3. Antimicrobial implant activity 
For the efficacy of the periodontitis treatment the sensitivity of the bacteria in the 
patients’ pockets against the drug is decisive: In case of resistance, the treatment fails, even 
if the drug reaches its target site. For this reason it was important to verify whether or not 
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the bacteria, which are present in the periodontal pockets of patients suffering from 
periodontitis, are sensitive to the drug (here, we selected doxycycline). To be able to do so, 
gingival crevicular fluid (GCF) samples from 13 patients (4 women, 9 men; from 35 to 69 
years old) were incubated on Columbia agar (containing or not doxycycline), enriched with 
defibrinated horse blood in Petri dishes. Upon 5 days of incubation, the number of Colony 
Forming Units (CFU) (per gram GCF) was counted. Table 1 shows the mean log (CFU)/g 
GCF values for 14 pocket samples. Importantly, no colonies formed in 13 out of the 14 
samples in the presence of drug; and the only growth observed (in sample D99) was 
identified as Candida albicans, which is a fungus. Thus, the calculated mean log CFU/g 
for bacteria was ≤ 3.42 (our detection level) for all the samples. In contrast, on 
doxycycline-free agar, much higher log CFU/g values were found, ranging from 5.37 to 
10.07. The differences of mean log CFU/g found between the two types of agar varied 
from 1.94 to 6.64. It is assumed that there was less than 1 bacterium over 100 to 
10,000,000 that may be resistant to doxycycline. This result indicates that doxycycline is 
suitable for the antibiotherapy of periodontitis. Furthermore, Table 1 shows that there was 
no clear relationship between the pockets’ depth and number of Colony Forming Units, 
indicating the diversity of the bacterial levels in the enrolled subjects. In addition to these 
studies on bacterial cocktails, also the activity of doxycycline against isolated bacterial 
strains, which were obtained from periodontal pockets of periodontitis patients was 
determined. For this purpose, the Minimum Inhibitory Concentration (MIC) of drug for 
specific strains was measured. Briefly, different dilutions were prepared and the 
concentration identified above which bacterial growth was inhibited. The results are shown 
in Table 2 and indicate that 8 out of the 10 strains are susceptible to doxycycline according 
to the Société Française de Microbiologie (SFM) requirements; and all strains were 
susceptible at the doxycycline concentration used in the investigated in situ forming 
implant formulations (5 or 10 %). 
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Table'1.'Susceptibility!of!periodontal!bacteria!from!periodontitis!patients!to!doxycycline!(n.m.!=!not!measured).!
Sample 
Pocket depth 
(mm) 
Mean log CFU/g of GCF 
on non selective agar 
Mean log CFU/g of GCF  
on doxycycline agar 
D86 n.m. 6.88 < 3.42 
D87 n.m. 8.08 < 3.42 
D88 7 7.10 < 3.42 
D89 9 8.21 < 3.42 
D90 9 6.63 < 3.42 
D91 6 5.37 < 3.42 
D92 9 7.70 < 3.42 
D93 6 7.84 < 3.42 
D94 7 8.04 < 3.42 
D95 7 8.68 < 3.42 
D96 6 8.15 < 3.42 
D97 8 7.72 < 3.42 
D98 5 10.07 < 3.42 
D99 6 7.97 3.42 
 
Table'2.'Minimum!inhibitory!concentration!(MIC)!of!doxycycline!against!periodontal!strains.'
Bacterial strain Reference MIC (mg/L) 
Streptococcus vestibularis D28A1 0.5 
Veillonella sp. D18B13 0.1 
Fusobacterium nucleatum  JD7 0.03 
Veillonella sp. D36A19 1.0 
Streptococcus mitis D29A5 32 
Streptococcus sanguinis D28A11 1.0 
Streptococcus australis D37A12 0.2 
Streptococcus salivarius D28A9 0.2 
Streptococcus cristatus D18A2 0.5 
Streptococcus sanguis D30A3 32 
 CHAPTER III 
 
! 136!
The activity of the in situ forming implants against the bacteria cocktails present in 
the patients’ periodontal pockets was measured as follows: 30 µL of the liquid 
formulations (containing 32 % PLGA RG 502 H, 10 % ATBC, 20 % Methocel® E50, 10 % 
doxycycline hyclate) were injected into cylindrical holes at the center of Columbia agar 
plates, enriched with horse blood and inoculated with 100- or 1000-times diluted gingival 
crevicular fluid (GCF) samples from patients. Upon contact with the agar gel, NMP 
diffused out of the formulations and water into the systems, resulting in PLGA 
precipitation and drug entrapment. The Petri dishes were incubated for 5 days under 
optimum culture conditions (35 °C, anaerobic atmosphere). In case of bacterial growth 
inhibition, an inhibition zone around the in situ formed implant was visible. The diameter 
of this zone was measured with a ruler. For reasons of comparison, also drug-free 
formulations were studied (as negative controls) and the commercially available drug 
product Parocline®  (as reference, with two of the GCF samples: D90 and D91). Figure 10 
shows the observed inhibition zone diameters. As it can be seen, the microorganisms 
present in all samples were susceptible to the in situ forming implants loaded with 
doxycycline as well as to Parocline® (note that this product contains a different drug: 
minocycline). The inhibition zone diameters varied from 1.9 to 5.7 cm, depending on the 
specific GCF sample, with 1 exception: For the sample D91-3, the inhibition zone of 
doxycycline-loaded implants was at least as large as the Petri dish. The negative controls 
(in situ forming implants free of drug) did not inhibit bacterial growth (*) or exhibited 
small inhibition zones (diameter ≤ 0.7 cm), with 1 exception: For the samples D91-2 and 
D91-3, the recorded inhibition zone diameter of the negative controls was 2.4 and 5.1 cm, 
respectively. This exception can be attributed to the low bacterial concentration present in 
these specific samples, namely: 88 and 9 CFU/g, respectively. Such a low contamination 
leads to non-representative numbers of Colony Forming Units resulting from incubation of 
0.1 mL solution. The bacterial loads in the other samples were much higher: For instance, 
1 mL D90-2 solution contained 160,000 CFU. As expected, the inhibition zone diameters 
were generally smaller in the case of 100-fold dilutions compared to 1000-fold dilutions 
(since the bacterial concentration was 10-fold higher). 
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Figure'10.!Antimicrobial!activity!of! in#situ! forming!implants!(32!%!PLGA!RG!502!H,!10! %! ATBC,! 20! %! Methocel®! E50,! 10! %! doxycycline! hyclate)! against! bacterial!cocktails!sampled!from!periodontal!pockets!of!periodontist!patients:!Inhibition!zone!diameters!measured!upon!incubation!of!gingival!crevicular!fluid!samples!in!agar!(“*”!indicates!that!no!inhibition!zone!was!detected;!“⊗”indicates!that!inhibition!zone!was!at!least!as!large!as!the!Petri!dish;!“100!x”!indicates!a!100[fold!sample!dilution;!“1000!x”!indicates!a!1000[fold!sample!dilution;!“#”!indicates!n!=!2!instead!of!3;!“!”!indicates!n!=!1!instead!of!3).!For!reasons!of!comparison,!drug[free!formulations!were!studied!as!negative!controls!and!Parocline®!as!a!reference!(with!some!samples).!
The observed variation in the inhibition zones can be explained by the different 
compositions of the contents of the periodontal pockets of the patients: It is well known 
that this microflora is highly diverse and the quality and quantity of bacteria present 
depends on many factors, including the severity of disease state. To better understand 
which bacterial strains are likely to be of importance, the dominant colonies in all the 
samples from periodontitis patients were isolated and identified. In this study, 23 
microorganisms were isolated: 21 anaerobes (3 gram positive, 6 gram negative obligate 
anaerobes and 12 gram positive facultative anaerobes) and only 2 aerobes (1 gram negative 
bacterium and 1 fungus). These results are in good agreement with data reported in the 
literature, showing the dominance of anaerobic bacteria in periodontal pocket [34–37]. The 
isolated microorganisms included both, initial colonizers (Streptococcus spp., Actinomyces 
spp., Veillonella spp.) as well as strains frequently present in more mature biofilms 
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(Fusobacterium spp., Prevotella spp.) [37]. The so-called microbial “orange complex” 
associated with periodontitis was also found, including black-pigmented Prevotella sp. and 
Fusobacterium nucleatum [34]. This indicates that the bacteria identified in this study are 
likely to be representative for the principal microorganisms present in periodontal pockets 
of periodontitis patients. 
Once having identified these microorganisms, it was interesting to determine how 
active the proposed novel in situ forming implants were against them. For this reason, the 
same experimental set-up was used as described above for the entire fluid samples from 
the periodontal pockets, but inoculating only the isolated bacteria. Figure 11 shows the 
measured inhibition zone diameters observed with in situ forming implants prepared from 
formulations containing 32 % PLGA 502 H, 10 % ATBC, 20 % HPMC (Methocel® E50) 
and 10 % doxycycline hyclate. For reasons of comparison, also drug-free systems were 
studied (as negative controls) and the commercially available Parocline® (as a reference, 
with some of the bacterial strains). Clearly, efficient growth inhibition was observed with 
all drug-containing systems in 22 out of 23 cases. The only exception was Candida 
pelliculosa, but this is a fungus (and not a bacterium), and it can be found in the 
physiological mouth flora. It is not surprising that doxycycline is not active against it. 
Depending on the type of microorganism, the inhibition zone diameter varied from 1.5 to 
6.5 cm (Figure 11). This variation is due to the different susceptibility of the respective 
bacteria to the drug. Importantly, the corresponding inhibition zone diameters observed 
with the placebo-formulations were generally much smaller, ranging from 0.0 to 3.4 cm. 
The 3.4 cm value was measured upon incubation of Prevotella nigrescens. Although this 
value is about 2-fold smaller than the corresponding value obtained with doxycycline-
loaded formulations (6.5 cm), it indicates a possible susceptibility of this bacterium to the 
drug-free implant systems, eventually because of the decrease in pH upon PLGA 
degradation. Furthermore, it can be seen in Figure 11 that the activity of the novel in situ 
forming implants was similar to the activity of Parocline® (in the case of the investigated 
strains). 
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Figure'11.!Antimicrobial!activity!of! in#situ! forming!implants!(32!%!PLGA!RG!502!H,!10!%!ATBC,!20!%!Methocel®!E50,!10!%!doxycycline!hyclate)!against!isolated#bacteria!
strains! obtained! from! gingival! crevicular! fluid! samples! of! periodontitis! patients:!Inhibition! zone! diameters!measured! upon! incubation! in! agar! (“*”! indicates! that! no!inhibition! zone!was! detected;! “#”! indicates! n! =! 2! instead! of! 3;! “!”! indicates! n! =! 1!instead! of! 3).! For! reasons! of! comparison,! drug[free! formulations! were! studied! as!negative!controls!and!Parocline®!as!a!reference!(with!some!bacterial!strains).!
In addition, it has to be pointed out that the inhibition zone diameters of the 
commensal oral bacteria were smaller than the ones of pathogenic bacteria. For example, 
the average inhibition zone diameter observed with 7 Streptococcus strains (commensal 
flora) was 1.9 cm, while the one from Prevotella sp. and Fusobacterium nucleatum 
(pathogenic strains) were 4.9 and 4.7 cm, respectively. This difference indicates that the 
investigated implants are likely to rapidly destroy pathogens and not as quickly inhibit 
commensals. Thus, the commensal flora will have an opportunity to continue to colonize 
the periodontal pockets of the patients, re-establishing the natural microbiological balance 
as in healthy subjects. This is a very important aspect in practice, since the current standard 
treatment “root planing” suffers from a high risk of re-colonization of the pockets with 
pathogenic bacteria. 
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4. Conclusion 
The novel composite in situ forming implants show a very promising potential as 
innovative local and controlled drug delivery systems for the treatment of periodontitis: 
They are likely able to overcome crucial current bottlenecks in this field, including 
unreliable residence times at the site of action (due to accidental system expulsion) and re-
colonization with pathogenic bacteria. Future studies should address the in vivo activity of 
these novel types of advanced drug delivery systems. 
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Conclusion 
Periodontitis is a highly prevalent disease worldwide. Its treatment is 
challenging due to the complexity of its etiology and common recurrence post-
treatment. In situ forming implant was reported to be an effective local periodontitis 
treatment, even though the lack of bioadhesiveness is still a limitation unsecuring the 
therapy efficacy. In this thesis, we developed biodegradable and bioadhesive in situ 
forming implants loaded with antibiotics for the treatment of periodontitis. By means 
of characterization techniques, the properties and antimicrobial activity of drug 
devices were evaluated. 
In the Introduction, general definition, cause and treatment methods of 
periodontitis were reviewed. Short summary about the antibiotherapy was shown 
including various systemic or local antibiotic delivery systems and their reported 
clinical results. Among that, in situ forming implants are particularly promising for 
the treatment of periodontitis. The formulation composition and their impact on the 
controlled drug release capacity of these drug devices were briefly introduced.  
Chapter 1 presented new in situ forming implants based on PLGA in NMP for 
the local treatment of periodontitis, with good mechanical properties by means of 
addition of a plasticizer ATBC and a second polymer HPMC. Indeed, these systems 
perform much higher adhesiveness than prior art systems and provide appropriate 
plasticity, which favor their residence times in the patients’ periodontal pockets. The 
ability to control drug release during more than 7 days and good antimicrobial activity 
against relevant Streptococcus strains makes these in situ forming implants very 
promising for improved periodontitis treatment.  
Chapter 2 focused on the controlled drug release capacity of the in situ 
forming implants and its mechanism. It was demonstrated that the presence of HPMC 
in the systems was a key parameter to increase the systems’ adhesive forces and limit 
system swelling. The role of HPMC in modifying drug release kinetics was exhibited 
by advanced characterization techniques such as EPR and NMR measurements. In the 
PLGA RG 504 H matrices, the presence of HPMC increased significantly the solvent 
exchange rates in in situ forming implants, leading to rapid PLGA precipitation 
throughout the device and a highly porous system structure. These phenomena 
resulted in high drug mobility within the implant and, thus, increased release rates. 
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The addition of HPMC is an interesting tool to achieve desired drug release kinetics 
of PLGA-based in situ forming implants.  
Chapter 3 investigates how the formulation composition determines system 
performance. In contrast to the substantial effect of HPMC in higher molecular weight 
PLGA (RG 504 H), the impact of HPMC is negligible in lower molecular weight 
PLGA (RG 502 H), irrespective of the type of drug. Interestingly, the increase in 
implant mass was reduced, irrespective of PLGA type. This was true for all 
investigated initial drug loadings and drug type, PLGA concentrations and HPMC 
polymer molecular weights. This insight can be very helpful for device optimization 
in the future, including other applications (e.g. for different drugs or drug 
combinations). 
 Chapter 2 and Chapter 3 showed that the proposed in situ forming implant 
formulations (loaded with 10 % doxycycline hyclate or 2 % minocycline 
hydrochloride) exhibited good antimicrobial activity against all the tested complex or 
isolated bacteria from periodontitis patients.  Interestingly, the implants more strongly 
inhibited the growth of pathogenic bacterial strains isolated from the periodontal 
pockets of patients suffering from periodontitis compared to bacteria encountered in 
healthy subjects. This preferential activity is highly expected to favor the re-
establishing of healthy microorganisms after treatment period.  
In the future, the in vivo activity of these novel types of advanced drug 
delivery systems should be addressed. 
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Résumé  
Les maladies parodontales sont des infections diverses des tissus parodontaux, y 
compris la gingivite et la parodontite. Ces maladies sont causées par un biofilm bactérien 
résidant sur les dents adjacentes à la gencive, conduisant à une inflammation des gencives. 
Alors que la gingivite est la forme la plus douce, qui ne nuit pas aux structures de soutien 
sous-jacent des dents et est réversible, la parodontite quant à elle mène à la perte de tissus 
conjonctifs et de soutien de l'os. 
Selon la classification de l'Académie américaine de parodontologie, la parodontite 
peut être divisée en plusieurs catégories: la parodontite chronique, la parodontite agressive, 
la parodontite associée à la maladie systémique et la parodontite nécrosante. Elles sont 
généralement caractérisées par une destruction du ligament alvéolo-dentaire, une 
résorption de l’os alvéolaire et une migration de la jonction épithéliale le long de la surface 
de la dent, menant à la formation de poches parodontales.  
La cause principale de ces maladies est la prolifération de bactéries pathogènes 
bouleversant l'équilibre naturel de défense de l'hôte et de la flore commensale. Ces 
organismes se développent sur les surfaces dentaires d’abord en tant que micro-colonies, 
puis s’attachent les uns aux autres et forment des biofilms. La gingivite est souvent causée 
par une hygiène buccale insuffisante, provoquant la formation de la plaque dentaire. Les 
autres facteurs qui peuvent contribuer à la cause de cette maladie sont la génétique, le 
tabac, la consommation d'alcool, les carences nutritionnelles, l'infection au VIH, 
l'ostéoporose, le diabète, le stress, la réponse de l'hôte altérée et certains médicaments. Les 
lésions gingivales non traitées peuvent évoluer en parodontite, dans laquelle la plaque 
s’élargit et remonte sous la gencive, créant encore un meilleur environnement pour les 
colonies bactériennes, notamment les bactéries à gram négatif et anaérobies. 
La microflore orale normale (108 bactéries/mL de salive) contient principalement 
des aérobies à gram positif  ainsi que plusieurs espèces pathogènes à faible virulence. Les 
espèces pathogènes associées à la parodontite se composent principalement d’anaérobies à 
gram négatif. Chaque type de parodontite présente une flore sous-gingivale spécifique avec 
ses micro-organismes propres. Le changement de composition bactérienne associé à 
l'apparition des souches bactériennes spécifiques dans les canaux radiculaires infectés 
pourrait être un facteur déterminant dans la progression de la maladie. Le premier 
complexe bactérien associé à la parodontite est appelé «complexe orange» et se compose 
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des bacilles gram négatif anaérobies strictes comme Prevotella intermedia et 
Fusobacterium nucleatum. La forme la plus sévère s’accompagne du  «complexe rouge» 
formé par l’association de 3 bactéries: Porphyromonas gingivalis, Tannerella forsythia et 
Treponema denticola. Le gram négatif facultatif tel que Actinobacillus (maintenant 
Aggregatibacterium actinomycetemcomitans) est aussi communément associé à cette 
maladie, en particulier chez les jeunes adultes. 
Le traitement des maladies parodontales vise à rétablir la santé parodontale en 
interrompant la progression de la maladie, en prévenant la récidive et en maintenant des 
dents en bonne santé. Cet objectif peut être atteint par diverses thérapies chirurgicales et 
non chirurgicales, en fonction de la maladie et de sa gravité. La première possibilité pour le 
traitement des maladies parodontales consiste en l'élimination de la plaque, qui est 
effectuée par le soin d'hygiène bucco-dentaire et le traitement professionnel appelé le 
détartrage et le surfaçage radiculaire. Ces 2 techniques doivent être réalisées régulièrement 
pour maintenir l'hygiène buccale et stabiliser la flore buccale normale, interrompant 
l'inflammation gingivale. Cette thérapie non chirurgicale peut avoir une bonne efficacité 
dans la parodontite initiale comme la baisse de l'inflammation des tissus et l’amélioration 
du « clinical periodontal attachment”. Toutefois, dans les cas graves, ce traitement 
mécanique ne suffit pas pour atteindre les résultats cliniques souhaités. Par exemple, la 
recolonisation des espèces pathogènes associées aux maladies et la récurrence de la 
parodontite sont très fréquentes. 
Afin de renforcer le traitement non chirurgical de la parodontite, une thérapie 
antimicrobienne est souvent utilisée comme complément au détartrage et au surfaçage 
radiculaire. L’antibiothérapie systémique est également utilisée pour le traitement de la 
parodontite sévère. Cependant, cette voie d'administration présente des désavantages en 
raison de leurs effets secondaires, à savoir l'hypersensibilité et l'intolérance gastro-
intestinale. Par ailleurs, la concentration du principe actif au niveau du site d'action (le 
parodonte) est assez faible et ne suffit pas pour un traitement antimicrobien efficace. Ces 
limites pourraient être améliorées par l'administration locale d’agents antimicrobiens. La 
mise en place d’un système à libération contrôlée contenant un principe actif dans la poche 
parodontale pourrait améliorer de manière significative sa concentration locale. En 
contrôlant la libération de ces systèmes, les effets secondaires pourraient également être 
réduits. 
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Cette forme galénique doit être facilement administrée et libérer l’antibiotique au 
sein de la poche parodontale à un taux optimum sur une longue période. Le premier 
système commercialisé sous-gingival est Actisite®: il est constitué de fibres de 
poly(éthylvinylacétate) (EVA) chargées en chlorhydrate de tétracyclines. Malgré une 
libération prolongée pendant 9 jours in vitro et une efficacité clinique démontrée, les 
cliniciens rapportent des difficultés avec la technique de placement d’Actisite®. Chez les 
patients, les principaux inconvénients sont l’anesthésie nécessaire pour le placement, 
l'inconfort pendant le traitement et des effets indésirables significatifs (rougeur gingivale, 
pigmentation de la langue). En outre, ce système doit être fixé par un adhésif cyanoacrylate 
à cause du manque de bioadhésivité. Le produit commercialisé Elyzol® contenant 25% de 
métronidazole peut être facilement placé dans la poche parodontale par une seringue 
fournie. Néanmoins, suite aux études cliniques, l'efficacité de ce gel utilisé en combinaison 
avec le détartrage et le surfaçage radiculaire est controversée. Ceci est probablement dû à 
la mauvaise rétention de gel Elyzol® à l'intérieur de la poche parodontale. De même, 
l'efficacité clinique de Periochip®, un insert biodégradable composé de gluconate de 
chlorhexidine à la gélatine hydrolysée n'a pas été confirmée. Cet insert adhésif peut 
maintenir la libération du principe actif pendant 7 jours. Toutefois, suite à une étude 
clinique systématique, les résultats cliniques et microbiologiques de Periochip® en 
combinaison avec le détartrage et le surfaçage radiculaire sont limités et controversés. Par 
ailleurs, le gel de minocycline à 2 % qui a été commercialisé sous plusieurs marques 
(Dentomycin®, Periocline®, Parocline®) semble être meilleur au niveau de la thérapie 
clinique. Il a été rapporté que le Dentomycin® fournissait une réduction importante du « 
probing depth » et du « clinical attachment gain” ainsi que de meilleurs résultats pour le 
« bleeding on probing”. Toutefois, ces gels manquent encore de biodégradabilité, d'où la 
nécessité de retrait du dispositif vide après le traitement. Un autre système injectable 
biodégradable largement étudié est Atridox®. Ce système est constitué d'un polymère 
biodégradable, l’acide polylactique (PLA) dissous dans le solvant biocompatible N-
méthyl-2-pyrrolidone (NMP) chargé à 10 % hyclate de doxycycline. Il s'agit d'un système 
de formation in situ en raison de son changement d’état de liquide à solide après l’injection 
dans la poche parodontale. Cet implant peut maintenir la libération de la doxycycline sur 7 
jours. Dans deux grandes études cliniques (n = 411), Atridox® a démontré une efficacité 
clinique supérieure à l'hygiène bucco-dentaire et au véhicule seul. Cependant, l’Atridox® 
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tend à sortir prématurément de la poche parodontale (mécaniquement), l’addition de colles 
parodontales a pour effet de minimiser cet inconvénient. 
Les implants se formant in situ (ISFI) sont des formulations galéniques liquides 
parentérales qui se transforment en dépôt (semi-) solide après injection par une seringue. 
L’ISFI a d'abord été étudié au début des années 1980 avec pour objectif de développer des 
formulations injectables antimicrobiennes pour le traitement local des maladies 
parodontales. Jusqu'à présent, l’ISFI retient encore beaucoup l'attention des chercheurs en 
raison de son avantage par rapport aux autres dispositifs d'administration de médicaments 
par voie parentérale tels que les liquides, les liposomes, les émulsions, les microsphères et 
les microparticules. Les principaux avantages des ISFI sont leur plus faible coût de 
production et un procédé de fabrication simple.  
Les ISFI peuvent être classés en 3 groupes principaux, en fonction du mécanisme 
de formation de l'implant: (i) les systèmes réticulés, (ii) les organogels solidifiant et (iii) les 
systèmes de séparation de phases. Parmi ceux-ci, le système de séparation de phase par 
échange de solvant est très attractif en raison de son grand potentiel commercial. En effet, 
cette thèse se concentre sur les implants se formant in situ à base d’échange de solvant, 
l’abréviation ISFI sera utilisée pour désigner les systèmes de séparation de phase par 
l’échange de solvant. La formulation de ces systèmes ISFI est généralement constituée d'un 
solvant, d’un polymère et d’un principe-actif. Des quantités relativement élevées de 
solvant sont utilisées dans la formulation d’ISFI pour dissoudre le polymère, formant une 
solution polymérique. Cette dernière est ensuite injectée dans le corps et se diffuse dans les 
tissus environnants, le solvant utilisé doit donc répondre à certaines exigences. Il doit être 
non toxique et biocompatible, par conséquent, il ne provoquera aucune irritation sévère des 
tissus ni de nécrose au site d'injection. Par ailleurs, le solvant doit être miscible à l'eau pour 
diffuser rapidement dans le fluide corporel et permettre à l'eau de diffuser dans la solution 
polymérique, conduisant à la précipitation du polymère. Les solvants préférés comprennent 
la N-méthyl-2-pyrrolidone, la 2-pyrrolidone, l'acétone, le diméthylsulfoxyde, en raison de 
leur capacité de solvatation et de leur biocompatibilité. Il existe un grand choix de 
polymères biodégradables qui peuvent être utilisés dans l’ISFI. Les polymères à faible 
degré de cristallinité et grande hydrophobicité sont préférables en raison de leur grande 
solubilité dans les solvants organiques. Des exemples de tels polymères sont les 
polylactides, les polycaprolactones et les acides poly(lactique-co-glycolique). Ils 
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présentent des régions plus amorphes pour améliorer la solubilité. Ces polymères sont 
également largement étudiés en raison de leur sécurité approuvée par la FDA et une longue 
histoire d'utilisation clinique. L’acide poly(lactique-co-glycolique) (PLGA) est un 
copolymère de l’acide polylactique (PLA) et de l’acide polyglycolique (PGA). La gamme 
des produits de PLGA est large en raison de la capacité de copolymérisation des deux 
polymères PLLA et PDLLA avec différents ratios de monomères. Le PLGA se dégrade 
dans l'eau par hydrolyse de ses liaisons esters. Pour les systèmes à libération contrôlée, le 
choix d'un PLGA avec une cinétique de dégradation appropriée est important pour obtenir 
une cinétique de libération souhaitée. Le PLGA est à ce jour considéré comme le polymère 
le mieux défini disponible pour les systèmes à libération contrôlée à l'égard de la 
conception et de la performance. Le choix du principe actif dépend de l'application de 
l’ISFI. Pour le traitement de la parodontite, les substances choisies sont des antiseptiques 
ou des antibiotiques à large spectre antibactérien approprié. Pour le traitement du cancer de 
la prostate, le peptide agoniste des récepteurs hormonaux, l’acétate de leuprolide a été 
choisi comme principe actif. Par ailleurs, de nombreux dispositifs d’ISFI ont été étudiés en 
utilisant de petites molécules comme le diclofénac sodique et l'aspirine ainsi que de 
grandes molécules de protéines comme l'albumine de sérum bovin et l’hormone de 
croissance humaine. Les propriétés de la substance active (le poids moléculaire, la 
solubilité, l'affinité pour le solvant) et sa teneur dans la formulation peuvent affecter son 
profil de libération à partir des systèmes d’ISFI. 
La libération du principe actif à partir de l’ISFI de PLGA est le résultat d'un 
processus physico-chimique complexe se produisant dans la matrice de PLGA, de 
l'injection de la solution polymérique jusqu'à la fin de la dégradation de la matrice. Ce 
processus commence par l'échange de solvant provoquant la précipitation du polymère, 
aboutissant à la formation d'un dépôt solide. Au sein de la matrice de PLGA, la présence 
d'eau provoque l'hydrolyse du PLGA, coupant les liaisons ester et augmentant la mobilité 
des chaînes polymériques. La diminution de la masse moléculaire du polymère conduit 
finalement à l'érosion de la matrice polymérique, ce qui pourrait affecter la libération du 
principe actif. En bref, le mécanisme sous-jacent de libération de la substance active peut 
se résumer à deux procédés principaux: la diffusion et l'érosion. Ces mécanismes peuvent 
se produire simultanément et sont influencés par des paramètres de formulation et par 
l'environnement du site d'injection. La diffusion a été décrite comme l'un des mécanismes 
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de libération principal contrôlant la libération du principe actif à partir de systèmes à base 
de PLGA. Elle est directement liée à la porosité de la matrice polymérique, et par 
conséquent au processus de formation de pores. Dans le cas de l’ISFI, l'échange de solvant 
se produit lors du contact de la solution polymérique avec l'environnement aqueux 
conduisant à une séparation de phases liquide-liquide et à la formation des pores. Le 
coefficient de diffusion du principe actif à partir de l’ISFI dépend du coefficient de 
diffusion dans les pores remplis par le liquide, sa porosité et sa tortuosité. Par conséquent, 
ce paramètre n'est pas constant mais il change en fonction du temps car l’altération de la 
structure du dépôt est induite par la dégradation du polymère. L'érosion commence quand 
le poids moléculaire du polymère passe en dessous d'un seuil de 15 kDa. Dans un premier 
temps, l'érosion augmente la formation des pores et augmente ainsi la vitesse de diffusion. 
Par ailleurs, l'érosion peut être considérée comme un vrai mécanisme de libération, 
induisant une libération directe de principe actif en même temps qu’une perte de masse du 
polymère. D'autres mécanismes de libération de la substance active à partir des systèmes à 
base de PLGA comprennent la diffusion au travers du réseau polymérique et le pompage 
osmotique. Dans le cas de l’ISFI, l'absorption de l'eau conduit à un gonflement du 
polymère. Ce phénomène peut alors compenser la pression osmotique à l'intérieur des 
systèmes. Par conséquent, la diffusion à travers des pores remplis d'eau est généralement le 
mécanisme de libération dominant. 
De nombreux facteurs peuvent influencer la libération du principe actif des ISFI de 
PLGA, y compris les paramètres de formulation et les propriétés de l'environnement du 
site d'injection.  Le solvant organique a un impact significatif sur la formation de la matrice 
polymérique et la libération de principe actif sous-jacente. En fonction de la force du 
solvant (la miscibilité dans l'eau), la matrice polymérique peut être poreuse ou presque 
non-poreuse. Les solvants ayant une grande miscibilité dans l’eau (NMP, DMSO...) 
favorisent une rapide séparation de phase liquide-liquide et par conséquent la formation de 
la structure poreuse, ce qui peut augmenter la libération du principe actif. En revanche, la 
structure plus uniforme créée par les solvants les plus faibles (la triacétine, l'acétate 
d'éthyle, le benzoate d'éthyle ...) conduit à une libération du principe actif plus lente. Les 
propriétés physico-chimiques du PLGA ont également un impact significatif sur la 
cinétique de libération du principe actif à partir de l’ISFI de PLGA. Tout d'abord, la masse 
moléculaire (Mw) est une propriété importante du PLGA, celle-ci est proportionnelle à la 
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longueur de la chaîne du polymère, et par conséquent proportionnelle à sa viscosité 
intrinsèque. Selon Ahmed et al. (2012), une Mw faible conduit à un polymère moins 
hydrophobe avec une augmentation du taux d'absorption de l'eau et de la dégradation de la 
matrice, ce qui entraîne une vitesse de libération plus rapide par rapport aux Mw élevées. 
Deuxièmement, une concentration en polymère plus élevée conduit à une augmentation de 
la viscosité et de l'hydrophobicité de la solution polymérique. Par conséquent, le taux 
d'afflux de l'eau, le taux de séparation des phases et la diffusion du principe actif dans le 
milieu de libération sont limités, conduisant à des taux de libération plus lents. Ensuite, le 
groupement situé à l’extrémité du PLGA peut être un acide carboxylique ou un ester, 
entraînant un changement de ses propriétés chimiques. Des polymères avec un groupement 
carboxylique sont plus hydrophiles, donc augmentent la vitesse d’absorption de l’eau, de 
l’hydrolyse et de l'érosion. Par conséquent, le groupe d'extrémité a un impact considérable 
sur le taux de libération du principe actif. Enfin, le PLGA peut se composer de n'importe 
quel rapport acide lactique/acide glycolique (L:G). Cette proportion influence la 
cristallinité du polymère et donc son absorption d'eau et sa vitesse de dégradation. Grâce 
aux propriétés plus hydrophile du PGA par rapport au PLA, le PLGA avec un L:G plus 
faible est moins hydrophobe que celui avec un rapport L:G plus haut. Par conséquent, il 
absorbe plus d'eau et se dégrade plus rapidement. Dans l’ISFI, le principe actif peut être 
dissous ou dispersé dans la solution polymérique, en fonction de sa solubilité dans le 
solvant organique. Etant donné que la diffusion est considérée comme le mécanisme 
principal de libération, la solubilité du principe actif dans le milieu de libération est un 
paramètre important. D'une part, la nature du principe actif peut modifier l'échange de 
solvant de la solution polymérique et ainsi modifier la vitesse de libération. Généralement, 
une substance active hydrophile conduit à un taux de diffusion et de dégradation plus élevé 
que les substances hydrophobes. Certains principes actifs acides (le N-acétyl cystéine, 
l'aspirine) ont montré qu’ils facilitaient la dégradation de la matrice de PLGA et donc 
amélioraient leurs libérations à partir de l’ISFI de PLGA. D’autre part, la libération du 
principe actif à partir de la matrice de PLGA dépend aussi de ses propriétés chimiques. Les 
substances basiques peuvent créer une interaction ionique forte avec le polymère, en les 
gardant dissoutes dans la matrice. Cette interaction protège les groupes carboxyliques 
terminaux du polymère, ce qui entraîne une érosion plus lente de la matrice et réduit la 
diffusion à travers la matrice. En revanche, en raison de leur faible interaction avec le 
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PLGA, les substances acides et neutres précipitent rapidement sous la forme de cristaux 
dans la matrice pendant la libération. Par conséquent, la solubilité de ces principes actifs 
dans la matrice hydratée devient un paramètre dominant affectant sa diffusion. Plusieurs 
additifs ont été ajoutés dans la formulation des ISFI de PLGA pour modifier ses propriétés 
de libération. Les polymères hydrophiles comme la polyvinylpyrrolidone (PVP) ou les 
Pluronics ont démontré un impact sur la vitesse de libération à partir des ISFI. L’addition 
d’un co-solvant, d’un plastifiant ou d’un excipient qui peut interagir avec le principe actif 
peut également affecter le profil de libération de l’ISFI. 
L’objectif de ces travaux était de développer de nouveaux implants biodégradables 
se formant in situ pour le traitement des maladies parodontales, les infections les plus 
fréquentes au monde. Ces implants permettront de délivrer localement le principe actif et 
de contrôler sa libération. L’avantage des implants se formant in situ est la possibilité 
d’épouser parfaitement la poche parodontale. Ces implants sont basés sur un polymère 
biodégradable et biocompatible, l’acide polylactique (PLA) ou l’acide poly(lactique-co-
glycolique) (PLGA). Il est aussi important de souligner que l’un des pré-requis pour ces 
nouveaux systèmes est de présenter une bonne bioadhésion et des propriétés mécaniques 
permettant d’éviter une expulsion prématurée hors de la poche parodontale. Les cinétiques 
de libération résultantes seront contrôlées sur au moins 7 jours avec une dégradation 
simultanée de la matrice polymérique. Les principaux objectifs de cette thèse incluaient: (i) 
la préparation et la caractérisation physico-chimique d’implants se formant in situ, (ii) 
l’étude de l’effet des paramètres de formulation et de procédé (ex: différents types et 
teneurs en polymère, agent bioadhésif et plastifiant) sur les cinétiques de libération 
résultantes, (iii) l’élucidation des mécanismes de libération sous-jacents en se basant sur 
les propriétés physico-chimiques des implants caractérisés par microscopie optique, suivi 
des cinétiques de libération, chromatographie à perméation de gel (GPC), résonance 
paramagnétique électronique (EPR) et (iv) l'évaluation de l'activité antimicrobienne des 
implants développés par des tests microbiologiques sur la flore complexe et sur des 
bactéries isolées du fluide gingival de patients atteints de parodontite. 
Dans un premier temps les travaux menés dans le cadre de cette thèse se sont 
attachés à développer de nouveaux implants se formant in situ avec un potentiel 
prometteur pour surmonter l'un des inconvénients majeurs liés au traitement local de la 
 RESUME 
 
 156$
parodontite: l’adhérence limitée aux tissus environnants, entraînant l'expulsion accidentelle 
d'au moins une partie des implants de la poche parodontale. Cela conduit à de fortes 
incertitudes quant au temps de résidence des systèmes au site d'action et ainsi au temps 
d'exposition au principe actif. Dans cette étude, l'addition de diverses concentrations de 
différents types de plastifiants (l’acetyltributyl citrate, ATBC et le dibutyl sebacate, DBS) 
et de polymères adhésifs (dérivés cellulosiques tels que l'hydroxypropyl méthylcellulose, 
HPMC) ont permis d’obtenir une augmentation significative de l’adhésion des implants à 
base de l’acide poly(lactique-co-glycolique) (PLGA). Ces systèmes sont formés in situ à 
partir des formulations liquides de N-méthyl-2-pyrrolidone (NMP). Il est important de 
noter que, dans le même temps, une bonne aptitude à la déformation plastique des implants 
a été obtenue et les cinétiques de libération du principe actif souhaitées ont pu être affinées 
à l'aide de plusieurs outils de formulation. L'activité antimicrobienne de ce nouveau type 
d'implants se formant in situ, chargés à l’hyclate de doxycycline, a été démontrée en 
utilisant la méthode de diffusion en gélose sur plusieurs souches de Streptococcus isolées à 
partir de la microflore buccale des patients souffrant de parodontite. 
L’objectif dans un deuxième temps visait à une meilleure compréhension des 
mécanismes de formation in situ des implants. Des implants se formant in situ à base de 
PLGA, d’ATBC, de chlorhydrate de minocycline, de NMP et d’HPMC, ont été préparés et 
caractérisés en détail in vitro. Pour cela différentes techniques ont été utilisées: la 
résonance paramagnétique électronique (EPR), la résonance magnétique nucléaire (1H 
NMR), le suivi de l’évolution de la masse et la cinétique de libération du principe actif 
dans différentes conditions, la microscopie optique, la chromatographie d'exclusion 
stérique (SEC), ainsi que des tests d'activité antibactériens utilisant des échantillons de 
fluide gingival des poches parodontales des patients atteints de parodontite. En se basant 
sur ces résultats, une vision approfondie sur les phénomènes physico-chimiques impliqués 
dans la formation de l'implant et sur le contrôle de la libération du principe actif a pu être 
acquise. Par exemple, les effets de l'ajout d’HPMC dans la formulation, qui améliore 
l'adhérence de l'implant et réduit le gonflement, ont pu être expliqués. De manière 
importante, les implants se formant in situ ont efficacement empêché la croissance 
bactérienne dans les poches parodontales des patients. Il est intéressant de noter que ces 
systèmes ont été plus efficaces sur la croissance des souches bactériennes pathogènes (par 
exemple le Fusobacterium nucleatum) que sur des souches physiologiques (par exemple 
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les Streptococcus). In vivo, on peut donc s'attendre à une action préférentielle contre les 
bactéries pathogènes permettant ainsi à la flore saine de recoloniser les poches 
parodontales. 
Enfin dans un dernier temps, l’impact de la composition des implants sur la 
performance des systèmes a été étudié. Les processus impliqués dans la formation de 
l'implant et dans le contrôle de la libération du principe actif sont complexes et les relations 
entre la composition des implants et ses performances sont encore obscures. Afin 
d’élucider ces relations, des techniques de caractérisation de pointe, telles que l'analyse 
EPR ont été utilisées pour mieux comprendre les implants se formant in situ basés sur deux 
différents types de PLGA, d’HPMC et de doxycycline ou de métronidazole. Il est 
intéressant de noter que l’ajout d’HPMC et de PLGA de plus faible poids moléculaire a 
légèrement diminué la libération du principe actif, alors que dans le cas de PLGA de poids 
moléculaire plus élevé, la vitesse de libération a substantiellement augmenté. Ces 
tendances peuvent être expliquées en se basant sur la cinétique du transport de masse au 
cours de la formation de l'implant et des structures internes des systèmes. En outre, 
l'activité antimicrobienne des implants contre les micro-organismes présents dans les 
poches parodontales de patients atteints de parodontite a été évaluée. Il est intéressant de 
noter que ces systèmes gênent plus efficacement la croissance des bactéries pathogènes 
que celle des micro-organismes physiologiques. Ainsi, une recolonisation de la flore saine 
dans les poches des patients peut être envisagée in vivo. 
Pour conclure, cette thèse présente des implants se formant in situ à base de PLGA 
qui se dissolvent dans le NMP, sont bioadhésifs et chargés en antibiotique (la minocycline, 
la doxycycline ou le métronidazole) pour le traitement des parodontites. L’ajout de 
diverses concentrations de plastifiants (l’ATBC et le DBS) et de polymères adhésifs 
(dérivés cellulosiques tels que l’HPMC) a apporté une bonne aptitude à la déformation 
plastique des implants. Parallèlement, les cinétiques de libération de substance active 
souhaitées ont pu être affinées à l'aide de plusieurs outils de formulation. En utilisant 
plusieurs techniques de caractérisation in vitro, une vision approfondie des phénomènes 
physico-chimiques impliqués dans la formation de l'implant et du contrôle de la libération 
du principe actif a pu être acquise. Par exemple, les effets de l'ajout d’HPMC dans la 
formulation, qui améliore l'adhérence de l'implant et réduit le gonflement, ont pu être 
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expliqués. En outre, l'activité antimicrobienne des implants contre les micro-organismes 
présents dans les poches parodontales de patients atteints de parodontite a été évaluée. Il 
est intéressant de noter que ces systèmes sont plus efficaces contre la croissance des 
souches bactériennes pathogènes que contre celle des souches physiologiques. Ces 
résultats préliminaires ouvrent des perspectives pour évaluer plus en détail ces 
formulations in vivo. 
 
